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Abstract
Background
Since its introduction in the early 1990s, minimally invasive gastro-oesophageal 
surgery for cancer has been growing in popularity. Despite this, published evidence 
on this type of technique is weak and its role in the management of gastric and 
oesophageal cancer remains controversial.
Aims
The aim of this thesis was to test the hypothesis that: minimally invasive gastro- 
oesophageal cancer surgery has superior outcomes compared to control studies of 
conventional open surgery; but current studies are methodologically inadequate to 
confirm this.
Methods
The first study (chapter 3) is a systematic review of the literature on minimally 
invasive gastro-oesophageal cancer surgery, outlining the differences between 
literature published in Eastern and Western countries
The following 3 chapters outline and use a phase II surgical study to obtain data on 
minimally invasive gastro-oesophageal cancer (MIGOCS.) The MIGOCS group was 
set up in 2005 amongst UK surgeons. An online database was developed to enable 
data collection and comprises 5 sections: demographics; pre-operative staging and 
assessment; surgical intervention; post-operative course; pathology and clinical 
outcome. The first study is retrospective collecting data up to December 2006; the 
second study is prospective with data obtained between December 2006- July 2008 
from centres around the UK utilising the MIGOCS database.
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Chapter 7 involves analysis of the learning curve in laparoscopic gastro-oesophageal 
cancer surgery using CUSUM (continuous surveillance monitoring) assessment. By 
studying operative time at each centre, improvement or deterioration in quality were 
detected.
Results
The systematic review of minimally invasive gastro-oesophageal surgery consists in 
the majority of case reports, with no randomised controlled trials of oesophagectomies 
and 4 (low quality) randomised controlled trials of gastrectomies. It demonstrates a 
mortality and morbidity of 2.3% and 46.2% respectively for oesophagectomies; 0.1% 
and 12.7% respectively for gastrectomies. Data from this review suggests that the 
minimally invasive approach is beneficial compared to open surgery in terms of 
reduced mortality, respiratory complications, blood loss and quicker return to a good 
quality of life (but not reduced hospital stay as expected.)
There are currently 60 MIGOCS member consultant surgeons from over 40 UK 
centres.
The retrospective study obtained data from 7 UK centres with an overall mortality and 
morbidity of 6.0% and 57% respectively for oesophagectomies and 7.7% and 13% 
respectively for gastrectomies.
The prospective study collected data from 7 UK centres, comprising a total of 258 
minimally invasive oesophagectomies and 33 minimally invasive gastrectomies. 
Overall mortality and morbidity were 2.5% and 56.6% respectively for 
oesophagectomies and 10.8% and 27.3% respectively for gastrectomies.
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CUSUM analysis varied considerably between centres. The two larger volume centres 
however demonstrated an improvement in their operative time with experience, with a 
possible pateau at around 30 procedures.
Conclusions
Published data suggests that the minimally invasive approach to gastro-oesophageal 
cancer has advantages over conventional open surgery. Data collected in this thesis 
does not overwhelmingly support published evidence, but does demonstrate that this 
technique is both safe and feasible even during the early part of a surgeon’s learning 
curve. It is the first study to provide an insight into outcomes of this type of surgery in 
a multicentre setting in the UK; and has made progress towards a randomised 
controlled trial.
Weaknesses and Intepretation of Findings
International literature on the subject of minimally invasive gastro-oesophageal 
surgery is at present limited and subject to both publication and selection bias.
Data presented in this thesis is weakened by the number of operations recorded and 
centres involved in the studies. This impacts on any interpretation of findings.
Further data collection, ideally in the form of a randomised controlled trial is therefore
vital.
8
Declaration
Except where noted in the acknowledgements or text, I declare that this dissertation is 
my own work, except where acknowledged, and is based on research that was 
undertaken by me in the Nuffield Department of Surgery, John Radcliffe Hospital, 
Oxford in conjunction with the University of Nottingham. No material included in 
this work has been submitted for a previous course, at this or any other academic 
institution, nor shall I agree to this happening. I am aware of and understand the 
School policy on plagiarism and the University Policy and Procedure regarding 
Academic Offences particularly that directed at plagiarism. I acknowledge that my 
work may be submitted to checks for irregularities e.g. online plagiarism detection 
software. I am aware that it is my own responsibility to retain a copy of this submitted 
work and I may be required to submit a second copy if asked by a member of 
University of Nottingham academic staff. I declare that there are no extenuating 
circumstances that have not formally been disclosed and which may have affected the 
standard of my work.
9
Acknowledgements
The work presented in this thesis could not have been achieved without the help and 
talents of a great many people. Firstly I am indebted to Mr Peter McCulloch, my 
supervisor in Oxford who provided me with the opportunity to do this research and 
whose patient guidance got me started. My thanks also go to my Nottingham 
supervisor Professor John Scholefield whose words of wisdom helped me finish my 
research and will always remain with me.
I am also grateful to Dr Gary Collins (Oxford) for his invaluable statistical support 
and input in evaluating learning curves; to Dr Ken Catchpole (Oxford) for always 
lending me an ear; to Mr Nick Maynard and Mr Bruno Sgromo (Oxford oesophago- 
gastric consultants) and to Mr James Catton, Mr Simon Parsons and Mr Neil Welch 
(Nottingham oesophago-gastric consultants) who inspired and helped keep me sane.
My thanks also go to Dr Peter Walton, Mrs Mary Kennedy and Mr Neal McCann of 
Dendrite computing systems for their invaluable assistance in setting up the online 
database and assistance in its ongoing management.
Perhaps one of my greatest thanks though has to go to members of the MIGOCS 
group, especially Mr Colm O’Boyle, Mr Richard Berrisford, Mr Saj Wajed, Mr Jim 
Byrne, Mr Don Menzies, Mr Krish Singh, Mr Haythem Ali and Mr Shaun Preston, 
not just for their donation of data to the register (making my thesis possible); but for 
their ongoing support and enthusiasm for minimally invasive gastro-oesophageal 
cancer surgery!
10
Finally I would like to thank my family and friends for their selfless support and who 
hopefully know how much I appreciate them. In particular, my thanks go to my father 
and brother; and to my mother whose courage and determination proved inspirational 
to the end.
11
List of Tables
Table 1.1: Guidelines for Referral of Upper Gastrointestinal Cancers
Table 1.2: Stage Groupings of Gastric Cancer
Table 1.3: Stage Groupings of Oesophageal Cancer
Table 1.4: American Society of Anaesthesiologists (ASA) Grading Criteria
Table 1.5: O-POSSUM Variables
Table 1.6: Outcomes of Gastro-Oesophageal Cancer Surgery in the UK 
Table 1.7: Types of Laparoscopic Surgery for Gastric Cancer 
Table 1.8: Types of Laparoscopic Surgery for Oesophageal Cancer 
Table 3.1: Inclusion and Exclusion Criteria for Systematic Review 
Table 3.2: Pre-Determined Criteria for Paper Selection for Further Review 
Table 3.3: Differences in Results reported between East and West Centres for 
Minimally Invasive Gastric and Oesophageal Cancer Surgery 
Table 4.1: O-POSSUM variables 
Table 4.2: ASA Grading Criteria
Table 5.1: Hospital Prolonging and Life Threatening Morbidity Related to Minimally 
Invasive Gastric and Oesophageal Surgery for Cancer 
Table 5.2: Main Operative Outcomes by Oesophagectomy Technique Utilised 
Table 6.1: Age and Gender of People Undergoing a Minimally Invasive Approach to 
Oesophagectomy and Gastrectomy
Table 6.2: Pre-Operative Histological Grade of Oesophageal Tumour Resected by 
Approach
Table 6.3: Morbidity from Minimally Invasive Gastro-Oesophageal Cancer Surgery
Table 6.4: Nodal Retrieval for Minimally Invasive Oesophagectomies and 
Gastrectomies
12
Table 6.5: Resection Margins for Minimally Invasive Oesophagectomies and 
Gastrectomies
Table 6.6: Length of Hospital and Intensive Care following Minimally Invasive 
Oesophagectomy and Gastrectomy.
Table 7.1: Minimally Invasive Oesophagectomies, Mean and Range of Operative 
Times by Centre
13
List of Figures
Figure 1.1: New Gastric Cancer cases in the UK, 2003 
Figure 1.2: New Oesophageal Cancer cases in the UK, 2004 
Figure 1.3: Siewert Classification
Figure 3.1: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta­
analysis Flow Chart of Study Selection
Figure 3.2: Operative Time for Minimally Invasive Gastro-Oesophageal Cancer 
Surgery
Figure 3.3: Blood Loss for Minimally Invasive Gastro-Oesophageal Cancer Surgery 
Figure 3.4: Length of Hospital Stay for Minimally Invasive Gastro-Oesophageal 
Cancer Surgery
Figure 4.1: Demographic Data Collection as seen on the MIGOCS Register
Figure 4.2: Pre-Operative Data Collected as seen on the MIGOCS Register
Figure 4.3: Operative Data Collection on the MIGOCS Register
Figure 4.4: Post Operative Course Data Collection as seen on the Register
Figure 4.5: Pathology Outcome as seen on the Register
Figure 5.1: Breakdown of Oesophagectomies Performed
Figure 5.2: Oesophagectomy Morbidity Breakdown by Approach
Figure 5.3: Estimated Blood Loss During MIOs
Figure 5.4: Operative Time of MIOs
Figure 5.5: Operative Time of MIGs
Figure 6.1: Breakdown of Oesophagectomies by Approach
Figure 6.2: Breakdown of Gastrectomies by Approach
Figure 6.3: Patient Age Range undergoing Minimally Invasive Oesophagectomy and 
Gastrectomy
14
Figure 6.4: Major (Life threatening) and Minor (Hospital prolonging) Morbidity 
Related to Minimally Invasive Oesophagectomy (by Approach)
Figure 6.5: Estimated Blood Loss During Minimally Invasive Oesophagectomies 
Figure 6.6: Operative Times for Minimally Invasive Oesophageal Cancer Resections 
Figure 6.7: Operative Times for Minimally Invasive Gastric Cancer Resections 
Figure 7.1: Box Plot of MIO Operating Times by Centre 
Figure 7.2: Index Plot of Operating Times by Centre 
Figure 7.3: Index Operating (and included Anaesthetic) Time at Exeter 
Figure 7.4: Simple CUSUM Plot and CUSUM Analysis to detect a change of 2 
Standard Deviations
Figure 7.5: Exeter CUSUM Plot- Effect of changing the mean operative time (to 
detect a change of 2 standard deviations)
15
AJCC American Joint Committee on Cancer
ALS Association of Laparoscopic Surgeons of Great Britain and Ireland
ASA American Association of Anaesthetists
AUGIS Association of Upper Gastrointestinal Surgeons of Great Britain and
Ireland
CEBM Centre of Evidence Based Medicine 
Cl Confidence Interval (95% unless otherwise stated)
CLO Columnar Lined Oesophagus
CONSORT Consolidated Standards of Reporting Trials 
CRAM Cumulative Risk Adjusted Mortality
CRT Chemoradiotherapy
CT Computerised Tomography
CUSUM Cumulative Sum Control
ECF Epirubicin, Cisplatin and protracted 5- Fluorouracil
EGC Early Gastric Cancer
EMR Endoscopic Mucosal Resection
ESD Endoscopic Submucosal Dissection
EUS Endoscopic Ultrasound
GC Gastric Cancer
HGD High Grade Dysplasia
HR Hazard Ratio
HRQL Health related Quality of Life
IDEAL Idea, Development, Exploration, Assessment, Long-term study
JJC Japanese Joint Committee
MIG Minimally Invasive Gastrectomy
MIGOCS Minimally Invasive Gastro-Oesophageal Cancer Surgery
MIO Minimally Invasive Oesophagectomy
MIS Minimally Invasive Surgery
NICE National Institute for Clinical Excellence
OC Oesophageal Cancer
O-POSSUM Oesophago-Gastric Physiological and Operative Severity Score for the 
enumeration of Mortality and Morbidity 
OR Odds Ratio
Index o f  Abbreviations
16
pPDT
PET
POSSUM
RCT
RR
RTI
TNM
UICC
VLAD
Probability value 
Photodynamic Therapy 
Positron Emission Tomography
Physiological and Operative Severity Score for the enumeration of 
Mortality and Morbidity 
Randomised Controlled Trial 
Relative Risk 
Respiratory Tract Infection 
Tumour, Node, Metastasis 
International Union Against Cancer 
Variable Life-Adjusted Display
Chapter 1: Introduction
1.1 Gastric Cancer
1.1.1 D efinition and Epidem iology
Gastric cancer (GC) is defined by the World Health Organisation as “a malignant 
epithelial tumour of the gastric mucosa with glandular differentiation” (Fenogilo- 
Prieser 2000.) Worldwide, it is the second leading cause of cancer-specific mortality 
in men and fourth in women (Crew 2006,) representing 3% of all cancers in the UK. 
GC has an annual incidence of over 8,100 people and mortality of approximately 
5,700 people in the UK alone (Cancer Research UK, 2007.) This compares to 192,000 
new diagnoses and 158,000 deaths per annum in Europe; with a 5 year survival of 
around 20% (Allum 2008, Mitry 2008.) Gastric cancer rates are higher in men (17.6 
compared with 9.8 females, per 100,000 people newly diagnosed) (Office for Nat 
Statistics 2003;) and it is essentially a disease of older age, with over 80% cases 
diagnosed in people over the age of 65 (Cancer Research UK 2003, see figure 1.1.)
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Figure 1.1 New Gastric Cancer cases in the UK 2003 (Source: Cancer 
Research UK, 2003)
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Since 1975, gastric cancer incidence in the UK has been decreasing from an overall 
rate of 22 to 10 per 100,000 population (Cancer Research UK 2007.)
Worldwide, incidence of gastric cancer is highest in Japan (more than 40 per 100,000 
population,) Eastern Asia, Eastern Europe and South America; whereas North 
America (10 per 100,000 in Canada,) Northern Europe and Africa have amongst the 
lowest incidences (Fenogilo-Preiser 2000.) Striking differences between gastric 
cancer rates in East and Western countries are apparent, both in terms of its 
pathological distribution and survival (Maruyama 1987, Wan 2006.) These 
differences suggest that ethic origin may play a role in its pathogenesis; however they 
are not sustained for a prolonged time following a change of environment (Stadtlander 
1999, Terry 2002, Kelley 2003.)
Screening is limited to countries with high incidences of GC, such as Japan and China, 
where it is cost effective and up to 50-80% of cases are detected in the early stages 
(Fenogilo-Preiser 2000.) In America, where there is no formal screening programme, 
the American Society for Gastrointestinal Endoscopy recommends endoscopic 
surveillance of high-risk individuals (with a history of gastric adenoma; familial 
adenomatous polyposis syndrome; hereditary nonpolyposis colon cancer syndrome; 
Peutz-Jeghers syndrome and Metenier’s disease) every 1 to 2 years (Gore 1997.)
In the absence of formal screening programmes, the majority of cases of GC present 
late in an advanced pathological state -nearly 65% in the US present with T3/4 
tumours and 85% with lymph node metastases (Hundahl 2000.) For those that are 
suitable for surgery with curative intent, there is a 40-65% risk of relapse and 
metastasis; and a median survival of 2 years, with a 20-30% 5 year survival rate
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(MacDonald 2001.) Following palliative procedures, median survival is 8.1 months 
and for those having no intervention, median survival is only 5.4 months (Philip 1997, 
Doglietto 2000, Hartgrink 2002.)
The anatomical subsite distribution of GC has changed over recent years in Europe, 
with an increase in proximal, particularly cardia tumours and a decrease in distal 
tumours (Dolan K 1999.) This has lead to the suggestion that the rise in cardia 
tumours, along with adenocarcinoma of the lower oesophagus may be related to a 
concurrent rise in gastro-oesophageal reflux disease (Lagergren 1999.)
Cancers of the body and antrum of the stomach have been linked with Helicobacter 
pylori infection (EUROGAST 1993, Eslick 1999, Fenogilo-Preiser 2000.) Whether 
this is via a process of genetic mutation involving chronic gastritis is unclear; but H. 
pylori is thought to increase the risk of GC by two to threefold and is associated with 
both diffuse and intestinal types of cancer. Other possible aetiological factors include 
smoking (Haung 2000, Gonzalez 2003;) dietary fibre intake (Terry 2001;) alcohol (in 
cardia tumours) (WRCF&AICF 1997;) lower socioeconomic status (CRAG 2002;) 
and predisposing conditions such as previous gastric surgery (Lundegardh 1994,) 
peptic ulcer disease (Macintyre 1994) and pernicious anaemia (Ye 2003.) Most gastric 
cancers are sporadic, but 8-10% have an inherited familial component (Fenogilo- 
Preisner 2000.)
1.1.2 Diagnosis
Early gastric cancer tends to present with vague symptoms of uncomplicated 
dyspepsia. Non-specific symptoms (when the cancer is superficial and potentially
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curable) are present in up to 50% of cases (Gore 1997.) Awareness of these “at risk” 
patients is vital for early diagnosis and referral; and table 1.1 highlights recommended 
referral guidelines for General Practitioners by the Department of Health. These 
guidelines however were designed to identify symptoms that have a high correlation 
with gastric cancer i.e. they are almost exclusively symptoms of advanced disease. 
Therefore since the guidelines are based on health economics, they do in fact 
contribute little to detecting early disease.
Table 1.1 Guidelines for Referral of Upper Gastrointestinal Cancers (NHS 2000)
- Dysphagia
- Dyspepsia combined with 1 or more of these alarm symptoms:
- Weight loss
- Anaemia
- Anorexia
- Dyspepsia in a patient aged 55 years or more with at least 1 of the following 
“high risk” features:
- Onset of dyspepsia less than 1 year
- Continuous symptoms since onset
- Dyspepsia combined with at least 1 of the following known risk factors:
- Family history of upper gastrointestinal cancer in more than 1 first 
degree relative
- Barrett’s oesophagus
- Pernicious anaemia
- Peptic ulcer surgery over 20 years ago
- Known dysplasia
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- Atrophic gastritis
- Intestinal metaplasia
- Jaundice
- Upper abdominal mass
Symptoms progress as the disease advances to cause anaemia, dysphagia, early satiety, 
weight loss, abdominal pain, vomiting and anorexia. Ulcerated tumours may result in 
bleeding, which can range from occult to massive.
Physical examination of early gastric cancer patients is often unremarkable. More 
advanced patients may demonstrate cachexia, lower extremity oedema, a palpable 
tumour mass, hepatomegaly, ascites or bowel obstruction. Lymphadenopathy may be 
present in the left axilla, left supraclavicular fossa (Virchow’s node,) and in advanced 
(metastatic) cases, a periumbilical (Sister Mary Joseph’s) nodule may be detected. 
Peritoneal seeding may result in ovarian involvement (Krukenberg tumour) or 
Blumer’s rectal shelf (drop metastasis into the peritoneal reflection in the prerectal 
and post-vesical space.) Advanced cases may rarely present with paraneoplastic 
syndromes such as cutaneous syndromes (dermatomyositis or acanthosis nigricans,) 
microangiopathic haemolytic anaemia, and chronic intravascular coagulation leading 
to venous and arterial thrombi (Trousseau’s syndrome.)
The gold standard investigation of GC is flexible endoscopy with biopsy. Clinical 
diagnosis is very inaccurate in distinguishing with pathological disease and therefore 
all “at risk” patients with reflux symptoms should be considered for endoscopy, 
despite an overall detection rate of 1-2% (Allum 2002.) Further information for 
staging the tumour varies between centres but generally includes endoscopic
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ultrasound (EUS,) computed tomography (CT,) staging laparoscopy +/- positron 
emission tomography (PET) scanning.
Screening for GC is controversial and at present only practised in countries with a 
high incidence of the disease such as Japan. This can be done by endoscopy, indirect 
photofluoroscopy or potentially by measuring serum pepsinogen concentration. 
Pepsinogen is a good marker as its levels are increased by H. pylori, which is 
responsible for gastric inflammation and glandular atrophy. This in turn may develop 
into GC when severe and extensive (Dinis-Riberio 2004, Yoshihara 2007.) (The 
pepsinogen I/Pepsinogen II ratio for atrophic gastritis has sensitivity of 96.1% and 
specificity of 97.7%; separately pepsinogen I has the highest specificity of 90.7% and 
pepsinogen II has a high sensitivity of 90.7% (Ivani 2010.)
1.1.3 Pathology
Ninety percent of gastric tumours are malignant and of these 95% are gastric 
adenocarcinomas (Schwartz 1996.) Although the stomach does not normally contain 
lymphoid tissue, it is the commonest site for gastrointestinal lymphomas. Other 
malignancies include squamous cell carcinoma, carcinoid tumours, adenoacanthoma 
and leiomyosarcoma. Gastric tumours can further classified by gross morphological 
and histopathological features: 
i) Macroscopic Classification (Bormann 1926)
- type I polypoid: well circumscribed polypoid tumours
- type II fungating: polypoid tumours with marked centre infiltration
- type III ulcerated: ulcerated tumours with infiltrative margins
- type IV: infiltrating: linitis plastica
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The Lauren classification is one of the commonest histological grading used, 
distinguishing gastric adenocarcinomas into two types: intestinal and diffuse (Lauren 
1965.)
Intestinal (well-differentiated) tumours consist of big irregular nuclei in large, distinct 
cells; which form gland-like tubular structures through cell cohesion. Diffuse 
(undifferentiated) tumours consist of small isolated cells or cell clusters, arranged in a 
non-polarised fashion; these tend to be associated with early metastasis and a more 
aggressive clinical course (Lauren 1965, Munoz 1968.)
Further microscopic classification (in addition to the intestinal and diffuse types 
described above) based on tumour morphology has been proposed by the World 
Health Organisation:
- papillary adenocarcinoma (exophytic lesions with long, fine or plump finger­
like processes containing connective tissue and fibrovascular cores)
- tubular adenocarcinoma (well-defined glandular lumens)
- mucinous/ colloid adenocarcinoma (greater than 50% intra-cellular mucin 
contain in the lesion.)
- signet-ring cell carcinoma (greater than 50% signet-ring cells, with the cell 
nucleus compressed to the edge of the cell by cytoplasm unsecreted mucin.) 
This type of morphology often demonstrates marked desmoplasia and an 
infiltrative gross appearance. Intramural spread, not involving the mucosa, can 
appear to form a linitis plastica-type tumour.
- adenosquamous carcinoma 
squamous cell carcinoma
ii) Microscopic Classification
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small cell carcinoma
- undifferentiated carcinoma (containing no glandular or other features such as 
mucus secretions.)
- other
Pre-Cursor Lesions
Based on studies of chronic Helicobacter pylori and its well established association 
with the development of gastric cancer (Forman 1991, Parsonnet 1991, EUROGAST 
1993,) the Correa hypothesis was proposed. This model suggests that there is 
progression from chronic gastritis to gastric atrophy with intestinal metaplasia to 
dysplasia prior to malignancy (Correa 1988.) Since gastric mucosa atrophy occurs 
with age some early phases of the process may be reversible. It is also unclear at 
present the relationship between intestinal metaplasia and intestinal dysplasia. 
Dysplasia grading itself is difficult and open to considerable inter-observer variation, 
with the higher grades being more likely to contain adenocarcinomas cells.
Early Gastric Cancer (EGC)
The term early gastric cancer originated in Japan and refers to adenocarcinomas 
confined to the mucosa or submucosa regardless of the presence, or absence of lymph 
node metastasis (Hirota 1993.) EGC is classified according to the Japanese 
Gastroenterological Endoscopic Society based on the tumour’s gross appearance into 
3 types (Murakami 1971):
- Type I polypoid: the tumour is greater than 0.5cm above the mucosal surface
- Type II superficial:
Type Ha elevated: flat elevation, thickening the mucosa less than 
0.5cm
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Type lib flat: no or minimal mucosa heightening
Type lie depressed: superficial, slightly depressed mucosal erosion
- Type III excavated: prominent, ulcer-like excavation/depression of the mucosa
Screening and intensive case finding coupled with heightened population awareness 
has resulted in a higher percentage of EGC diagnosed in Japan compared with 
Western countries. This in turn means more patients are suitable for curative surgery 
and improved surgical outcomes.
Grading
Adenocarcinoma grades are based on the degree of glandular differentiation into well, 
moderately and poor differentiated subtypes:
Grade X: cannot be assessed
- Grade 1: well-differentiated (tumour comprises more than 95% of glands)
- Grade 2: moderately differentiated (tumour comprises 50-95% of glands)
- Grade 3: poorly differentiated (tumour comprises less than 49% of glands)
Staging
Treatment decisions are usually formed referring to the American Joint Committee on 
Cancer (AJCC) and the International Union Against Cancer (UICC) (Green 2002, 
UICC 2002.) The Japanese have a separate classification system for gastric cancer 
patients, formed in association with the Japanese Gastric Cancer Association (JGCA 
1998.) The main difference between the two systems is derived from the classification 
of lymph nodes, the UICC utilises the number of involved lymph nodes, whereas the 
JGCA system uses the site and distance of metastatic lymph nodes from the primary 
tumour.
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Tumour stage assessed prior to intervention is given the prefix V  (‘clinical’), 
postoperatively by a ‘p’ and during or after neoadjuvant treatment by a ‘y \
TNM Classification (UICC 2002)
- Primary Tumour (T)
Tx -  primary tumour cannot be assessed 
TO - no evidence of primary tumour
Tis -  carcinoma in situ: intraepithelial tumour without invasion of the 
lamina propria
T1 - tumour invades lamina propria or submucosa 
T2 -  tumour invades the muscularis propria or submucosa 
T2a -  tumour invades muscularis propria 
T2b -  tumour invades subserosa
T3 -  tumour penetrates the serosa (visceral peritoneum) without
invasion of adjacent structures
T4 -  tumour directly invades adjacent structures
- Regional Lymph Nodes (N)
A minimum of 15 should be examined. Nodes included are: perigastric nodes 
along the greater and lesser curvature; and the nodes along the left gastric, 
common hepatic, splenic and coeliac arteries.)
Nx -  regional lymph node(s) cannot be assessed 
NO -  no regional lymph node metastasis 
N1 -  metastasis in 1-6 regional lymph nodes 
N2 -  metastasis in 7-15 regional lymph nodes 
N3 -  metastasis in more than 15 regional lymph nodes
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- Distant Metastasis (M)
Mx -  presence of distant metastasis cannot be assessed 
MO -  no distant metastasis 
Ml -  distant metastasis
(n.b. In 2010, subsequent to data collection for this thesis the TNM grading system 
has undergone further alteration.)
Lymph Node Tiers according to Japanese Rules 
Lymph node station 
Nl: 1. Right cardiac
2. Left cardiac
3. Lesser curve
4. Greater curve
5. Suprapyloric
6. Inffapyloric
N2: 7. Left gastric artery
8. Common hepatic artery
9. Coeliac axis
10. Splenic hilum
11. Splenic artery
N3: 12. Hepatoduodenal ligament 15. Middle colic artery
13. Retropancreatic 16. Para-aortic
14. Superior mesenteric artery
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Table 1.2: Stage Groupings of Gastric Cancer
Stage Tumour Nodes Metastasis 5 year survival (%) 
Post surgery
0 Tis NO MO 99
la T1 NO MO 99
lb T1 N1 MO 90
T2a/b NO MO 88
II T1 N2 MO 79
T2a/b N1 MO 71
T3 NO MO 69
IIIA T2a/b N2 MO 52
T3 N1 MO 46
T4 NO MO 52
IIIB T3 N2 MO 23
T4 N1 MO 26
T4 N2 MO 16
IV Any T Any N Ml 10
Data for 5 year survival post-surgery from Maruyama et al 1986
1.1.4 Treatment
A multidisciplinary approach regarding treatment planning of all patients with gastric 
cancer is considered mandatory to guarantee optimal quality of care. All management 
decisions and standards for potentially curative therapy involve members of a 
specialist team who are involved in policy decisions and adhere to a documented 
clinical policy agreed throughout each cancer network. All outcomes are audited and 
participation in National data collection and clinical trials are encouraged. The 
specialist oesophago-gastric cancer team includes: oesophagogastric surgeons;
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medical gastroenterologists; oncologists; radiologists; pathologists; clinical nurse 
specialists and anaesthetists.
All potential curative therapy options are reviewed in the context of a subjective and 
objective assessment of patients’ physical and mental fitness before reaching a group 
MDT decision. This allows appropriate treatment and increased continuity of care for 
the patient. Increased specialisation has improved trial recruitment; training and 
research opportunities; and provided better perioperative and overall patient outcome.
Surgical resection of the primary tumour and regional lymph nodes remains the 
treatment of choice for gastric cancer and is recommended for stages Tis-T3 N0-N2 
MO or T4N0M0 (ESMO 2005.) Options of adjuvant or neoadjuvant therapy (in 
addition to surgery) should also be considered in view of the high frequency of 
relapses following surgery (Lim 2005.)
Although the treatment determines patient prognosis to a large extent, other factors 
such as patient co-morbidity (Prytherch 1998) and tumour stage (Siewert 1998, 
Adachi 2000) at presentation play an important role. Current staging modalities 
focusing on tumour invasion and lymph node involvement do not take these factors 
into account. Nomograms, which provide individual prognosis based on prognostic 
variables, are therefore being developed (Kattan 2003.) The nomograms assist in 
patient counselling, follow-up scheduling and clinical trial determination. They have 
been developed for several tumours and have been shown to provide better 
discriminating predictions, regardless of the extent of lymphadenectomy than the 
AJCC staging system (Peeters 2005.)
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Although surgery remains the mainstay of treatment for gastric cancer, non-surgical 
options, such as chemoradiotherapy and endoscopic therapy (with curative intent) for 
HGD and early gastric cancer are available (see under oesophageal cancer treatment 
for more details of the latter.) However, chemoradiotherapy, chemotherapy or 
radiotherapy alone, without surgery demonstrate no survival benefit in patients with 
gastric cancer (SIGN 2002.)
Potentially Curative Treatment
Neo-adjuvant therapy (chemotherapy, chemoradiotherapy, radiation, or 
immunotherapy, either alone, or in combination) has been used in those with locally 
advanced tumours or with high risk of recurrence. In this setting, chemotherapy may 
allow down-staging of an unresectable primary tumour prior to surgery or eradicate 
occult micrometastatic disease.
Perioperative Adjuvant Chemotherapy
The aim of systemic therapy for gastric cancer is to reduce the chances of recurrence 
following successful surgical resection. Neo-adjuvant treatment has been shown to 
increase the survival outcome of selected patients (Sun 2009) and perioperative 
chemotherapy plus surgery has been adopted as standard practice in the UK (Rao 
2008.)
The MRC ST02 (MAGIC) randomised controlled trial compared gastric cancer 
surgery alone with 3 cycles of pre and post-operative chemotherapy - ECF (epirubicin, 
cisplatin and protracted 5-FU) - combined with surgery (Cunningham 2003,2006, 
Chua 2007.) There were 253 and 250 patients respectively in each arm and the 
primary trial endpoint was overall survival. The trial demonstrated perioperative
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chemotherapy significantly downstaged T and N stage; improved resectability (by 
10%;) progression-free (HR 0.66; 95% Cl 0.53-0.81; p <0.001) and overall survival 
(HR for death 0.75; 95% Cl 0.60-0.93; p= 0.009;) with an acceptable postoperative 
mortality rate of 6%. Five year survival increased in the trial from 23% in the control 
group to 36% in those treated by perioperative chemotherapy. Decreased patient 
tolerance to chemotherapy was however noted early post-gastrectomy (possibly 
related to poor food intake capacity) with only 40% patients receiving both cycles of 
postoperative treatment. The trial recommended considering ECF as standard 
perioperative chemotherapy treatment for resectable gastric cancer. Further trials 
such as the MRC ST03 (looking at bevacizumab) are currently evaluating different 
chemotherapy regimes.
A recent meta-analysis of 17 randomised controlled trials (3838 patients) with a 
median follow up of 7 years demonstrated that postoperative adjuvant chemotherapy 
based on a fluorouracil regime was associated with reduced risk of death in patients 
with gastric cancer compared to surgery alone (GASTRIC Group 2010.) Adjuvant 
chemotherapy was associated with a statistically significant benefit in terms of overall 
survival (HR, 0.82; 95% Cl 0.76-0.90; P0.001) and disease-free survival (HR, 0.82; 
95% Cl 0.75-0.90; P < 0.001;) five year survival increased from 49.6% to 55.3% with 
chemotherapy.
Intraperitoneal Chemotherapy
Intraperitoneal chemotherapy is attractive in view of the pattern of hepatic and 
peritoneal recurrence in gastric cancer. The most positive trial comes from Japan and 
utilises mitomycin C (Hagiwara 1992.) Fifty patients with serosal involvement were
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randomised to receive immediate treatment or observation. At 2 years, survival was 
68.6% v 26.9%, with the treatment group maintaining an advantage at 3 years. 
Treatment was reported to be well tolerated. However a subsequent trial aiming to 
repeat these results was suspended due to serious toxicity (Rosen 1998.)
A recent systematic review of intraperitoneal chemotherapy identified 14 studies, 
involving 914 patients with gastric cancer, 819 of them receiving intraperitoneal 
chemotherapy (Matharu 2011.) Twelve studies were rated methodologically poor and 
there were 2 randomised controlled trials. In the better conducted trials it was 
concluded that intraperitoneal chemotherapy and surgery prolonged survival more 
than surgery alone.
Postoperative Chemoradiotherapy
Radiotherapy is not routinely used in gastric cancer treatment. The US Gl-Intergroup 
INT 0116 (SWOG 9008) study compared surgery alone to postoperative 
chemoradiotherapy (Macdonald 2001.) Following a median follow up of 3.3 years, 
the trial demonstrated an improved disease-free survival (49% v 32%) and a 9% 
overall survival benefit (52% v 41%) in the chemoradiotherapy arm. Although 
treatment related mortality was only 1%, significant gastrointestinal and 
haematological morbidity occurred (73% having grade 3 or 4 toxicity) and only 64% 
completed chemoradiotherapy treatment. A criticism of this trial is that 54% of 
patients receiving surgery alone had a DO resection, which does not translate into 
routine practice. (This was verified in a subsequent paper by the group utilising the 
Maryuama Index, confirming that surgical undertreatment clearly undermines 
survival — Hundahl 2002.)
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A recent study by Dikken et al suggested that adjuvant chemoradiotherapy provides 
survival andnrecurrence benefit over D1 but not D2 resections i.e. limited but not 
systematic lymphadenectomies (Dikken 2010.) Ninety one patients with gastric 
adenocarcinomas undergoing surgery with chemoradiotherapy were compared to 694 
patients from the Dutch Gastric Cancer group trial (Bonenkamp 1999) with a median 
follow-up of 19 months. Local recurrence after 2 years was significantly earlier in the 
surgery alone group (17% v 5%; p= 0.0015.) Separate analysis of patients who 
underwent D1 resection showed fewer recurrences after chemoradiotherapy (2% v 8%; 
p= 0.001;) whereas comparison of the D2 groups demonstrated no significant 
difference. Furthermore, chemoradiotherapy significantly improved survival after a 
microscopically irradical (Rl) resection.
Palliative Chemotherapy
In cases of stage IV (metastatic) gastric cancer, palliative chemotherapy should be 
considered (Van Cutsem 2008) with ECF regimes being the gold standard in the UK. 
Early randomised trials of palliative chemotherapy versus best supportive care clearly 
show improved survival (8-12 months compared with 3-5 months) (Murad 1993, 
Pyronen 1995, Glimelius 1997.)
A Cochrane review by Wagner et al involving 27 studies aimed to assess and compare 
the efficacy and tolerability of chemotherapy in patients with advanced gastric cancer 
(Wagner 2006.) Analysis of chemotherapy versus best supportive care (HR= 0.39; 95% 
Cl 0.28-0.52) and combination versus single agent, mainly fluorouracil-based 
chemotherapy (HR=0.83; 95% Cl 0.74-0.93) for advance gastric cancer, demonstrated 
significant overall survival benefits in favour of chemotherapy and combination 
chemotherapy respectively.
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Surgical Treatment
Surgery is the cornerstone of management in patients with resectable gastric tumours, 
aiming for tumour free-margins combined with at least D1 resection (1 field 
lymphadenectomy.) It remains the only potential curative option and is recommended 
for gastric cancer stages Tis-T3N0-N2M0 or T4NOMO (ESMO 2005) and will be 
discussed further in chapter 1.4.
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1.2 Oesophageal Cancer
1.2.1 Definition and Epidemiology
Oesophageal cancer (OC) is defined as a neoplasm arising from the oesophageal 
submucosa. It is the ninth commonest cancer diagnosed in the UK and represents 3% 
of all cancer deaths (Cancer Research UK, 2007.) Worldwide, OC is the fourth most 
common cancer diagnosed in men, and wide variation occurs between countries and 
ethnic groups. The highest reported worldwide incidence occurs in the so-called Asian 
“oesophageal cancer belt,” which stretches from eastern Turkey, through north­
eastern Iran, northern Afghanistan and southern Russia to northern China.
The incidence of oesophageal cancer per annum in the UK is greater than 7,600 
persons and mortality is around 7,400; with the highest rates being recorded in 
Scotland (Cancer Research UK 2002.) This rate has steadily increased over the last 
twenty five years, particularly in men, rising from 8.8 to 14.2 per 100,000 population 
between 1975 and 2004 (European age-standardised,) with a corresponding female 
rate rising from 4.8 to 5.6. The male to female ratio has increased over recent years 
with a 5 to 10 fold ratio being reported for adenocarcinomas (Cancer Research UK 
2007.) The risk of cancer increases with age, with few people diagnosed before the 
age of 40 years (see figure below.)
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Figure 1.2: New Oesophageal Cancer cases in the UK, 2004 (Source: 
Cancer Research UK 2007)
Etiological causative factors differ between squamous and adenocarcinomas of the 
oesophagus. Alcohol, tobacco, social deprivation and male sex have all been 
demonstrated as risk factors for squamous cell carcinomas (Lagergren 2000, CRAG
2002, Engel 2003;) as well as predisposing conditions such as pernicious anaemia (Ye
2003. ) Adenocarcinomas have been linked to obesity, gastro-oesophageal reflux 
(Chow 1998, Lagergren 1999) and Barrett’s oesophagus (Dulai 2002.)
1.2.2 Diagnosis
Most patients with oesophageal cancer present with dysphagia with/without 
odynophagia. Weight loss is frequently associated and is an independent indicator of 
poor prognosis- especially if the body mass lost is greater than 10% (Fein 1985.) 
Other symptoms include those similar to chronic gastro-oesophageal reflux (although 
cancer is uncommon in this group of patients (Shaheen 2002;) dyspnoea, cough, 
hoarseness; back, retrosternal or right upper abdominal pain, may also feature and 
reflect the presence of unresectable disease.
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Physical examination of OC patients is often unremarkable, although metastatic 
disease may result in lymphadenopathy (particularly Virchow’s node), hepatomegaly 
and pleural effusions.
The gold standard of diagnosis is oesophageal endoscopy, which may reveal a friable, 
ulcerated lesion, and biopsy. Further investigations which assist in staging patients 
include CT scan, EUS, PET (+/- CT), bone scintography and laparoscopy +/- 
peritoneal washings. Despite this, shortcomings in clinical staging persist in up to 25- 
35% of patients (Krasna 1996.) This may result in either unnecessary operations 
(understaging) or overstaging which denies patients potentially curative surgery 
(Holsher 1994.)
Population-based screening is untenable except in certain high risk areas such as 
Anyang County, China (Yang 2002.) This is due to the relatively low incidence of 
oesophageal carcinoma, minimal early symptoms and rarity of hereditary disease 
(Jochem 1992, Risk 1999, Lagergren 2000.)
Current chemoprevention trials targeted at oesophageal cancer are mostly aimed at 
patients with Barrett’s oesophagus, where it has been demonstrated that cancer 
incidence could decrease as much as 45% (Jankowski 2004.) Two large randomised 
trials at present are looking at this group of patients: the Barrett’s Oesophagus 
Surveillance Study (BOSS) (Bampton 2005) and the Aspirin Esomeprazole 
Chemoprevention Trial (AspECT) (Jankowski 2006,) their results are eagerly awaited.
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1.2.3 Pathology
More than 90% of oesophageal cancers are squamous-cell carcinomas or 
adenocarcinomas (Daly 2000.) Other rarer types of oesophageal cancer include: 
melanoma, leiomyosarcoma, carcinoid and lymphomas.
In the West over the last 25 years, the incidence of adenocarcinoma has increased and 
surpassed that of squamous cell carcinoma (Devesa 1998, Law 2005.)
The cervical oesophagus is an uncommon site of disease; three-quarter of 
adenocarcinomas are found in the distal oesophagus, whereas squamous-cell 
carcinomas are found equally in the middle and lower oesophagus (Daly 2000, 
Siewart 2001.) The incidence of distal adenocarcinomas of the oesophagus, 
specifically oesophago-gastric junctional tumours has increased; suggesting an 
association with a concurrent rise in gastro-oesophageal reflux disease (Lagergren 
1999.)
Metaplasia-Dysplasia-Carcinoma Sequence
Progression of columnar lined oesophageal epithelium to cancer is thought to occur as 
a result of locally produced cytokines, oxidative damage and bile acids in the 
refluxate. These create a microenvironment which stimulates metaplastic stem cells in 
a stepwise progression via molecular events through metaplasia, dysplasia and 
eventually adenocarcinoma (Jankowski 1999.)
Dysplasia is defined as “an unequivocal neoplastic alteration of epithelium which has 
the potential to progress to invasive malignancy but remains confined within the 
basement membrane within which it arose” (Riddell 1983.) It can further be classified 
according to nuclear and cytoplasmic architectural dysmaturation into low or high 
grade (low grade being a more stable phenomenon.)
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The natural history of low grade dysplasia is still not fully understood. The majority 
of patients remain stable or regress to Barrett’s metaplasia without dysplasia; however 
the risk of progression to high grade dysplasia or cancer is between 10-28% (Sharma 
2006, Lim 2007.)
High grade dysplasia (HGD) is associated with a focus of invasive adenocarcinoma in 
30-40% of patients (Barr 2005.) Therefore if persistent, HGD should be considered 
for resection or ablation. Once cancer develops it may spread rapidly; 14-21% of T1 
(submucosal) lesions and 38-60% of T2 lesions (invading muscle) will spread to 
lymph nodes (Collard 2001, Siewart 2001.)
Barrett’s Oesophagus
Barrett’s oesophagus is defined as “a metaplastic condition in which any part of the 
normal squamous epithelium has been replaced by macroscopically visible columnar 
epithelium which is histologically confirmed” (Gillies 2010.) In the UK, the diagnosis 
does not need the histological identification of specialist intestinal metaplasia (Watson 
2005,) unlike other parts of the world, such as the USA (Sampliner 1998.)
At endoscopy, Barrett’s oesophagus is visualised as an irregular edge of pink mucosa 
with interspersed tongues of columnar epithelium in otherwise normal pale squamous 
epithelium. Standard measurement of the extent of Barrett’s oesophagus uses the 
Prague C&M criteria (Sharma 2006.) This measures the circumferential (C value) and 
maximum extent (M value) of columnar mucosa above the gastro-oesophageal 
junction.
40
Barrett’s oesophagus is characterised by three histological types:
i) gastric fundal type epithelium with mucus secreting cells
ii) gastric junctional type epithelium with mucus secreting cells
iii) specialised columnar epithelium with mucus secreting goblet cells 
amounting to intestinal metaplasia.
The mucosal instability of Barrett’s oesophagus, especially in longer segments 
increases the risk of progression to dysplasia and thus carcinoma - the risk of cancer 
being 30-125 times higher than in the general population, or 0.5% per annum 
(Theisen 2004.)
The screening of individuals with chronic reflux symptoms to detect Barrett’s 
oesophagus or cancer is not currently recommended in the UK (Loft 2005.) However 
current UK guidelines recommend individuals with Barrett’s oesophagus without 
dysplasia should undergo surveillance endoscopy every 2 years. This is based on a 
computerised mathematical model assuming a risk of approximately 1% per annum of 
developing adenocarcinomas in Barrett’s oesophagus (Loft 2005.) Biopsies should be 
taken from all 4 quadrants of the oesophagus at 2cm intervals, obtaining at least 8 
biopsies to confidently diagnose Barrett’s oesophagus (Harrison 2007.)
The management of HGD remains controversial (Barr 2006.) Traditionally patients 
who were fit enough underwent an oesophagectomy. More recently endotherapy 
techniques, including endoscopic mucosal resection (EMR) have been used as an 
attractive alternative to radical surgery; however their long-term efficacy remains 
unclear (Das 2008.)
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Staging
Oesophageal cancer is staged according to the UICC guidelines, assisting treatment 
decisions (and prognosis.)
(Similar to gastric cancer, in 2010, the TNM classification of oesophageal cancer has 
undergone modification following data collation for this thesis.)
TNM Classification (UICC 2005)
- Primary Tumour (T)
Tx -  primary tumour cannot be assessed
TO -  no evidence of primary tumour
T1 - tumour invades lamina propria or submucosa
T2 -  tumour invades the muscularis propria or submucosa
T3 -  tumour penetrates the serosa
T4 -  tumour invades adjacent structures
Regional lymph nodes (N)
Nx -  lymph nodes cannot be assessed 
NO -  no lymph node metastasis 
N 1 -  distant metastasis 
Distant metastasis (M)
Mx -  presence of distant metastasis cannot be assessed 
MO -  no distant metastasis
Tumours of the lower oesophagus: Mia -  coeliac node involvement
Mlb -  other distant metastasis
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Tumours of the thoracic oesophagus: Mlb -  distant metastasis including non- 
regional lymph nodes
Tumours of the upper thoracic oesophagus: Mia -  cervical node involvement
Mlb -  other distant metastasis
Table 1.3: Stage Grouping of Oesophageal Cancer
Stage Tumour Node Metastasis 5 Year Survival (%)*
0 Tis NO M0 >95
I T1 NO M0 50-80
IIA T2-3 NO M0 30-40
IIB Tl-2 N1 M0 10-30
III T3 N1 M0 10-15
T4 Any N M0
IVA Any T Any N Mia <5
IVB Any T Any N M2b <1
* Data from Enzinger P. et al (2003)
1.2.5 Treatment
As with gastric cancer, a multidisciplinary approach should be taken to decide the 
management of oesophageal cancer patients (Adams 2006.) With improved diagnosis, 
staging and treatment there has been a small but significant improvement in survival 
from oesophageal malignancy over recent years. At present the treatment of locally 
advanced oesophageal cancer results in 5 year survival rates of 15-20% (Graham 
2007.)
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Overall, more than 50% of patients have unresectable or metastatic disease at 
presentation (Enzinger 2003;) and lymphatic dissemination is an early event, with 
positive lymph nodes being present in 30-40% of early (submucosal) tumours 
(Akiyama 1994.)
Although both squamous cell carcinoma and adenocarcinoma of the oesophagus are 
responsive to chemotherapy, the treatment of choice remains surgical resection with 
curative intent. (Surgery will be considered later in this chapter.)
Potentially Curative Treatment 
Preoperative Radiotherapy
The theoretical advantages of preoperative radiotherapy include: a more easily 
defined target volume; improved tumour oxygenation at treatment; potential to reduce 
pre-operative tumour volume and peri-operative tumour cell spillage; reducing the 
likelihood of microscopic residual disease and local recurrence.
A meta-analysis of 5 randomised trials from 1147 patients in randomised trials 
compared the outcome of preoperative radiotherapy to immediate surgery (Amott 
2005.) It reported a hazard ratio of 0.89 (95% Cl 0.78-1.01) with an absolute survival 
benefit of 4% at 5 years; which did not meet statistical significance. This would 
indicate minimal benefit with little evidence of improved respectability.
Postoperative Radiotherapy
Postoperative radiotherapy has the advantage of targeted use for selected patients at 
higher risk of recurrence. Most randomised controlled studies include only squamous 
cell carcinomas. Fok et al prospectively looked at adenocarcinomas and squamous 
cell carcinoma in 130 patients (Fok 1993.) Both curative and palliative resections
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were studied (although different radiotherapy doses were administered and groups 
were analysed separately.) In the study, significant morbidity (37%) and mortality 
(21%) related to bleeding from the transposed intrathoracic stomach. The median 
overall survival was shorter in the radiotherapy group (8.7 months v 15.2 months;) 
however there was a lower intrathoracic recurrence rate (5.1 v 8.5 months in the 
palliative resection group, although similar - 9.9 v 11.0 months in the curative 
resection group.) Of note, the radiation dose per fraction (3.5Gy) was high and this 
may have impacted on results.
A larger Chinese trial (Xiao 2003) included 495 patients randomised to surgery alone 
or surgery and postoperative radiotherapy. This produced significant results although 
had questionable ethics (patients were unaware of being in a trial.) Compared to the 
UK population a higher proportion of stage Ila disease was included, with apparent 
high quality surgery and wide field radiotherapy. Analysis of results showed 1-, 3- 
and 5-year survival in stage II disease between the surgery and surgery with 
postoperative radiotherapy groups (67.5%, 23.3%, 13.1% v 75.5%, 43.2%, 35.1% 
respectively.) Relapse patterns were different in both arms, with significantly less 
recurrence in the neck, supraclavicular fossa and mediastinum. Unlike other studies, 
toxicity to the transposed stomach was minimal.
There is reasonable evidence therefore to suggest postoperative radiotherapy may be 
of benefit to stage II squamous carcinoma of the oesophagus. In the UK however 
many patients will have received preoperative chemotherapy and so the addition of 
postoperative radiotherapy is outside current evidence base. Furthermore the benefit 
for patients with adenocarcinomas and its justification is less clear outside the context 
of a clinical trial.
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Preoperative chemotherapy aims to downstage tumours, thereby improving 
operability and to treat occult disease as early as possible in order to reduce 
recurrence. In some patients it may improve swallowing and so improve weight and 
nutritional status preoperatively. However in non-responders are exposed to 
chemotherapy side-effects as well as delays in surgical intervention. Preoperative 
chemotherapy appears to achieve consistently good response rates in both 
adenocarcinomas and squamous cell carcinoma, ranging from 47% (Schlag 1992) to 
61%(Bamias 1996.)
The Medical Research Council (MRC) 0E02 study is the largest and probably most 
influential trial on this topic (forming the basis of recommended treatment in the UK 
— SIGN 2002.) Eight hundred and two patients were randomised to 2 courses of 
cisplatin and a 4 day infusion of 5-FU followed 3-5 weeks later by surgery or 
immediate surgery alone. A 5-year survival benefit was demonstrated to be 23.0% v 
17.1% respectively with a HR of 0.84 (95% Cl 0.72-0.98.) The treatment effect was 
found to be consistent for both squamous and adenocarcinomas. The current OE05 
study aims to build on these results comparing OE02 chemotherapy with 4 cycles of 
ECX (epirubicin-cisplatin-capecitabine) with a trial target of 1300 randomised 
patients.
An updated Cochrane review (Malthaner 2006) of 11 randomised trials involving 
2019 patients concludes that there is some evidence to suggest that preoperative 
chemotherapy increases survival but this was inconclusive (HR 0.88; 95% Cl 0.75- 
1.04.) In addition there was no evidence of benefit in terms of tumour recurrence from 
preoperative chemotherapy (RR 0.81; 95% Cl 0.54- 1.22.) Trials reported toxicity 
risks from chemotherapy that ranged from 11%-90%.
Preoperative Chemotherapy
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Few trials address the question of adjuvant postoperative chemotherapy. The 
American Intergroup Trial (INTO 113) had an adjuvant component coupled with 
preoperative treatment, however only 32% completed the postoperative phase (Kelsen 
2007.) This highlights problems with this type of approach, especially in a patient 
group that often has a prolonged postoperative phase in which performance status 
often delays chemotherapy. Improved patient selection and postoperative supportive 
care may make this approach more practical.
Preoperative Chemoradiotherapy (CRT)
The combined effects of chemotherapy and radiotherapy aims to enhance tumour cell 
death and improve outcome.
The Walsh study has influenced practice especially in America (Walsh 1996.) In the 
trial, 113 patients with adenocarcinomas received cisplatin and 5-FU with 40 Gy in 3 
weeks of radiotherapy. The CRT arm had an overall survival benefit (median 16 v 11 
months; 3 year survival 32% v 6%.) Radiotherapy technique and fractionation dose 
may explain the not inconsiderable morbidity (13%) in this series; and the poor 
survival in the surgery arm of the trial is also notable compared to other trials.
Consistent pathology reporting is vital and grading of response has been described by 
Mandard et al (Mandardl994.) Five response grades are described from no 
identifiable tumour (complete response, grade 1) to absence of regression (no 
response, grade 5.) This paper, looking at clinicopathological correlations following 
preoperative chemoradiotherapy, demonstrates evidence that pathological complete 
response confers survival advantage over those with no response; (tumour regression
Postoperative Chemotherapy
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grade 1-3 versus 4-5 after multivariate analysis was a significant, p<0.001, predictor 
of disease-free survival.)
A systematic overview of preoperative chemoradiotherapy by Geh et al analysed 26 
trials (1335 patients) for factors influencing pathological complete response (Geh 
2006.) It found evidence that increasing radiotherapy dose (p= 0.006,) 5-FU doses (p= 
0.003) and cisplatin (p= 0.018) are linked to higher response rates. However 
increasing radiotherapy treatment time (p=0.035) and increasing median age (p=0.019) 
reduced the probability of complete pathological response.
Neoadjuvant Chemotherapy or Chemoradiotherapy?
A review by Courrech Staal et al looked at 38 papers, involving 3640 patients 
receiving neoadjuvant CRT for oesophageal cancer (Courrech Staal 2010.) Toxicity 
was reported in 10 papers (mostly neutropaenia) and CRT treatment related mortality 
was 2-3%, (post-operative mortality was not uniformly reported, but in hospital post- 
oesophagectomy mortality post chemotherapy was 5.2%.) R0 and complete response 
rates were 88.4% and 25.8% respectively; and 5-year survival was 16-59% in all 
patients and 34-62% in the complete response group. The authors concluded that 
chemoradiotherapy has a temporary negative effect on quality of life.
Overall, precise results regarding neo-adjuvant chemoradiotherapy are conflicting and 
the survival benefits seem to be minimal (Fiorica 2004, Greer 2005, Graham 2007.) 
Surgery alone for stage III disease is not likely however to be considered acceptable 
in the UK or America. The good outcomes of surgery alone in stage I and II disease 
make neoadjuvant therapy more difficult to justify.
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Reports of early experiences of CRT in the UK in terms of operative risk and toxicity 
vary considerably. The results of 0E02 have meant that UK centres have continued 
with a chemotherapy approach in the current 0E05 study.
Definitive Chemoradiotherapy
With an increasingly elderly population there will be greater numbers of patients 
“inoperable” on the basis of local disease, co-morbidity and performance status that 
would benefit from treatment that is not considered palliative. Indeed it is clear that 
there are long term survivors in series of definitive non-surgical management (Earlam 
1980, Al-Sarraf 1997.) In squamous carcinoma (where lymph node spread is 
unpredictable) there is increasing evidence that primary CRT with surgery as salvage 
may be beneficial (Wilson 2000, Bedenne 2007.)
A study by Teoh et al compared the quality of life in 81 prospectively randomised 
patients with squamous oesophageal cancer (using EORTC QLQ-C30 and QLQ- 
OES24 modules) (Teoh 2011.) In patients undergoing either definitive 
chemoradiotherapy or surgery, the study concluded that at up to 6 months the surgical 
group had worse physical functioning and fatigue symptoms than the 
chemoradiotherapy group (p <0.001 and p +0.021 respectively.) At 2 years however 
these differences became insignificant.
Endoscopic Therapy
Endoscopic interventions have become a viable alternative for some patients with 
early-stage oesophageal (especially for squamous cell carcinoma) or gastric cancer or 
HGD, in whom surgical intervention has been deferred. Non-surgical treatments have 
the advantage of low morbidity and mortality with the preservation of the digestive
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tract and better quality of life - compared with surgical alternatives (Ell 2000, NICE 
2003.) Techniques can only be considered curative when lymph node metastasis is not 
present at the time of treatment.
Photodynamic therapy (PDT,) argon beam ablation, endoscopic mucosal resection 
(EMR) and endoscopic submucosal dissection (ESD) are the best studied non-surgical 
approaches at present.
PDT has high remission rates for HGD and early-stage oesophageal adenocarcinoma 
(Tokar 2006,) but it is expensive, not widely available and has treatment related side 
effects, including photosensitivity reactions, oesophageal strictures, vomiting and 
chest pain. Histological assessment is the only reliable assessment to accurately 
measure the depth of HGD, early oesophageal or gastric cancer; the use of ablative 
therapies that destroy the primary tumour must be considered with caution. They 
should be considered only in centres where EMR is not accessible and patients are 
unfit for surgical resection. Ablative techniques are useful to treat residual margins of 
mucosal lesions that have positive margin involvement post-EMR. Sagawa et al 
reported 27 patients with “intramucosal” EGC with argon beam coagulation (Sagawa 
2003.) During a median follow up of 30 months, 96% patients were reported tumour- 
free, with no complications; however no long-term follow up was stated.
Tumours suitable for EMR or ESD include: elevated or flat lesions less than 2cm in 
size; depressed lesions less than 1cm without ulceration; mucosal invasion only; well 
differentiated and no lymphatic infiltration (Clark 2009.) Although Ono et al have 
extended absolute indications to include lesions up to 3cm in size (Ono 2001.)
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EMR or ESD, used alone or in combination with ablative techniques can achieve 
complete remission in more than 90% of patients, although its role in the management 
of early neoplastic changes is still being defined (Tokar 2006, Pech 2007.) The strip 
technique of EMR was first described by Tada et al (Tada 1993.) Risks include 
bleeding and perforation, although major complications are less than 1% (Ell 2000.) 
Benefits including additional staging information can be provided by EMR/ESD since 
it involves lesion biopsy and may demonstrate pathological evidence of submucosal 
invasion necessitating an oesophagectomy (Ell 2000, Fujita 2001.) This increase in 
accuracy compared to PDT means that it is more effective and preferred in the 
treatment of gastric HGD (SIGN 2002.)
A trial by Ono et al demonstrated good treatment results from EMR for EGC (Ono 
2001.) Sixty nine percent (278/405) of intramucosal cancers were resected with a 
clear margin. Of the 127 that did not achieve complete initial resection, 14 were 
treated operatively and 9 endoscopically; the remainder had intensive follow up.
Local recurrence occurred in 17 lesions treated conservatively, 1 lesion treated 
endoscopically and 5 lesions that had complete resection. There were no gastric 
cancer-related deaths after a median follow up period of 38 months (range 3-120 
months.) Bleeding and perforation (5%) were the 2 reported major complications and 
there were treatment-related mortality.
Palliative treatment
At diagnosis 50-80% of oesophageal cancers are inoperable -compared with 30-50% 
of gastric cancers (Bonenkamp 2001, Mitani 2002.) Holistic palliative care is 
therefore important in the management oesophageal cancer.
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Squamous Carcinoma of the Oesophagus
The standard treatment for advanced or recurrent squamous carcinoma is cisplatin- 
containing chemotherapy. Indications are limited by the age and performance status of 
patients and the relative infrequency of the disease. The indication to improve 
symptoms and quality of life are often local and adequately treated by (metal) stenting. 
However responses around 35% can be achieved with cisplatin and 4-5days 5-FU 
infusion (Bleiberg 1991.) Response rate is variable and can range from 3-6 months. 
Radiation however carries a high risk of local complications such as 
oesophagotracheal fistulae (Enzinger 2003.)
Adenocarcinoma of the Oesophagus
Stage IV (advanced) disease should be considered for palliative chemotherapy, since 
15-30% of patients treated with fluorouracil, a taxane (paclitaxel or docetaxel) or 
irotecan experience tumour shrinkage of at least 50% (Enzinger 2000.) Responses of 
35-55% have also been reported using cisplatin in combination with these agents 
(Ilson 2000, Ross 2002.) However, although symptoms may be palliated by 
chemotherapy, responses are usually transient, typically lasting no longer than a few 
months and survival rarely exceeds one year.
Palliative Brachytherapy
Brachytherapy involves placement in the oesophagus (proximal to the tumour) of a 
high-dose-rate radioactive substance (usually iridium 192.) This is usually done as a 
daycase procedure and does not require a general anaesthetic. The aim is to get direct 
tumour cell kill or increase local radiation dose if used in combination with external 
beam radiation.
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A randomised multicentre trial in the Netherlands evaluating 209 patients 
demonstrated single-dose brachytherapy gave better relief from dysphagia than metal 
stenting with equivalent cost (Homs 2004.) Stent placement had more complications 
than brachytherapy (36 of 108 v 21 of 101; p= 0.02,) which were mostly the result of 
delayed haemorrhage (although dysphagia relief improved more rapidly after stent 
placement.) Groups did not differ for recurrent or ongoing dysphagia (p=0.81,) or for 
median survival (p=0.23.) Quality of life scores were in favour of brachytherapy 
compared with stent placement.
Oesophageal Dilatation
Dilatation alone should be reserved for patients with expected survival less than 4 
weeks who are unable to swallow saliva, or for relieving dysphagia whilst more 
definitive treatment is planned (Allum 2002.)
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1.3 Oesophagogastric Junction Tumours
Oesophagogastric junctional adenocarcinomas represent an increasing proportion of 
oesophageal and gastric malignancies and are predominately a Western phenomenon 
(Blot 1991, Powell 1992.) This rapid rise is thought to be related to increased 
adenocarcinoma rates in cases of Barrett’s metaplastic epithelium, combined with an 
increase in proximal gastric tumours (Salvon-Harman 1994;) which in turn may be 
linked to a rise in gastro-oesophageal reflux disease (Lagergren 1999.) 
Adenocarcinomas arising from the oesophagogastric junction pose difficulties in 
terms of classification and management.
Siewert et al (Siewertl996) proposed a classification system based on the three 
origins of the junctional tumour (see figure 1.3):
Type I -  adenocarcinoma of the distal oesophagus, the tumour centre being 1 - 
5 cm above the anatomical cardia.
Type II -  true tumour of the cardia; the centre is sited less than 1cm above and 
2cm below the anatomical cardia.
Type III -  gastric carcinoma with its centre 2-5 cm below the anatomical 
cardia.
Figure 1.3 Siewert classification
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Each type of tumour results in different lymphatic spread: type I spreads in a cephalic 
direction to mediastinal nodes and caudally to the coeliac axis; whereas type II and III 
metastasis almost exclusively spread caudally to the coeliac axis, splenic hilum and 
para-aortic nodes (Stein 2000.) Most surgeons therefore treat type I tumours as 
oesophageal lesions and type III as gastric carcinomas. Controversy however exists 
regarding the exact management of type II tumours and whether a total gastrectomy 
or extended oesophagectomy should be performed, each has its proponents and 
treatment should be decided on a case by case basis. (Resection for junctional tumours 
is discussed above in the sections on oesophagectomy and gastrectomy.)
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Chapter 1.4 Open Surgery
Surgical resection with curative intent is the treatment of choice for localised 
oesophageal and gastric cancer, in the absence of medical contraindications. In the 
Western world (based on studies in the UK and Sweden) resection rates are about 25% 
(Rouvelas 2005, Al-Sarira 2007.)
The aim of surgery for gastric and oesophageal cancer should be a R0 resection 
(clearance of proximal, distal and circumferential margins.)
Oesophagectomy remains the highest mortality elective procedure within the sphere 
of gastro-intestinal surgery, with true in-hospital mortality rates probably remaining 
around 5-10% globally (Whooley 2001, Jamieson 2004;) with gastrectomy being only 
slightly less risk (Cummins 2001, SAGOCS 2006.) In the UK recent figures 
published by the National Oesophago-Gastric Cancer Audit (2010) suggest that in 
hospital mortality is 4.5% (95% Cl 3.7-5.5) for oesophagectomies and 6.0% (95% Cl 
4.8-7.4) for gastrectomies.
With improved staging, selection and peri-operative care, mortality has fallen and 
postoperative survival has risen to around 32% at 5 years in contemporary reports 
(Siewart 2000.)
Evidence suggests that oesophageal and gastric resection should be carried out in high 
volume specialist units by frequent operators as institutional volume is inversely 
related to peri-operative mortality and morbidity (Halm 2002, Birkmeyer 2003,
Killeen 2005.) This is however subject to ongoing debate (Thompson 2007.) A 
systematic review and meta-analysis of case volume on cancer mortality by Gruen et 
al compared 101 publications (Gruen 2009.) This demonstrated a significant volume 
effect; with each doubling of hospital case volume, the odds of perioperative death 
decreased by 0.1-0.23. The paper did however contain common methodological
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limitations such as failure to control for potential confounders, post hoc categorisation 
of provider volume and unit of analysis errors.
1.4.1 Pre-operative Management and Selection o f Patients for 
Oesophageal and Gastric Resection
The aim of pre-operative assessment is to optimise the patient’s physiological status 
and gain an objective evaluation of postoperative outcome. This is especially 
important given the high mortality and morbidity risks of this type of surgery as 
outlined above and the high risk of post operative pulmonary complications (Griffin 
2002, Bailey 2003.) Despite a number of identified risk factors such as increasing age, 
impaired functional status, diabetes and impaired pulmonary and cardiac function 
(Bailey 2003, Steyerberg 2006,) predicting postoperative outcomes remains an 
inexact science with no consensus on selection criteria; although evidence suggests 
that poorer outcome correlates with increasing co-morbidity complexity (Golubovic 
2002.) Co-morbidity especially cardio-respiratory impairment is common in patients 
considered for oesophago-gastric surgery (Bailey 2003.) In addition there is a 
variation in preoperative and socioeconomic risk factors between patients with 
oesophageal squamous cell carcinoma and adenocarcinomas (Bollschweiler 2000.)
Preoperative clinical Risk Predictors
A common a simple classification of preoperative risk and physical status is that of 
the American Society of Anaesthesiologists (ASA,) see table below. Although this is 
a crude scoring system, it does provide a universal global assessment score, with 
morbidity and mortality increasing as ASA grade increases,
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Table 1.4: American Society of Anaesthesiology (ASA) Grading Criteria
Grade Definition
ASA 1 Normal healthy patient
ASA 2 Patient with mild systemic disease
ASA 3 Patient with a severe systemic disease that limits activity but is not incapacitating
ASA 4 Patient with incapacitating disease that is a constant threat to life
ASA 5 Moribund patient not expected to survive 24 hours with or without surgery
The Physiological and Operative Severity Score for the enumeration of Mortality and 
morbidity (POSSUM) was proposed in attempt to further evaluate surgical risk. It 
combines both the patient’s physiological score with a score that reflects the 
magnitude of surgery being undertaken. POSSUM and a later modified system 
Portmouth-POSSUM (Prytherch 1998) however have been demonstrated to have a 
poor predictive accuracy for oesophageal surgery (Zafirellis 2002.) Therefore O- 
POSSUM a risk-adjusted surgically-specific model for predicting outcome after upper 
gastrointestinal surgery was developed (Tekkis 2004.) O-POSSUM has been 
demonstrated to accurately predict mortality following gastrectomy but be less so 
post-oesophagectomy (Largarde 2007,) see table below:
Table 1.5: O-POSSUM variables
Physiological Score Operative Severity Score
Age (years) Operative severity
Cardiac signs/chest radiograph Presence of malignancy
Respiratory history/chest radiograph Mode of surgery
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the pylorus. Reconstruction commonly involves a Roux-en-Y jejunal loop or Polya 
reconstruction -although jejunal interposition pouches have been reported (Wan 2006.) 
The gastroduodenal anastomosis can either be sutured or stapled. A randomised trial 
by Hori et al (Hori 2004) looked at 187 patients receiving a distal gastrectomy and 
found similar levels of anastomotic complications in both groups (leakage being 1.1% 
v 2.1% and anastomotic stenosis developing in 4.3% v 1.1% in the mechanical 
stapling v hand sewn anastomosis respectively; anastomotic bleeding occurred in one 
patient in both groups.) Other outcome measures such as general complications, 
length of stay, recovery of gastrointestinal function and radiological diameter of the 
anastomosis were comparable between groups.
In the case of type III junctional adenocarcinomas, a total gastrectomy is 
recommended (with a proximal in situ 5cm margin.) Controversy exists regarding the 
management of type II junctional tumours, which some advocate should be treated by 
extended total gastrectomy rather than subtotal oesophagectomy due to lymph node 
drainage towards the coeliac axis (von Rahden 2006.)
Reconstruction after gastric resection aims to allow adequate nutritional intake, 
minimally altering physiology, preventing bile reflux into the oesophagus and not add 
to the mortality and morbidity of the resection. Duodenal bypass and duodenal 
continuity comprise the main types of reconstruction. Duodenal bypass involves 
closure of the duodenal stump and the proximal jejunum, usually using a Roux-en-Y 
technique, provides continuity. Duodenal continuity techniques involve either joining 
the gastric remnant to the duodenal stump (Bilroth 1) or interposing a segment of 
proximal jejunum between the gastric remnant or oesophagus and the duodenal stump. 
There is no evidence that preservation of duodenal continuity improves quality of life, 
nutritional parameters or weight (Yu 2002.) Recent Japanese studies suggest a Roux
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reconstruction has functional and symptomatic advantages compared to Bilroth 1 
reconstruction (Nunobe 2007, Kojima 2008.)
Pouch construction after total gastrectomy should be considered. A study by Lehnert 
et al looked at 19 prospective randomised trials, including 856 patients, comparing 
reconstructive procedures after total gastrectomy (Lehnert 2004.) Median mortality 
irrespective of reconstruction was 0% (range 0-22;) and procedure related morbidity 
was non-significant between groups. Jejunal pouch reconstruction but not restoration 
of duodenal passage was associated with improved food intake and weight gain in the 
early post-operative months. Some trials also demonstrated some improvement in 
long term quality of life.
Lymphadenectomy
The incidence of lymph node metastasis ranges from 3-5% for mucosal tumours, 16- 
25% for submucosal and 80-90% in patients presenting with stage III or IV disease 
(Gore 1997, Onate-Ocana 2000.)
Lymphadenectomy, with a minimum of 15 lymph nodes (Van Cutsem 2008) should 
be performed to increase staging accuracy, reduce locoregional recurrence and 
thereby improve survival outcome. Controversy exists regarding the exact extent of 
lymph node dissection and if it should involve a gastrectomy plus nodal sampling 
(DO); be limited to the perigastric lymph nodes (D1;) or include the regional N1 and 
N2 lymph nodes beyond the perigastric region (D2) (van de Velde 2005.) The D2 
lymphadenectomy definition more recently has been upgraded to the removal of more 
than 15 nodes irrespective of nodal station, allowing comparison between surgical 
outcomes in different countries. Extended Lymphadenectomy (D3,) a more radical en 
bloc resection including third-tier nodes is also occasionally carried out (mostly in
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Japan;) and removal of node stations 13-16 (D4) has only been reported to be of 
benefit in Japan (Maruyama 1987.) An estimation of the likelihood of disease in 
unresected regional lymph nodes can be calculated by the “Maruyama Index of 
Unresected Disease” (Kampschoer 1989.)
In the Japanese Rules for Gastric Cancer Surgery the minimum requirement for an 
effective resection of gastric cancer is a systematic D2 lymphadenectomy.
A Cochrane review by McCulloch et al looked at 2 randomised (Bonenkamp 1999, 
Cuschieri 1999,) and 11 cohort studies of limited (Dl) versus extended (D2) lymph 
node dissection (McCulloch 2004.) Meta-analysis of randomised trials did not derive 
any survival benefit for D2 resection (risk ratio= 0.95; 95% Cl 0.83-1.09,) but 
demonstrated increased postoperative mortality (RR 2.23; 95% Cl 1.45-3.45.) Pre­
specified subgroup analysis suggested a possible benefit in stage T3 or greater 
tumours (RR=0.68; 95% Cl 0.42-1.10.) Non-randomised comparison showed no 
benefit for extended dissection (RR 0.92; 95% Cl 0.83-1.02,) but decreased mortality 
(RR 0.65; 95% Cl 0.45-0.93.) Subgroup analysis demonstrated apparent benefit in 
UICC stage II and Ila. However, a number of confounding variables such as learning 
curve, lack of blinding, compliance with technique studied and surgical experience 
(individual and centre) may have affected study outcomes. Treatment decisions 
regarding the extent of lymphadenectomy tend now to be made on surgical opinion.
Despite the Cochrane review evidence regarding Dl versus D2 remains controversial. 
The Dutch Gastric Cancer group (Bonenkamp 1999) included in the review (with 
confounding variables in the study as mentioned above) published an update of results 
in 2010 (Songun 2010.) The multicentre randomised controlled study involved 711
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patients; overall 15 year survival was 21% (82 patients) for the D1 group and 29% (92 
patients) for the D2 group (p=0.34.) Gastric cancer-related deaths was significantly 
higher in the D1 group (48%, 182 patients) compared to the D2 group (37%, 123 
patients;) local recurrence between groups was 22% versus 12% respectively; and 
regional recurrence 19% versus 13% respectively. However patients undergoing a D2 
procedure had a significantly higher operative mortality compared to D1 resections 
(10% versus 4%; 95% Cl 2-9; p=0.004;) higher complication rate (43% versus 25%; 
95% Cl 11-25; pO.OOOl;) and reoperation rate (18% versus 8%; 95% Cl 5-15; p= 
0.00016.)
Splenectomy is indicated in addition to gastric resection for cancer when either direct 
invasion of the spleen or pancreatic tail or removal of the splenic hilum (station 10) 
lymph nodes -positive nodes being more likely in proximal cancers (Maruyama 1989.) 
The addition of a splenectomy may increase the risk of thromboembolic and septic 
complications post surgery (Orsuji 1999.) The evidence of station-10 
lymphadenectomy improves survival is conflicting (Schmid 2000, Kikuchi 2002;) in 
view of these concerns splenectomy is being increasingly avoided unless specifically 
indicated.
Distal pancreatectomy is indicated in gastric cancer when either direct invasion of the 
pancreatic tail has occurred, or for removal of the splenic artery (station-11) lymph 
nodes. There is no place for routine distal pancreatectomy in gastric cancer surgery.
En bloc pancreatic resection significantly increases morbidity (including pancreatic 
leak, fistula, acute pancreatitis and abscess formation) and mortality when compared 
to gastrectomy with or without splenectomy (in both Western and Japanese studies) 
(Kitamura 1999.) The survival benefit of station-11 lymphadenectomy in patients 
with positive nodes is reported to be 15-20% in Japan (Maruyama 1999;) however the
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benefit for proximal third cancers were to have a distal pancreatectomy is calculated 
to be 2% (Raimes 2010) -  less than the increased mortality. More recent Japanese 
studies have now confirmed that there is no survival benefit even for proximal third 
tumours of the stomach (Kodera 1997.)
Palliation
Tumour size, histological type and differentiation should be considered when 
selecting patients for palliative surgery. Surgery may be considered in cases of 
chronic bleeding of gastric body and antral tumours (although laser therapy is often 
utilised;) and in cases of gastric outlet obstruction. However, in the latter case, the 
radicality of surgery has to be balanced with the risks of a nutritionally depleted, frail 
patient who may have a prognosis of less than 6 months and may never sufficiently 
recover from surgery to derive any benefit. In these cases, a gastrojejunostomy may 
be performed. In patients with a relatively poor life expectancy placement of a stent 
may be more beneficial than a gastrojejunostomy (Jemink 2007.)
Post Operative Issues
Nutrition
Nutritional support is important in the post-operative stage, as all patients lose 10% or 
more of their body weight in the first 3-6 months (Lehnert 2004.) In common with 
oesophageal cancer resection, nutrition is preferable by the enteral route (Braga 1998, 
Bozzetti 2001;) and both pre- and post-operative nutritional support has been shown 
to decrease hospital stay and post-operative complications (Braga 2002, Gianotti 
2002.)
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Enhanced Recovery
Fast-track or enhanced recovery has successfully been introduced in colorectal 
surgery (Eskiciogiu 2009) and is increasingly being applied to gastric cancer surgery 
(Grantcharov 2010, Wang 2010.) This approach aims to reduce post-operative 
hospital stay, reduce hospital costs and improve patient satisfaction. Wide acceptance 
of this approach however is limited by concerns regarding patient safety (Kehlet 
2005.)
Post-operative Complications
The more common complications post-gastrectomy include:
- cardiopulmonary complications
- duodenal stump leak
- anastomotic leak
- infection (including intra-abdominal sepsis and post-splenectomy infections)
- pancreatic fistula
Late sequelae and complications include: early satiety, early dumping syndrome, 
reactive hypoglycaemia, diarrhoea, bile reflux and nutritional problems (general 
malnutrition and weight loss as well as specific deficiencies such as iron and vitamin 
B12.)
Quality o f Life
Potentially curative gastrectomies for cancer have a detrimental effect on patient 
quality of life. A study by Avery et al looked at 58 consecutive patients undergoing 
curative surgery using a validated questionnaire (EORTC QLQ-C30) and site-specific 
module (QLQ-ST022) before surgery and for 2 post-operative years (Avery 2010.) 
Thirty patients (52%) patients were alive after 2 years. In the first 3 post-operative
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months HRQL was significantly reduced (mean 10 or more points) in all dimensions 
except emotional and cognitive function; in this group functional aspects recovered by 
6 months.
A study evaluating the benefits of laparoscopic versus open gastrectomy in the first 3 
postoperative months found improved global health (p<0.0001) in the former group. 
This prospectively randomised study looked at 164patients and utilised EORTC QLQ- 
C30 and QLQ-ST022 questionnaires preoperatively and postoperatively on regular 
follow up visits (Kim 2008.)
1.4.3 Oesophageal Cancer Resection
Patient Selection
Mortality and morbidity post oesophagectomy have been steadily falling over the last 
20 years. Reasons for this include: increased specialised units; multidisciplinary 
approach; better patient selection; earlier diagnosis and improved perioperative 
management (DoH 2001.) Despite this, oesophagectomy for cancer should only be 
considered when a potentially curative R0 resection (complete macroscopic and 
microscopic cancer removal) is planned.
Those with localised tumours (TI, T2) tumours, who are medically fit, should be 
considered for curative surgery. Neoadjuvant therapy should be considered for T2 
tumours. Patients with advanced tumours (T3N1) are recommended for consideration 
for randomised controlled trials assessing surgery combined with novel multimodal 
therapies (Allum 2002.)
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In addition to meticulous preoperative evaluation to stage the tumour and estimated 
surgical risk, nutritional support, optimisation of respiratory care and mental 
preparation of patients should be considered.
Operative Approach
There are various techniques utilised for attempting curative oesophageal cancer 
resection both in terms of approach and radicality. The method of surgical approach to 
ensure tumour resection, adequate lymphadenectomy and safe reconstruction depend 
on tumour location, extent of spread and the fitness, age and morphology of the 
individual patient. Carcinoma of the hypopharynx and cervical oesophagus tend to 
undergo pharyngolaryngo-oesophagectomy. Upper middle-third tumours of the 
oesophagus usually are approached by a three-phase subtotal oesophagectomy such as 
McKeown’s. Middle and lower third tumours can be approached by two-phase 
subtotal oesophagectomies via right thoracotomy, such as the Ivor-Lewis approach, or 
by left-sided subtotal oesophagectomy. The transhiatal approach can be considered 
for upper and lower-third oesophageal tumours.
The transthoracic approach has the benefits of direct visualisation and thorough 
dissection of the thoracic oesophagus and perioesophageal/perigastric nodal tissue. 
Therefore it allows complete tumour resection and reduces the risk of residual disease 
and micrometastatic tumour spillage. The direct transthoracic approach substantially 
reduces the risk of damage to adjacent structures, particularly the thoracic duct, aorta, 
bronchus and azygous vein. The commonest open transthoracic procedures are: the 
Ivor-Lewis oesophagectomy (right thoracotomy and laparotomy) and McKeown 3- 
stage oesophagectomy (right thoracotomy followed by laparotomy and neck incision
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with cervical anastomosis); less common approaches are the left thoracotomy 
approach and the left thoraco-abdominal oesophagectomy.
The transhiatal oesophagectomy is probably the oncological equivalent of the 
transthoracic approach, but may have superior outcome in terms of reduced 
cardiopulmonary complications; no potential anastomotic leakage in the chest (which 
can result in mediastinitis;) and decreased operative duration -thereby resulting in a 
lower morbidity and mortality (Wu 2003.) It involves a laparotomy with blunt 
dissection of the thoracic oesophagus and positions the anastomosis in the neck. 
Further details of transhiatal oesophagectomy are clearly described elsewhere (Pinotti 
1983) as is the Ivor-Lewis oesophagectomy (Crofts 2000.)
At present there are selected indications for a transhiatal oesophagectomy: carcinoma 
of the hypopharynx and cervical oesophagus; intraepithelial squamous carcinoma of 
the oesophagus; patients with high grade dysplasia within a Barrett segment (Griffin 
2010.)
Four randomised controlled trials comparing transthoracic and transhiatal approaches 
have failed to demonstrate significant differences between them (Goldmine 1993, Chu 
1997, Jacobi 1997, Hulscher 2002.) The strongest evidence comes from the Dutch 
trial by Hulscher et a l This looked at 220 patients with adenocarcinomas of the 
middle and lower oesophagus. In hospital mortality was not significant between 
groups (P= 0.45.) Although survival difference was not significant, at five years there 
was a trend towards survival benefit in the extended approach: disease-free survival 
was 27% in the transhiatal group compared to 39% in the transthoracic group (95% Cl 
-1 -  24% for the difference;) whereas overall survival was 29% compared with 39% 
respectively (95% Cl -3 -  23%.) Results of this trial remain controversial, since
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although no survival benefit was detected between the groups, an ongoing trend 
towards better 5-year survival for type I tumours was demonstrated. In addition, 
patients with limited positive nodes (1-8) had significantly better outcome post 
transthoracic oesophagectomy (where logically extended lymphadenectomy would be 
most beneficial;) node negative patients did well and higher nodal burden patients did 
poorly irrespective of surgical radicality.
Whichever approach is utilised, proximal resection is recommended to be 10cm above 
the macroscopic tumour and 5cm distal to it when the oesophagus is in its natural 
state -since longitudinal spread is characteristic of all types of oesophageal tumour 
(Allum 2002.) Adenocarcinoma of the lower oesophagus commonly infiltrates the 
gastric cardia, fundus and lesser curve. In these cases, the resection, which again 
should be made 5cm distal to the macroscopic tumour should include some degree of 
gastric resection and abdominal lymphadenectomy.
Type I oesophagogastric junction tumours are recommended to be treated by a 
subtotal oesophagectomy with sleeve resection of the gastric cardia and lesser curve 
in addition to the lymph nodes around the left gastric pedicle (Griffin 2010.) Type II 
junctional tumours may be treated in a similar fashion dependent on surgical 
preference.
Lymphadenectomy
Nearly 80% of patients undergoing surgery have positive lymph nodes due to the 
extensive submucosal lymphatic drainage of the oesophagus. The extent of nodal 
resection therefore impacts on patient prognosis post complete resection, both in 
terms of locoregional and systemic recurrence (Wu 2003.) A study by Rizk et al
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demonstrated the minimal number of nodes required for accurate staging was 18 and 
involvement of more than 4 lymph nodes had survival similar to Ml disease (Rizk 
2006.)
Nodal Dissection Fields
Abdominal single field node dissection involves the right and left cardiac node; lesser 
curvature, left gastric, splenic artery and hepatic nodes.
Two field Iymphadenectomy involves the abdominal dissection described above plus 
thoracic lymphadenectomy (including para-aortic nodes along the thoracic duct; right 
and left pulmonary hilar nodes; para-oesophageal nodes; tracheal bifurcation nodes; 
and in Japan, nodes along the left recurrent laryngeal nerve.)
Three field dissection extends the two field lymphadenectomy to the neck, removing 
the brachiocephalic, deep lateral and external cervical nodes, and the anterior deep 
cervical nodes adjacent to the recurrent laryngeal nerve chains in the neck.
In Japan (for squamous cell carcinomas), there is considerable enthusiasm for a 3- 
field lymphadenectomy (neck, thorax and abdomen); although this has not routinely 
been adopted in the West (Shimada 2006.) Enthusiasts of this approach argue that up 
to 30% of patients with mid- or distal oesophageal tumours have concurrent cervical 
lymph node métastasés (Altorki 2002, Lerut 2004.)
Conduit and Anastomosis Placement
The commonest conduit utilised is the stomach (with vagotomy.) When this is not 
available colonic or jejunal interposition can be used.
Most reconstructions are prevertebral (posterior mediastinal.) This route tends 
provides the shortest distance between the abdomen and thoracic apex and neck
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(Bartels 1993, Gawad 1999.) Alternative less common routes of reconstruction are 
anterior mediastinal (retrosternal) and rarely prestemal. A meta-analysis of 6 
randomised controlled trials showed no significant difference in outcome following 
anterior and posterior mediastinal routes (Urschel 2001.) Relative risk (95% 
confidence interval; P value) expressed as posterior versus anterior mediastinal route 
(treatment versus control) was 0.56 (0.17, 1.82; P= 0.34) for mortality; 1.01 (0.35, 
2.94; P= 0.98) for leaks; 0.43 (0.17,1.12, P= 0.08) for cardiac complications; and 
0.67 (0.34,1.33, P=0.26) for pulmonary complications.
Two levels of anastomosis exist: subtotal oesophagectomy with neck anastomosis or 
oesophagogastrectomy with superior mediastinal anastomosis, each has its proponents. 
In a randomised trial evaluating 83 patients by Walther et al, both procedures were 
found to be equally safe (with 5 year survival rates of 29% for chest anastomosis and 
30% for chest anastomosis (Walther 2003.)) Surgical principle emphasis of 
anastomotic technique is placed on: adequate blood supply; tension-free anastomosis; 
accurate epithelial edge approximation; precise layer-to-layer suturing with primary 
healing.
Studies of sutured versus stapled oesophagogastric anastomosis have demonstrated no 
difference in leak rates or other complications (Valverde 1995, Law 1997.) The 
prospective randomized controlled trial by Law et al compared patients with 
squamous cell carcinoma of the thoracic oesophagus undergoing a Lewis-Tanner 
oesophagectomy; 55 had a hand-sewn anastomosis and 50 a stapled anastomosis. 
Leakage rates were 1.6% and 4.9% (p= non-significant) for hand-sewn and stapled 
anatomosis respectively; anastomotic strictures were found in 5 (9.1%) patients in the
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hand-sewn group and 20 (40%) in the stapler group (p= 0.0003); anastomotic 
recurrence occurred in one patient in each group.
The addition of a pyloroplasty (allowing gastric drainage) reduces postoperative 
gastric outlet obstruction, but has little effect on other early and late complications 
(Urschel 2002.) This paper was a meta-analysis of 9 RCTs, which included 553 
patients (with Jadad scores ranging from 1-4.) Pyloric drainage versus no drainage 
had a RR 0.92, (95% Cl 0.34-2.44, p=0.86) for operative mortality; and RR 0.25 (95% 
Cl 0.04-1.60, p= 0.36) for pyloric drainage complications. For late bilary reflux there 
was a non-significant trend favouring the non-drainage group; and scintographic 
gastric emptying time (pyloric drainage/no drainage) was 0.53.
Postoperative Issues
Nutrition
Nutrition is important in the peri-operative period. Some surgeons routinely site 
feeding jejunostomies either pre- or peri-operatively to help maintain gut integrity and 
function and provide adequate nutritional support (Sica 2005.) Studies have 
demonstrated that pre-operative nutritional support (which can be targeted) have 
improved post-operative outcome and decreased hospital stay (Braga 2002, Gianotti 
2002.) In addition to these benefits, post-operative feeding has also been shown to 
improve wound healing (Braga 1998,2002.) If possible nutrition should be 
administered enterally (Braga 1998, Bozzetti 2001.) A recent systematic review 
comparing 5 RCTs and 1 case-controlled trial (with 344 patients) analysed nutritional 
access routes following oesophagectomy and failed to find strong evidence 
supporting single feeding route access (Markides 2011.) However due to the
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significant risk of dislodgement of nasojejunal and nasoduodenal tubes, it suggests 
that feeding jéjunostomies may be superior.
Immunonutrition has also been purported to be beneficial in patients undergoing 
oesophageal resection by reducing inflammatory response and improve post-operative 
immune response (Sakurai 2007.)
Intensive Care and High Dependency Unit Admission 
Historically patients were routinely admitted to intensive care units following 
oesophagectomy. Increasingly, patients are now being extubated and managed safely 
in a high dependency environment -with the provision of intensive care for 
complications (Chandrashekar 2003, Robertson 2006.)
Enhanced recovery
There is increasing interest in the development of standardised care pathways, 
providing a fast-track or enhanced recovery for patients following oesophagectomy 
(Cerfolio 2004, Low 2007.) This uses a multi-disciplinary approach; optimising peri­
operative parameters affecting patient rehabilitation such as avoiding prolonged 
mechanical ventilation, early nutritional support, early ambulation and goal-directed 
management pathways. In addition to reduced length of stay it has been demonstrated 
to improve patient satisfaction and reduce costs (Zehr 1998, Cerfolio 2004.)
Postoperative Complications
Meticulous attention to the maintenance of fluid balance and respiratory care, 
including pain control and chest physiotherapy, are essential in the immediate 
postoperative period. Common complications include:
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- respiratory problems (failure, effusions, infection, acute respiratory distress 
syndrome)
cardiac problems (arrhythmias, myocardial infarctions, congestive cardiac 
failure)
- anastomotic leak
- chylothorax
- benign anastomotic strictures
- recurrent laryngeal nerve palsy
- gastric outlet obstruction
Quality o f  Life
Survivors face a long and difficult path back to a reasonable quality of life, so that 
oesophagectomy patients appear to derive no benefit unless they survive more than 2 
years (Blazeby 2000;) and even after 3 years post-resection may still suffer persistent 
problems with physical function and specific symptoms (Lagergren 2007, Djarv 2008.) 
Quality of life is therefore an important outcome measure during surgical treatment 
making (Parameswaran 2008.)
1.4.4 UK Multicentre Trials o f Outcome in Gastric and Oesophageal 
Cancer Resection
The Assessment of Stomach and Oesophageal Cancer Outcomes from Treatment 
(ASCOT) multicentre, prospective cohort study commenced in 1999 (Cummins 2001.) 
It aimed to ascertain the current state of UK practice for treatment of gastro- 
oesophageal cancer, including stage, co-morbidity and outcomes, at a time of intense 
public scrutiny. Results were obtained from 24 hospitals between 1st January 1999
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and 31st December 2002, comprising of 955 patients undergoing oesophagectomy or 
gastrectomy (of a total o f2087 cases submitted) (McCulloch 2003.) Of these, 27% 
were ASA III or IV; 20% had a POSSUM score < 20; operative mortality was 20%. 
Total morbidity for surgical complications was 108 (18.3%) for gastrectomies (3.2% 
were anastomotic leaks;) 72 (19.7%) for oesophagectomies (5.5% were anastomotic 
leaks;) of these cases 10.2% and 10.4% respectively (p=0.905) required a second 
operation. Medical complication morbidity was 191 (32.4%) for gastrectomies (11.0% 
cardiovascular related and 20.2% pulmonary;) and 190 (52.1%) for oesophagectomies 
(15.6% cardiovascular in origin and 40.5% respiratory in causation.)
ASCOT was novel in the ascertaining UK NHS practice. Its participants were self- 
selected and therefore not necessarily representative of UK practice due to self­
selection; and mortality and morbidity results were higher than many contemporary 
reports; however the Scottish national audit at the time reported similar mortality for 
gastrectomy (Thompson 2002.) Reported results also compared unfavourably with 
international results, possibly as a result of differences in patient population and 
superior treatment effects due to selection and publication biases. ASCOT results 
were however affected by a number of contributing factors resulting in high mortality 
rates: low volume centres; liberal selection criteria for operation; high frequency of 
unrelated systemic disease (occult cardiovascular disease being higher in the UK than 
many other European countries (British Heart Foundation 2003;) poor quality or 
inappropriately radical surgery; poor quality post-operative care (McCulloch 2003.) 
ASCOT managed to collect data from 2/3rds of hospital episode statistics, although 
individual trust figures varied considerably. Submission was voluntary and unfunded; 
omitted data varied from 5-10% (Warsi 2002.)
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The National Oesophago-Gastric Cancer Audit was set up after MIGOCS and 
published its findings in 3 reports (2008-2011) collating data from October 2007 to 
June 2009. Like ASCOT it provides a multicentre report on UK management of 
gastro-oesophageal cancer, with data on over 17,000 patients. It encompassed 
information on patient demographics, diagnosis, staging and treatment planning; 
curative treatment (including neoadjuvant therapy) and short-term outcomes- such as 
30 and 90-day mortality, morbidity, unplanned returns to theatre; palliative 
oncological, endoscopic and radiological treatment and their short-term outcomes. 
Unlike the MIGOCS database it more comprehensively covered gastro-oesophageal 
cancer treatment in the UK and successfully involved many more centres. Although it 
included minimally invasive resections, data collection was less focussed on 
technique details than in MIGOCS providing limited feedback to enable procedure 
development. Below (table 1.6) compares the morbidity, mortality and lymph node 
retrieval between open and minimally invasive approaches published in the 2010 
National Oesophago-Gastric Audit, with the added comparison where information 
allows from the 2002 ASCOT report.
Both studies demonstrated the difficulties of multicentre data collection. Following 
initial centre recruitment, regular encouragement of data acquisition is frequently 
required; with mechanisms for data quality assurance to ensure completed data entries 
and accurate entries for all eligible patients (the latter also being reliant on the 
integrity of those entering data.) Support facilities to assist any difficulties 
encountered in data entry and appropriate database evolution are also beneficial to 
optimise database success.
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Oesophagectomy (%) Gastrectomy (%)
NA open 
(n=1541)
NA minimally 
invasive 
(n= 659)
ASCOT
(n=241)
NA open 
(n=1226)
NA minimally 
invasive 
(n= 186)
ASCOT
(n=257)
30-day mortality 4.1 3.2 3.7 4.7 3.2 4.3
Re-operation 9.9 11.1 10.4 7.3 7.7 10.2
Anastomotic leak 7.4 10.5 5.5 5.7 7.0 3.2
Respiratory complication 13.8 10.8 40.5 6.9 9.7 20.2
Cardiac complication 5.9 3.6 15.6 3.9 3.2 11.0
Wound infection 4.5 2.4 7.9 3.2 3.8 3.9
LN retrieval 1-5 4.5 2.1 11.6 25.5 25.7 39.7
LN retrieval 6-14 26.1 18.8 26.2
LN retrieval >15 69.4 79.1 62.2 74.6 74.3 60.3
Table 1.6 Outcomes of Gastro-Oesophageal Cancer Surgery in the UK courtesy 
of the National Oesophago-Gastric Audits published in 2004 and 2010.
NA= National Oesophago-Gastric Audit (2010 published data)
ASCOT data taken from 2004 AUGIS report 
LN= Lymph Node
Chapter 1.5 Laparoscopic Surgery
Advances in surgical technology have made minimally invasive gastric and 
oesophageal cancer surgery possible and since the early 1990s, it has been gaining 
popularity (Cushieri 1992, DePaula 1995, Azagra 1999.) Whilst the minimally 
invasive approach is technically feasible, it is still an investigational technique, with 
limited evidence regarding its safety and efficacy, and has an as yet undefined role.
Over 5000 cases have been reported in the literature of minimally invasive surgery 
(MIS) for gastro-oesophageal cancer, with a myriad of techniques used. Most of the 
published evidence is in the form of case series, with only 3 randomised controlled 
trials of gastrectomy (Hayashi 2005, Huscher 2005, Lee 2005) and none of 
oesophagectomy. Case numbers in the reported series tend to be small, with a few 
exceptions (Kitano 2007;) most are single centre and five year results are limited 
(Luketich 2003, Cristano 2005.)
A large proportion of the experience reported in the literature regarding laparoscopic 
oesophago-gastric cancer surgery is anecdotal and mainly comes from South East 
Asia.
To date, two thirds of the literature published regarding minimally invasive 
gastrectomies comes from the East where there are high incidences of gastric cancer; 
whereas laparoscopic oesophageal resection publications mainly are from Western 
countries (Gemmill 2007.) This difference has resulted in differences in the evolution 
of the techniques and the data published. Compared to the West, Eastern countries 
such as Japan and Korea have major differences in their patient population, social 
influences, surgical philosophy and infrastructure; which impacts on outcomes such
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as length of stay and lymph node retrieval, and causes outcomes that may not reflect 
those found in other settings.
It must be remembered though, that in common with all evidence in surgical literature, 
information on an evolving technique is subject to considerable imprecision, 
publication and selection bias (Lilford 2004) and there is continual improvement as 
the technology advances.
A more detailed analysis of the current evidence and problems in conducting 
randomised controlled trials will be discussed in later chapters.
1.5.1 Main Approaches in Oesophago-Gastric Cancer
A variety of techniques and practices are described in the literature, each of which has 
its proponents, with no consensus on which method is optimal.
Gastrectomy
Most minimally invasive approaches are applied to early gastric cancer (confined to 
the mucosa and submucosa) and encompass a spectrum of techniques, including 
function preserving surgery and treatment modalities using either laparoscopy or 
endoscopy. For the purposes of this thesis endoscopic techniques have been excluded. 
The table below outlines laparoscopic approaches used for gastric cancer:
Table 1.7: Types of Laparoscopic Surgery for Gastric Cancer
wedge resection
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intragastric mucosal resection
local resection with adjacent lymphadenectomy
segmental resection
pylorus-preserving gastrectomy
proximal gastrectomy
laparoscopy-assisted or totally laparoscopic distal subtotal or total 
gastrectomy (with lymphadenectomy)
Each type of minimally invasive intervention has its prerequisites for clinical 
application and the extent of lymphadenectomy (like with open surgery) remains 
controversial. All techniques however tend to be less extensive than conventional 
distal subtotal or total gastrectomy with D2 lymphadenectomy.
Oesophagectomy
Many different approaches to minimally invasive oesophagectomy are being 
performed (see table 1.8.) The most common procedure currently being performed 
the thoracoscopic oesophagectomy with gastric mobilisation via laparotomy and 
cervical oesophagogastrostomy (Law 2002.)
Table 1.8: Types of Laparoscopic Surgery for Oesophageal Cancer
laparoscopic gastric mobilisation, thoracotomy with intrathoracic 
oesophagogastrostomy
thoracoscopic oesophagectomy with gastric mobilisation via 
laparotomy and cervical oesophagogastrostomy
thoracoscopie oesophagectomy with gastric mobilisation via 
laparotomy and intrathoracic oesophagogastrostomy 
thoracoscopic oesophagectomy, laparoscopic gastric mobilisation and 
cervical oesophagogastrostomy
thoracoscopic oesophagectomy, laparoscopic gastric mobilisation with 
hand-assisted device 
transmediastinal endodissection
laparotomy and laparoscopy-assisted transhiatal mobilisation 
total laparoscopic transhiatal oesophagectomy
1.5.2 Potential Benefits and Problems
The potential benefits of a laparoscopic approach to surgery are well known, 
including better visualisation, reduced post-operative pain, shorter hospital stay (and 
in some case less high dependency care,) quicker functional recovery and improved 
quality of life when compared to conventional, open resection (van den Broek 2004, 
Huscher 2005.) The short term benefits however vary widely in published reports.
Minimally invasive resections have their drawbacks. Procedures tend to take longer 
(Hyung 2006;) operative costs are higher (Adachi 2001;) learning curves are evident 
(Kim 2005, Jin 2007) requiring high levels of technical skill and adaptation from 
other complex gastrointestinal procedures; data on long term follow up is limited and 
critics question the oncological adequacy of the technique.
The benefits and limitations of a minimally invasive surgical approach to gastric and 
oesophageal malignancy will be discussed in further detail in subsequent chapters.
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Chapter 1.6 Problems in Conducting Randomised Controlled 
Trails and Possible Solutions
Randomised controlled trials (RCTs) are considered the gold standard approach to 
compare treatments (NHS HTA 1992.) However RCTs of surgical practice encounter 
particular methodological issues (Stirrat 1992, McCulloch 2002, Lilford 2003) and 
frequently result in small, poorly conducted trials; with inadequate, low quality 
reporting, especially of complications (Martin 2002, Balasubrumanian 2006, Jacquier 
2006.) A review of “surgical research” by Horton et al demonstrated that nearly half 
of all novel surgical techniques were reported as case series, with almost 10% 
reported as RCTs (Horton 1996.)
In order to try and improve the poor quality of RCTs published especially with respect 
to poor methodology, incomplete and inaccurate reporting, the Consolidated 
Standards of Reporting Trials (CONSORT) statement was published (Altman 2001.) 
The statement consists of a flow diagram and checklist to aid RCT reporting, 
outlining acceptable ways to perform and report clinical trials; thereby facilitating 
both the critical appraisal and the interpretation of RCTs. Subsequent to the adoption 
of the CONSORT statement by many leading medical journals, the quality of RCTs 
has demonstrated an improvement (Moher 2001, Plint 2006.) However, inadequate 
and low quality reporting standards of surgical interventions are still apparent, making 
interpretation of their results difficult (Jacquier 2006.)
Medical interventions and trials contrast to surgical ones not just from a quantative 
but a qualitative perspective. Medical trials are often relatively simple and 
straightforward involving drug or protocol introductions and are therefore amenable 
to blinding and standardised protocols. Surgical interventions frequently include
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procedures and device development, intrinsically requiring some degree of 
personalisation. They are influenced by innate preferences’ of the surgeon and limited 
by individual surgical skill; thus inevitably introducing potential confounding factors 
and contamination. These characteristics, often term “equipoise” are addressed in 
more detail later. Patient accrual is frequently slow compared to medical drug trials; 
requiring multicentre involvement in order for trial numbers to obtain statistical 
significance in a relatively short time period (Dimick 2001.) Recruitment is also 
difficult if the two treatment arms differ significantly, such as a surgical versus 
medical trial (Stirrat 1992.)
1.6.1 Development Phases of Surgical Trials
This can be considered in a number of phases, as outlined in the Idea, Development, 
Exploration, Assessment, Long-term (IDEAL) study recommendations (McCulloch 
2009):
(Simulator or animal studies if they exist are considered as stage 0.)
Stage 1. Idea (Proof o f Principle.)
Novel techniques describing approach and establishing feasibility are reported as case 
reports or small case series. At this stage the concept proven, and technical 
achievements, disasters and notable successes are published. Single case studies can 
also be used to identify potential adverse side effects, for example reporting to the UK 
Medical Devices Agency.
Stage 2a. Development
The technique is adopted and disseminated by a cohort of interested surgeons, who 
develop it by a series of small steps (rarely involving more than 30 patients,)
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establishing its effectiveness. Publications are usually uncontrolled, individual, 
retrospective case series which address safety, technical and procedural success; they 
tend to constitute poor quality of “evidence.”
Stage 2b Exploration
More surgeons learn the procedure, expanding eligible patient selection and refining 
the technique. This stage is amenable for research databases; explanatory or feasibility 
randomised clinical trials looking at clinical short-term outcomes; for learning curve 
evaluation and mentoring issues.
Stage 3 Assessment
The intervention having stabilised can expand, with well-defined indications. 
Comparative data can be obtained from a controlled trial and for full evaluation the 
procedure compared with conventional surgery (ECST 1998, Neumayer 2004.)
Middle and long-term outcomes, quality of life and cost-effectiveness can be assessed.
Stage 4 Long-term studies (Surveillance and Quality Control)
Continual monitoring of established technique results is required to ensure initial 
success levels are maintained and identify any adverse effects. This involves audit, 
registries and rare-case reports. All patients and surgeons qualify to perform the 
intervention as rare events, long-term outcomes and quality assurance are assessed.
The IDEAL framework of evaluation and stages of surgical innovation by the Balliol 
collaboration has been utilised to evaluate a number of surgical techniques 
(McCulloch 2009.) Examples of this include: minimally invasive oesophagectomy 
(Blazeby 2011) and urology (McCulloch 2011.)
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This approach provides a good model for the evolution of novel surgical techniques 
and offers methods of evaluation at each stage of development. However the order 
suggested does not always reflect real life situations when technique evolution may 
result in a systemically different approach or non-operative management. It does not 
entirely incorporate evaluation by simulation or animal studies prior to human trials 
such as that by natural orifice transluminal endoscopic surgery (NOTES (Flora 2008;) 
or address comparison of a non-operative intervention and surgical technique, such 
proton-pump inhibition versus antireflux surgery for reflux oesophagitis (Lundell 
2007.)
The IDEAL framework does not always easily apply to the earliest stages of surgical 
technique evolution, where there may be no definite divide between the first two 
stages. A novel approach may be applied out of necessity to solve a problem and 
repeated on future occasions prior to realisation of the development of an innovative 
technique. The exact timepoint at which formal scientific and ethical framework 
needs to be applied is therefore difficult to define and implement.
1.6.2 Potential Problems in Randomised Controlled Trials
1 Trial Definition
A clear treatment definition and description are a prerequisite of therapeutic 
evaluation (Campbell 2000, Altman 2001.) Unlike pharmaceutical interventions, 
surgical interventions are often complex, multifactorial and difficult to standardise, 
with healthcare professionals being integral to patient outcome. There is therefore a 
need to report details of:
- The surgeons’ “experience”, which may affect morbidity and introduce bias 
(Bonenkamp 1995, Devereaux 2003, Lilford 2004.)
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- The volume of centre activity - since large volume centres tend to have better 
outcomes (van Lanschot 2001, Halm 2002, Birkmeyer 2003.)
- Explicit reporting of all components of the intervention such as: preoperative care, 
the principle procedure, peri- and post-operative care (including anaesthetic 
management and rehabililitation.)
- Outcome measures need clear definition; disease timeline and intervention timing 
may also impact on outcome.
2. Learning Curve (Practice Effect) and Trial Timing
Ideally innovative techniques should be evaluated by trials performed prior to take up 
in clinical practice providing a control for intervention comparison (i.e. while there is 
still equipoise.) However randomisation between familiar and new techniques 
introduces bias (Bonenkamp 1999, Cook 2009,) a problem that has few parallels in 
pharmaceutical trials.
Technique development can also be inhibited by too early RCT analysis and reflect 
the learning curve rather than the therapeutic effect of the procedure (Reeves 1999, 
Yang 2009.) This learning curve includes the surgeon, procedure, supporting team 
(surgical, nursing, anaesthetic) and patient. Trial timing is thus complicated by 
external factors in addition to surgeons learning individually at different rates, usually 
via an apprenticeship structure (Cook 2004.) This may be improved by collection of 
comprehensive data including the surgeons personal procedure-based learning (Cook 
2007.)
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3. Equipoise
Patient preference in entering trials can limit RCT recruitment, especially where there 
are known disadvantages (Prescott 1999, Harrison 2007.) Many patients do not wish 
their treatment decision to be made by chance alone (Toumoux 2006.) In type 3 trials 
(comparing surgical and non-surgical treatments,) 82% of recruitment problems were 
found to be related to patients’ equipoise (Solomon 1995.)
Surgeons are often criticised for their poor understanding of clinical epidemiology 
(Solomon 1995, Rothenberger 2004.) Their attributes, including surgical knowledge, 
inherent skills and previous experience will influence any surgical intervention 
leading to outcome variability (Ergina 2009.) Inherent surgical personalities impact 
on trials. Surgical affinity for quick decision making with incomplete information 
(McCulloch 2005,) may result in difficulties in conscious individual certainty despite 
collective uncertainty, between two treatments required for RCTs. Surgeons also 
frequently believe catastrophic events will occur without intervention, which may not 
always be the case, for example delayed surgery in the treatment of necrotising 
pancreatitis (Buchler 2000.)
4. Sample size
Increasing sample size can improve trial precision; however the rarity of some 
conditions means that patient recruitment is slow (Solomon 1995) and can be difficult 
in emergency presentations with consent and randomisation issues (McCulloch 2002.) 
Long-term studies may help where the learning curve is less integral, but selection 
criteria and risk-adjustment for patient comorbidity is both complex and important 
(McCulloch 2009.)
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Adequately powered sample sizes can rarely be achieved in single centre studies, 
where their generalisation is always questionable; multicentre studies however have 
their own limitations, confounding factors and barriers (McCulloch 2002 and 2005, 
Mohammed 2009.)
4. Quality Control Monitoring
Surveillance, data quality monitoring, surgeon-specific effects and surgical 
performance (including identifying surgical outliers) impact on studies and the 
reliability of any outcomes measured. Quality assurance literature has suggested 
focussing on structure, process and outcomes to measure the standard of surgical care 
(Birkmeyer 2004.) However many outcomes assessing short-term clinical measures of 
technical success and harm are not standardised and thus not reproducible (Ergina 
2009.) Additionally they often depend on from whose perspective is being measured 
e.g. patient versus surgeon. This is especially significant in quality of life studies.
The degree of individual surgical vigilance, experience and judgement can also 
impact on results. This can be significant when an intervention has occurred from the 
early detection of complications and thus reduced measured outcomes.
5. Masking or Blinding
Blinding the operative surgeon to the actual procedure is difficult, especially where 
there are visible sequelae and permanent, non-reversible structural changes. It is 
possible however to blind the surgeon to the allocation group with the outcome being 
measured by independent third parties or stakeholders with standardised endpoints. 
The wound itself can even be concealed, though this is seldom done (Poolman 2007.)
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Patient blinding by sham or placebo surgery is ethically controversial and tends to be 
used in cases where a suitable comparison is not available or sham surgery has limited 
risk (London 2002, Mosely 2002.) This is problematic when assessing subjective 
outcomes by both clinician/researcher (Moher 1999) and patient (Hrobjartsson 2001.)
The absence of masking can result in bias. This can be of performance (surgical and 
other care providers or patients choosing concurrent interventions;) attrition 
(differential follow up withdrawal;) and detection (differential outcome assessment.) 
(Higgins 2008.)
1.6.2 Proposed Solutions
Despite the quality of RCTs having improved since the publication of the CONSORT 
statement as outlined earlier, the methodological aspect of many surgical trials still 
needs addressing. In some cases for ethical or pragmatic reasons RCTs may not 
feasible, especially in the initial stages of novel surgical technique development. In 
these situations alternative trial designs and approaches are necessary, often making 
the technique closer to being amenable to a RCT, such as those described below. 
These suggestions include those proposed in the IDEAL model (McCulloch 2009.)
Stepped Wedge Trials (Cook and Campbell 1979)
This type of trial design involves the sequential roll-out of an intervention to 
participants (individuals or clusters) over a number of time periods (Brown 2006.) 
Although all participants receive the intervention, the order of their involvement is 
random. This (parallel) trial design is beneficial where the intervention is forecast to 
be potentially harmful and/or for logistical, financial or practical reasons participation
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cannot occur simultaneously. However it introduces complexities to statistical 
interpretation and increases trial duration. An example of this type of trial is that by 
Wilmink et al which looked at the incidence and mortality of ruptured abdominal 
aortic aneurysms in a GP setting (Wilmink 1999.)
Tracker Trials (Lilford 2000)
By evaluating, or “tracking” new treatments as they evolve over time, prior to 
stabilisation (when a RCT can be carried out,) unbiased comparisons can occur at 
each stage of development, detecting poor performances rapidly and providing an 
early warning. The protocols and sample size for this type of trial should be flexible in 
order to maximise data and outcome measurements (which require complex analysis.) 
Although conceptually attractive, incorporating the difficulties of incremental and 
stepwise innovation, tracker trials are challenging in practice.
An example of this type of trial is the endovascular aneurysm repair trial (EVAR 
2003.)
Expertise-Based Design (Devereaux 2005)
Patients are randomly allocated to surgeons with expertise in different procedures, 
protecting against bias and allowing surgeons with strong preferences to participate 
(similar to cluster randomisation.) This type of study requires more surgeons and 
encounters numerous potential confounding factors.
Databases
Surgical databases are a fundamental part of surgical practice and can allow the 
retrospective initiated comparative studies of prospectively collected data; evaluation 
of temporal trends and the identification of late or rare effects of treatment.
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The quality of evidence of this type of data, compared to RCTs is a subject of 
continuing debate (Benson 2000, Raftery 2003.) It requires surgeons to be willing to 
enter data and be subject to scrutiny of their outcomes. Databases are reliant on the 
integrity participants in assuring the validity and completeness of data, which often 
contain inadvertent errors (thus this approach should ideally contain quality control 
checks.)
Phase II (S) Surgical Studies (McCulloch 2002)
This type of study acts to bridge the gap between case series and randomised 
controlled trials, similar to oncological phase II studies. It aims to aid development of 
a satisfactory definition of the procedure; determine adequate measures of surgical 
quality; evaluate the learning curve of participants; identify suitable sample sizes and 
end points for a randomised trial, and develop the required consensus and familiarity 
with working together to allow the trial to develop organically. (This approach has 
been considered in this thesis regarding the development of minimally invasive 
gastro-oesophageal cancer surgery, which is currently at stage 2b of the IDEAL 
guidelines.)
Phase IIS trials aim to indicate suitable timing for a RCT, and using a “tracker” design, 
enable randomisation to be introduced early (Lilford 2000.)
Quality Control Studies and the Learning Curve
Quality control of evolving techniques can be monitored by studying the learning 
curve and continuous unit performance surveillance (Beiles 2004, McCulloch 2009.) 
Several sequential probability ratio tests can be applied to address surgical learning 
curve such as CUSUM (Cumulative Sum Control) (Novick 2003, Speigelhalter 2004),
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VLAD (Variable Life-Adjusted Display) (Lovegrove 1997) or CRAM (Cumulative 
Risk Adjusted Mortality) plots (Polonieck 1998.)
Charts such as CUSUM, monitor the improvement (or deterioration) of surgical 
practices and are sensitive to small outcome changes (Steiner 1999,) “triggering” 
when failure frequency significantly exceeds that which is expected.
Indications of changes in outcome detected by these methods can be utilised to 
indicated whether a RCT is possible or further prospective data collection (with 
regular Bayesian analysis) is needed first (Raskob 1985, Felli 1999.)
1.6.4 Conclusions
The IDEAL framework and recommendations provides a description for the 
development novel surgical techniques and alternative approaches to developing 
study designs.
Surgical research involves multiple obstacles to performing RCTs. A comprehensive 
approach should therefore be considered with accurate, standardised clinical and 
patient-reported outcomes, prospectively design and application of quality control 
measures. This should occur after initial surgical intervention development, providing 
evidence-based comparisons between interventions (McCulloch 2009.)
Phase II surgical trials, tracker trials, stepped-wedge and expertise-designed trials are 
all examples of trials designed to address the need for evidence-based comparisons 
between established ad novel surgical techniques. In this thesis, a phase II surgical 
trial design has been utilised as it addresses many of the difficulties encountered in 
surgical trials, such as trial definition; quality control; learning curves; and aims to 
encourage a RCT between participants as one of its conclusions. It thus provides the 
integration of rigorous scientific evaluation and the natural development of minimally
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invasive upper gastrointestinal cancer surgery (hopefully overcoming many of the 
difficulties that have thus far delayed its development.)
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Chapter 2 Hypothesis and Aims of this Thesis
The aim of this thesis was to test the hypothesis that: minimally invasive surgery has 
apparently superior outcomes to conventional, open surgery but current studies are 
methodologically inadequate to confirm this.
In order to test this hypothesis the following were looked at:
- Problems and possible solutions in conducting a randomized controlled trial of 
surgical technique.
- The current evidence in the literature regarding minimally invasive gastro- 
oesophageal cancer surgery.
- The development of a phase II surgical trial (as a means to bridge the gap between 
case series and randomized controlled trials.) This was aimed to generate data to 
enable power calculations required to perform a randomised controlled trial.
- Retrospective and prospective results of a study of MIGOCS in a multicentre UK 
setting. This represented stage 2a and b of the IDEAL guidelines utilising a disease 
register developed between members of the MIGOCS group.
- Definition of the learning curve associated with new techniques such as MIGOCS 
utilising CUSUM (cumulative sum control) methodology.
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- Development of a randomized controlled trial in minimally invasive surgery 
comparing it to open techniques. Whilst a RCT was not actually reached in this thesis, 
it is the ultimate aim and gold standard to be achieved by phase 2 surgical study 
methodology. It was hoped that this study will aid definition of the techniques used in 
minimally invasive gastro-oesophageal cancer surgery; help develop consensus; give 
an idea of required end points and power calculations in order to move towards a RCT,
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Chapter 3 -  A Systematic Review of Minimally Invasive 
Resection for Gastro-Oesophageal Cancer
3.1 Introduction
Minimally invasive approaches to gastro-oesophageal cancer surgery have been 
gaining popularity since the early 1990s. A key question in the evolution this type of 
approach (like any novel technique) needs to be its safety and efficacy, prior to the 
widespread dissemination of practice. At present, apart from individual papers 
(mostly published by single surgeons operating in single centres) the answer to this 
question remains unknown.
3.2 Methods
3.2.1. Literature Search Strategy
Using PubMed and Embase as primary sources, an electronic literature search of 
articles published between 1992 and June 2006 (the date of the search) was performed. 
The main search terms used were: gastric cancer, oesophageal cancer, minimally 
invasive, laparoscopic and surgery. Logical combinations of these and related terms 
(stomach, oesophagus, neoplasm, and carcinoma) were used to maximise sensitivity. 
Articles printed in the English language, or with an English abstract were used and the 
criteria was further restricted to articles related to humans rather than simulations or 
animal studies. Articles without an available abstract were not retrieved. Six selected 
surgical journals (British Journal of Surgery, Surgery, Annals of Surgery, Surgical 
Endoscopy, Archives of Surgery, European Journal of Surgical Oncology) were hand
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searched; apparently relevant articles were identified in the reference list of full text 
articles and retrieved (as a supplementary strategy.)
3.2.2 Article Selection Process
Full text articles were retrieved from English abstracts that contained pre-selected 
eligibility criteria. All articles reporting 6 or more minimally invasive resections for 
gastric or oesophageal carcinomas (including high grade dysplasia but not including 
benign conditions or Gastro-Intestinal Stromal Tumours- GISTs-) and which provided 
a minimum set of basic operative technique details and post-operative outcome data 
were retrieved. Articles using hand assisted and hybrid techniques were included as 
long as part of the operation was attempted or completed laparoscopically or 
thoracoscopically. Review articles, case reports, articles containing less than six 
patients and those that did not specify the surgery performed or the conditions treated 
were excluded. Robotic, endoscopic studies and those on children were also excluded. 
Only the most recent article by a set of authors that had published cumulative, 
sequential or overlapping reports were analysed to avoid inadvertent double analysis 
of cases. We were interested in evaluating the clinical results of minimally invasive 
resection, and therefore articles were excluded where the abstract made no mention of 
any of the following: operative blood loss, operating time, mortality, morbidity, 
length of hospital stay.
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Table 3.1: Inclusion and Exclusion Criteria for Systematic Review
Criteria Inclusion Exclusion
Trial Design Randomised Controlled Trial Case Review article
matched series Case report
Case series Duplicate/sequential data
Data Operative details and post-operative Minimal outcome data
data provided
Number of cases 6 cases < 6 patients
Pathology High Grade Dysplasia and Cancer GISTS, benign conditions
Operative approach Hand-assisted/hybrid provided Robotic
approach involved laparoscopic/ Endoscopic
thoracoscopic element
Age Adult Paediatric
3.2.3 Quality Assessment of Retrieved Articles
Each included article was appraised by two reviewers, who independently assessed 
the methodological quality of the selected articles.
3.2.4 Data Extraction and Recording
A pre-designed proforma (see table 3.2) was utilised for each retrieved full text article 
to extract relevant operative and outcome information. Articles were classified as 
case series; case matched studies or randomised trials. Case series were defined as 
analysis of a series of people undergoing gastrectomy or oesophagectomy (with no 
comparison group;) case matched studies were analysis of a series of people 
undergoing oesophagectomy or gastrectomy by a minimally invasive technique with a 
comparison group (that may be historical) of the same type of surgery but open in
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approach. Information on patient numbers, age and sex, tumour site and stage, 
operations performed and techniques used, operative time, blood loss, conversion rate, 
complications, morbidity, mortality, adequacy of the cancer resection and indicators 
of speed and quality of recovery were collected. Results were subdivided into those 
for gastrectomy and oesophagectomy. Due to very clear differences in the profile of 
the Western and Eastern literature, separate analyses of the studies from Western and 
Eastern authors were performed.
(Western included North America, Europe and Australasia; Eastern included the 
Middle and Far East, in particular Japan, Korea and China.)
Table 3.2: Pre-Determined Criteria for Paper Selection for Further Review
Study Parameters 
Study Authors 
Journal Citation
Study Design: case series/prospective cohort/non-randomised comparison/RCT/other
Number of patients studied: in minimally invasive group/in other groups
Minimally invasive operations studied: comparator operation
Mortality: number of deaths within 30 days/number of procedures OR Not Recorded
Morbidity: overall complication rate quoted OR Not Recorded
Anastomotic Leak rate: number of reported leaks/number of procedures OR Not
Recorded
Respiratory complication rate: total respiratory complications recorded/number of
procedures OR Not Recorded
Blood Loss: mean loss in ml, OR Not Recorded
Operating Time: mean time in minutes OR Not Recorded
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approach. Information on patient numbers, age and sex, tumour site and stage, 
operations performed and techniques used, operative time, blood loss, conversion rate, 
complications, morbidity, mortality, adequacy of the cancer resection and indicators 
of speed and quality of recovery were collected. Results were subdivided into those 
for gastrectomy and oesophagectomy. Due to very clear differences in the profile of 
the Western and Eastern literature, separate analyses of the studies from Western and 
Eastern authors were performed.
(Western included North America, Europe and Australasia; Eastern included the 
Middle and Far East, in particular Japan, Korea and China.)
Table 3.2: Pre-Determined Criteria for Paper Selection for Further Review
Study Parameters 
Study Authors 
Journal Citation
Study Design: case series/prospective cohort/non-randomised comparison/RCT/other
Number of patients studied: in minimally invasive group/in other groups
Minimally invasive operations studied: comparator operation
Mortality: number of deaths within 30 days/number of procedures OR Not Recorded
Morbidity: overall complication rate quoted OR Not Recorded
Anastomotic Leak rate: number of reported leaks/number of procedures OR Not
Recorded
Respiratory complication rate: total respiratory complications recorded/number of
procedures OR Not Recorded
Blood Loss: mean loss in ml, OR Not Recorded
Operating Time: mean time in minutes OR Not Recorded
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Conversion rate: number of conversions to open/number of procedures OR Not 
Recorded
Length of hospital stay: mean time in days OR Not Recorded
RO resection rate: number of adequate resections OR Not Recorded
Lymph node retrieval: total number of lymph nodes removed at operation OR Not
Recorded
Quality of Life: length of patient follow up and any recorded formal measurement of 
quality of life post-operatively OR Not Recorded
3.2.5 Statistics
Where data were provided the sum events and denominators of the mean figures were 
determined. Weighted means were used where the data only gave summary statistics 
for the study as a whole. Where figures were available for only a subset of the 
included studies, the number of studies and patients on which the statistic is based is 
noted. Statistics were limited to simple descriptive calculations with no statistical 
significance tests for comparison between the various minimally invasive operative 
techniques. This was felt inappropriate due to reporting bias, considerable variation in 
the patient selection criteria and different technical approaches to resection performed 
between articles.
3.3 Results
188 abstracts were analysed for review following the initial search, 132 were rejected 
and 46 met pre-determined criteria (see figure 2.1.) Of the rejected papers there were 
48 case reports; 31 reviews; 18 sequential/ duplicate papers; 14 did not meet 
minimum outcome criteria; 13 were non-cancer cases; 4 involved robotics; 4 were
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endoscopic cases and 2 involved paediatric patients. The 46 selected included 23 
oesophagectomy papers and 23 gastrectomy papers; these comprised 3 randomised 
controlled trials (Lee 2005, Hayashi 2005, Huscher 2005,) 8 case-matched reports (2 
and 6 respectively) and 35 (21 and 14 reports respectively) were case series. Most of 
the papers were from single centre institutions and many recorded retrospectively (16 
oesophagectomy and 15 gastrectomy papers.)
Calculation of the Jadad score of the randomised controlled trials is 3 for the papers 
by Huscher et al and Lee et ah, and 4 for that by Hayashi et al (Jadad 1996.) Points 
were scored for the description of randomisation; withdrawals and dropouts; method 
of randomisation being appropriate and in the case of the paper by Hayashi et al, an 
appropriate method of blinding was described. Although the Jadad score is quite 
simplistic, it assists in independently assessing the methodological quality of clinical 
trials. It demonstrated the quality of evidence of the trials is average and double 
blinding, difficult to perform in surgical trials was lacking in all 3 papers. Ethical or 
governance arrangements are mentioned in few papers and unless otherwise stated 
outcomes were measured by the publishing authors or their clinical teams i.e. results 
are not blinded and therefore susceptible to bias.
Outcome reporting in other studies was done in nearly all cases by the group 
responsible both for operating and reporting data i.e. no blinding occurred.
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Figure 3.1: PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-analysis) Flow Chart of Study Selection (adapted from Moher 2009)
Case numbers ranged from 11 to 222 patients undergoing oesophagectomy (mean 58
patients) and 7 to 1294 (mean 111 patients) had a gastrectomy.
1398 patients were reported as having undergone some form of minimally invasive
oesophagectomy, and 2546 as undergoing laparoscopic or laparoscopy-assisted
gastrectomy. 3 patients had oesophago-gastrectomies, 62 underwent wedge
resections of stomach or non-classical gastrectomies, 2069 had distal gastrectomies
(partial, subtotal or antral), and there were 220 total and 192 proximal gastrectomies.
Of the oesophagectomies, 405 patients (7 studies) were performed using a completely
minimally invasive technique; 103 (2 studies) used a laparoscopic mobilization and a
thoracotomy; 561 patients (8 studies) a thoracoscopic technique with laparotomy for
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gastric mobilisation; 82 patients (4 studies) underwent hand-assisted laparoscopic 
mobilisation and as part of either transhiatal (Van den Broek 2004, Bemabe 2005) or 
3-stage procedure (Suzuki 2003, Martin 2005;) and in 41 patients (1 study) another 
technique was used (a mediastinoscope (Tangoku 2004.) Majority of gastrectomy 
cases reported were from Eastern authors whilst most of the oesophagectomy studies 
were from Western countries (see Table 3.2.) (For clarification purposes, ‘Eastern 
countries’ refers to the Far East -  mainly Japan, Korea and China-, and ‘Western 
countries’ refers to Western Europe, North America and Australasia.)
The number of patients who cancer was found to be unresectable following 
commencement of surgery was not stated in any of the papers.
i) MORTALITY
All reports stated mortality rates. Within 30 days of operation, 32 out of 1398 
oesophagectomy patients (2.3%), and 3 out of 2562 (0.1%) of gastrectomy patients 
died.
ii) MORBIDITY
21 oesophagectomy studies reported morbidity rates. Of a total of 1359 patients 628 
had a reported complication (major and minor), (46.2%.) 21 gastrectomy studies 
reported on morbidity, which affected 323 out of 2534 patients (12.7%.)
iia) RESPIRATORY TRACT INFECTIONS
20 and 18 studies of oesophagectomy and gastrectomy respectively reported on 
postoperative respiratory tract infections; the cumulative rates being 13.1% (167 out 
of 1268 patients) and 0.6% (15 out of 2429 patients) respectively.
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iib) LEAK RATE
22 oesophagectomy studies reported leak rates, affecting 106 out of 1381 patients 
(7.7%.) 19 gastrectomy studies reported leaks, in 37 out of 2433 patients (1.5%.)
iii) OPERATIVE TIME (see Figure 3.2)
Overall operative time was mentioned in 19 oesophagectomy studies (comprising of a 
total of 975 patients), with a weighted mean operative time of 281.2 minutes. All 
gastrectomy studies quoted operative times (total: 2562 patients;) the weighted mean 
operative time (excluding wedge resections) was 249.9 minutes.
Figure 3.2 Operative Time for Minimally Invasive Gastro-Oesophageal Cancer 
Surgery
Operative time for Minimally Invasive Gastric and Oesophageal Cancer
Surgery
□ Oesophagectomy 
■ Gastrectomy
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Operative time (mins)
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iv) ESTIMATED BLOOD LOSS (see figure 3.3)
19 oesophagectomy studies estimated blood loss (1055 patients,) with a weighted 
mean loss of 315.7 ml. 21 gastrectomy studies reported estimated blood loss (1171
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patients,) the weighted mean loss being 191.6 ml (wedge resections were again 
excluded from this calculation.)
Figure 3.3 Blood Loss for Minimally Invasive Gastro-Oesophageal Cancer 
Surgery
Estimated Blood Loss for Minimally Invasive Oesophageal and 
Gastric Cancer Surgery
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v) CONVERSION RATE
19 oesophagectomy and 9 gastrectomy studies reported conversion rates. The mean 
conversion rate for oesophagectomies was 4.9% (56 of 1138 patients,) and for 
gastrectomies a mean rate of 1.2 % (21 of 1715 patients.)
vi) LYMPH NODE RETRIEVAL
106
14 oesophagectomy (607 patients) reported on lymph node retrieval per operation; 
with a weighted mean number of 17.6 (range of means 2-79.) 18 gastrectomy studies 
(932 patients) stated lymph node retrieval, with a weighted mean of 28.3 (range 1-78.)
vii) R0 RESECTION RATE
Only 8 oesophagectomy reports (222 patients) and 3 gastrectomy reports (77 patients) 
stated their R0 rate clearly, with overall (weighted mean) success amongst these being 
91.0% for oesophagectomies and 100% for gastrectomies.
viii) LENGTH OF HOSPITAL STAY (see Figure 3.4)
17 oesophagectomy papers reported their length of stay, with a mean of 11.0 days 
(range 2- 195 days.) This was quoted in 18 gastrectomy papers, with a mean of 13.4 
days (range 3-61.)
Figure 3.4 Length of Hospital Stay for Minimally Invasive Gastro-Oesophageal 
Cancer Surgery
Length of Stay for Minimally Invasive Gastric and Oesophageal Cancer Surgery
9 ->
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Length of stay (days)
ix) QUALITY OF LIFE (POST-OPERATIVE)
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Only one paper addressed quality of life (Luketich 2003.) This study included 140 
laparoscopic oesophagectomy patients (with cervical anastomosis) and utilised a 
short-form 36 (SF36) and the Gastro-Oesophageal Reflux disease-Health Related 
Quality of Life Scale. It found low dysphagia scores and most patients had no reflux. 
Compared to the US population, physical scores reported were not statistically 
significant; mental component scores were however slightly but significantly 
(p=0.001) lower than the US mean. Post operative scores indicated preservation of 
quality of life.
Table 3.3 Differences in Results reported between East and West Centres for 
Minimally Invasive Gastric and Oesophageal Cancer Surgery
Oesophagectomy Gastrectomy
Total East West Total East West
Number of 
studies
23 6 17 23 17 6
Number of 
Patients
1398 293 1105 2546 2427 119
Mortality 2.3% 1.4% 2.5% 0.1% 0.04% 1.7%
Morbidity 46.2% 26.6% 50.4% 12.7% 12.2% 21.5%
Leak rate 7.7% 6.5% 8.1% 1.5% 1.5% 1.1%
Respiratory
complications
13.1% 8.1% 14.2% 0.6% 0.6% 0.9%
Blood loss (ml) 315.7 382.4 303.1 191.6 192.2 185.4
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Operative time 
(mins)
281.2 271.3 338.6 249.9 251.8 204.1
Conversion
ratio
4.9% 5.1% 4.9% 1.2% 1.0% 6.7%
Hospital stay 
(days)
11.0 11.3 10.0 13.4 14.1 11.8
R0 rate 91.0% 84.8% 92.6% 100% 100% 100%
Lymph node 
yield
17.6 22.3 14.9 28.3 10.6 30.0
3.4 Discussion
This review of over 3960 operations reported in 46 papers confirms that minimally 
invasive gastric and oesophageal cancer surgery is increasingly being reported in the 
literature from centres worldwide; and that these reports indicate that it is both safe 
and feasible. However the overall quality of these reports is low and therefore must be 
treated with great caution. This, combined with the fact that minimally invasive 
surgery (MIS) remains an investigational technique, not a treatment alternative, adds 
force to the argument that better evidence on outcomes is urgently needed, so that 
decisions about adopting it can be made on a more secure basis. Majority of the 
literature currently consists of case series, one of the weakest study designs 
recognised by all hierarchies of scientific evidence (CEBM.) Other studies compare 
historical or select open procedures to laparoscopic procedures, but the validity of 
such comparisons is extremely doubtful (Kunz 1998, Juni 2002.)
Only 3 randomised trials have been published in the English language, all being small
single institution studies of distal gastrectomy; with a low Jadad score of 3 or 4 (Lee
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2005, Hayashi 2005, Huscher 2005.) Whilst the results suggest advantages for the 
minimally invasive approach, it must be considered that these studies by pioneers are 
likely to favour the minimally invasive approach with which the authors are 
acknowledged experts. Generalisation of results is therefore likely to be difficult. 
Larger, multi-institution trials are necessary before any claims can be made for the 
superiority of the minimally invasive approach in normal surgical practice.
The results also demonstrate differences between East and West. A high proportion of 
the gastrectomy studies have been carried out in Japan and Korea, where major 
differences in the patient population, social influences, surgical philosophy and 
infrastructure affect outcomes such as length of stay and lymph node retrieval, 
producing results which may not reflect those found in other settings. Restricting the 
study to the English language literature may have led to the omission of some studies, 
but is unlikely to have influenced our summary outcome estimates very much (Moher 
1996, Egger 1997, Juni 2002.) Among published literature, those with significant 
results are more likely to be published in English, be cited and published repeatedly; 
leading to English language bias, citation and multiple publication bias (Egger 1998.) 
Previous work suggests the omitted studies are likely to be smaller and of lower 
quality than those included (Colditz 1989.)
The value of less than 6 patients was an arbitrary number used to exclude case reports 
(which with the exception of one including 5 patients were mostly focussed on 1-3 
cases;) but include the maximal number of case series in the study.
Since valid direct comparisons with contemporary open surgery are lacking, it is not 
possible to make confident statements about the potential benefits of minimally
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invasive surgery. Rough comparisons with recent reports on open surgery suggest 
that reduced mortality, respiratory complications, blood loss and more rapid return of 
quality of life are areas in which minimally invasive surgery might prove superior. 
Leak rates were very low for gastrectomy, but were similar to those in reports of open 
surgery for oesophagectomy. Perhaps surprisingly, length of hospital stay and overall 
morbidity rates (for oesophagectomy) did not show any evidence of being areas of 
benefit. Operating times reported appear longer than those that might be expected 
from open operations, which would mirror the experience of previous laparoscopic 
procedures. None of these conclusions can be accepted with any certainty because of 
the large number of clear potential sources of bias in the studies reported. Patients 
selected for minimally invasive surgery are unlikely to have been representative of the 
population of cancer patients presenting to the reporting centres. Particularly in the 
early stages of their experience, prudent surgeons are likely to have selected patients 
with smaller tumours and to have avoided candidates with obvious serious co­
morbidity. Some of the findings reported are unexpected, given the theoretical 
benefits of minimally invasive surgery. The exceptionally low leak rate amongst 
laparoscopic gastrectomy patients, for example, could not have been predicted, since 
there is no reason to expect that laparoscopically formed anatomises will be superior 
to those performed during open surgery.
Surgeons whose results were unsatisfactory may have been less inclined to publish 
than those who were happy with their outcomes, and this suspicion of probable 
publication bias indicate is lent some support by the apparently skewed data on 
gastrectomy conversion rate. The apparent discrepancies between some of the 
findings, which suggest excellent outcomes (for example leak rates, mortality, RO 
resection rate) and others which suggest no benefit or potential problems (e.g. length
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of stay, nodal yield) also suggest a significantly heterogeneous and possibly biased 
data sample. The reports describe a variety of different techniques, and it is not clear 
whether any of these carry significant advantages over others. Oesophagectomy in 
particular has been performed in several ways which differ importantly from each 
other, and the literature in this area is heavily influenced by one particular unit with a 
very large series which reports excellent results, but whose technique, perhaps not 
surprisingly, has gradually evolved through time (Luketich 2002.)
The reporting of outcome data is variable. Whilst all papers stated 30 day mortality 
rates, 4 papers (2 gastrectomy and 2 oesophagectomy) did not report overall 
morbidity. Data reporting of all outcomes measured in the review is not universal with 
all papers, especially gastrectomy conversion rates. Whether this is intentional or an 
oversight is questionable and may have impacted on results of the review. (Although 
an attempt to minimise this was made by using weighted means to analyse outcome 
results.)
Less than half of the papers report seeking and obtaining ethical permission for data 
collection. This may be as majority of data was collected retrospectively on individual 
disease-specific registers with anonymous demographics. However the lack of 
reporting introduces the possibility of hidden bias in patient selection as well as 
outcome reporting.
Reflecting on these findings with the benefit of experience of previous advances in 
minimally invasive surgery, it seems clear that there is a danger of repeating scenarios 
that proved unhelpful to progress in the past. The lack of good quality evidence (with 
minimal binding,) together with the encouraging results reported from a clearly biased
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literature carries the risk of polarising the surgical community into sceptics and 
enthusiasts without ensuring that the evidence required to reach consensus between 
the two is obtained. A successful randomised trial requires a group of surgeons with 
sufficient experience of the procedure to reach agreement on the appropriate question, 
and to reach consensus on the definition of the procedure to be tested against open 
surgery. Consensus would be greatly enhanced by previous experience of co­
operating and sharing data in a common format and by analysis of individual and unit 
experience to demonstrate the position on the learning curve of group members. It 
therefore seems that a prospective non-randomised co-operative study conducted by 
the surgeons interested in developing these techniques would be a very helpful 
preliminary step towards a randomised trial. Such a study could allow the evaluation 
of learning curves, the estimation of treatment effects for the purposed of power 
calculations, and the development of measures of quality for the procedure. Most 
importantly, it would promote consensus and co-operation amongst surgeons by 
requiring them to become familiar with entering their results in standard format. This 
kind of study would require smaller funds than a RCT, and could be facilitated by 
nesting it within the activities of relevant specialist organisations, such as AUGIS.
We have previously designated this type of study “Phase IIS” by analogy with the 
Phase II studies regularly performed in oncology (McCulloch 2002.) The problems of 
the current literature on minimally invasive gastrectomy and oesophagectomy 
illustrate the need for better evidence with which to make decisions about the future 
place of this type of surgery. A Phase IIS type study would be very helpful at this 
stage in the development of these techniques, and could act as a “bridge” between the 
current case-series based literature and multicentre randomised trials.
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Since the publication of the above chapter in the British Journal of Surgery, there 
have been multiple articles published on the subject of minimally invasive 
oesophagectomy and gastrectomy. Most papers remain retrospective series of highly 
selected patients. To date, there have been 2 further reviews on oesophagectomies, 
although no completed randomised controlled trials (the protocol for the Traditional 
invasive versus minimally invasive, TIME, trial by Biere et al has however been 
published (Biere 2011).) There has been one further review of gastrectomies 
(performed in Western centres.)
More recent data from systematic reviews, suggest a mortality rate of 2.9% and 
morbidity of 46% in minimally invasive oesophagectomies (Decker 2009.)
Comparing the totally MIE approach to open surgery, no significant difference was 
found between groups for major morbidity or pulmonary complications OR 0.88 (95% 
Cl 0.35-2.14) and OR 1.05 (95% Cl 0.42-2.66, p=0.91) respectively. It remains 
acknowledged however that MIE has been reported in case series and case-control 
studies where bias in study design may have occurred.
Strong et al analysed minimally invasive gastrectomies in the West (Strong 2009.)
They demonstrated that MIG had similar findings to those published in the East, with 
decreased length of hospital stay, decreased narcotic use, fewer complications and 
equivalent short-term oncological outcome (however no overall comparison statistics 
are quoted.)
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Chapter 4 -  A Phase II Surgical Trial of Minimally Invasive Gastro- 
Oesophageal Cancer Surgery
4.1 Introduction
Minimally invasive approaches to gastro-oesophageal cancer surgery are increasingly 
being reported in the literature, mostly in the form of case series, with few randomised 
controlled trials of distal gastrectomy (3 to date published in the English language:
Lee 2005, Hayashi 2005, Huscher 2005;) and none of minimally invasive 
oesophagectomy. Further detailed evaluation of minimally invasive surgeiy in this setting 
is therefore clearly required as its popularity increases in order to prevent a potential conflict 
of interest between enthusiasm and safety concerns. This would also aim to satisfy the 
demands for clinical governance whilst avoiding the stifling of innovation.
The gold standard for the evaluation of interventions is a randomised controlled trial 
(RCT) (NHS/DoH 1992.) RCTs are notoriously difficult when applied to surgical 
techniques, especially in terms of defining a learning curve, intervention definition 
and the need for both quality control and consensus between participating surgeons.
Integration of prospective audit and quality control with modified randomised trials may 
provide a means of overcoming some of the existing difficulties that need to be recognised in 
the development of new surgical techniques. In order to do this, we have developed a 
preliminary phase II surgical trial prior to conducting a RCT, similar to oncological phase II 
trials (McCulloch 2002.) This would act to bridge the gap between case series and RCTs and 
aid:
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- the development of a satisfactory definition of the procedure , the trial question and 
quality control measures
- collection of data in order to enable power calculations, identifying suitable sample 
sizes and end points for a RCT
allow evaluation of participant learning curves
- enable the evolution of consensus and the required familiarity with trial participants 
working together to allow organic trial progression.
The aim of this preliminary “phase IIS” study has been to establish and compare the 
standards of care in minimally invasive gastro-oesophageal cancer surgery, initially 
by means of a multicentre, retrospective cohort database; followed by a period of co­
operative prospective non-randomised data collection. The results of this study would 
then be analysed and used to design a study involving expanded data collection in a 
prospective, randomised trial comparing surgical techniques.
4.2 Method
The MIGOCS (Minimally Invasive Gastro- Oesophageal Cancer Surgery) group was 
established between experienced surgeons in 2005 as independent research 
collaboration. It has the formal approval of the Association of Upper Gastro­
intestinal Surgeons for Great Britain and Ireland (AUGIS) and the Association of 
Laparoscopic Surgeons (ALS) and the National Institute for Clinical Evidence (NICE.) 
More recently, MIGOCS has been adopted by ALS as part of a comprehensive suite 
of minimal access surgical registers.
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The MIGOCS group currently includes over 60 consultant surgeons from centres 
around the UK and Europe and is concerned with research study. It is not a society, 
has no supervisory role and does not advise on mentoring, regulation or accreditation 
issues.
Through expert consensus discussions, utilising an iterative process of development 
and an initial troubleshooting period, an online registry for recording of results was 
developed, available at: http://rsl.e-dendrite.com/csp/rnigocs/frontpages/rnigocs.
The register consists of 5 sections, comprising: (i) demographic details; (ii) pre­
operative assessment and staging; (iii) surgical intervention; (iv) post-operative course; 
(v) pathology and clinical outcome.
Entry of data on the register was intended to be done by MIGOCS members (or their 
nominated representatives) in the centre performing the surgery, with technical 
support as required. Reality however meant that in all but one centre the data was 
placed on the register by the research fellow with information provided by MIGOCS 
members.
i) Demographic Details
Only fundamental patient identification is collected on the database (date of birth, 
gender and date of operation) in order to ensure patient confidentiality and adhere to 
the Data Protection Act. (Subject to ethical approval this aspect of data collection may 
be expanded in the future as the trial develops towards randomisation.)
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Figure 4.1: Demographic Data Collection as seen on the MIGOCS Register
ii) Pre-O perative Assessm ent and  Staging
Patient selection criteria significantly affect surgical outcomes. The MIGOCS dataset 
records:
- Initial TNM staging
- Pre-operative chemotherapy
- Staging modalities utilised
- Tumour details - position, dimensions and Siewert type (where relevant.)
- Pre-operative health status - physiological O-POSSUM score (the website is 
linked to calculation sites) and ASA (American Association of Anaesthetists) 
grading.
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O-POSSUM (Oesophago-Gastric Physiological and Operative Severity Score for the 
enumeration of Mortality and Morbidity) (Tekkis 2004.)
This provides a prediction model of risk-adjusted post-operative mortality specific for 
oesophago-gastric mortality allowing comparisons of outcome despite different 
demographic characteristics and referral patterns. This approach has been 
demonstrated to accurately predict mortality post-gastrectomy but is poor in 
accurately predicting outcome following oesophagectomy (Lagarde 2007.) Variables 
used in the calculation of an O-POSSUM score were stated in chapter 1.
ASA Grade (American Society of Anaesthesiology)
This aids the classification of pre-operative physical status and risk and although it 
has limitations, it is a useful global tool, is used universally and is familiar. The 
grades are defined in the table found in chapter 1.
TNM (Tumour Node Metastasis) Stage
This is based on the joint UICC (International Union Against Cancer), AJCC 
(American Joint Committee on Cancer) and JJC (Japanese Joint Committee) staging 
classification first developed in 1986 and last updated (prior to work for this thesis) in 
2003. The system provides an anatomical classification, where T represents the extent 
of the primary tumour; N the presence or absence and extent of lymph node 
involvement; and M the presence or absence of distal métastasés. It is outlined further 
in chapter 1.
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Siew ert Type
This is explained in further detail in chapter 1. This classifies gastro-oesophageal 
tumours according to their location (Siewert 1996.) Type 1 tumours arise l-5cm above 
the anatomical cardia and are tumours of the distal oesophagus. Type II tumours are 
true cardia tumours and arise within 1cm above and 2cm below the anatomical gastric 
cardia. Type III tumours are gastric in origin and arise 2-5cm below the anatomical 
cardia.
Figure 4.2: Pre-Operative Data Collected as seen on the MIGOCS Register
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Hi) Surgical Intervention
Selected operation details are recorded to enable the evaluation of approaches and 
techniques. Information requested includes:
- Operating surgeon and assistant(s)
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- Port placements and sizes (additionally giving an indication of patient positioning)
- Anastomosis performed (sutured/stapled/both)
- Nodal dissection
- Thoracic dissection details (where applicable)
- Operating statistics - anaesthetic time (mins,) operating duration (mins) and blood 
loss (mis.)
Figure 4.3: Operative Data Collection on the MIGOCS Register
MIGOCS - Minimally Invasive Gastro-oesophageal Cancer Surgery
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iv) Post-O perative Course
This section analyses:
- Discharge date (automatic calculation of length of stay in days.)
- Morbidity -  including cardiorespiratory complications; chyle and anastomotic 
leaks (and related gastric conduit ischaemia;) infection; haemorrhage; the 
requirement for a second operation and what this involved.
- Post-operative course - intensive care stay (days;) post-operative transfusion; the 
number of days to: free fluids, diet, bowel action, walking and cessation of parental 
analgesia.
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Figure 4.4: Post Operative Course Data Collection as seen on the Register
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v) Pathology’ and  C linical Outcome 
Recorded data involves:
- Tumour pathology - pTNM staging, the involvement of resection margins, the 
total lymph node yield and the number that are positive for cancer.
- Clinical outcome - patient health related quality of life at 3, 6 and 9 months 
post-operatively, date and site of recurrence and date of death (where relevant.)
This final section is currently aimed more at prospective data collection and requires 
further development -  including scoring systems required to evaluate quality of life 
and 5 year survival data.
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Table 4.5 Pathology Outcome as seen on the MIGOCS Register
To validate complete and accurate data collection, randomised checks of data entry 
from all units was carried out at regular intervals by a research fellow. This involved 
email requests of data and/or occasional site visits. Completed data entry was then 
locked from further alterations. This was done by the register’s administrator 
preventing further retrospective changes to the primary data entry and ensuring no 
data tampering which may introduce bias or statistical skewing. In the event of 
missing or incomplete data, units concerned were contacted.
Reports
- Information registered is retrievable by each unit themselves (but not data from of 
other units.)
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- A central office compiled regular anonymised comparative and summary reports, 
including learning curve analysis.
Consensus Conferences
Regular discussions about technique quality measures and learning curves are 
mandated, moving towards a randomised controlled trial.
Ethics
The MIGOCS project is based around a disease-specific registry and involves no 
experimental intervention, which exempts it from Research Ethics oversight, 
subjecting it instead to the rules of Audit and Governance review, with which it is 
fully compliant.
4.3 Results
Please see chapters 5 and 6 for a detailed report of results.
4.4 Discussion
The register was initially developed in 2005 following a series of meetings between 
interested clinicians with experience in upper gastrointestinal cancer surgery, utilising 
the knowledge gained by one of the group (Mr P McCulloch) from the ASCOT study 
(Cummins 2001.) Its comprehensive database (aided by its ease of use by online 
access) means that it helps fulfil the requirements of clinical governance and 
revalidation of all doctors; thereby providing further incentive for data collection. The 
database has undergone further modifications since its conception in 2005, following 
meetings with those using it, using Delphi methodology. The database has retained its
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clear layout, with drop-down menus; links have been made to other websites e.g. for 
the calculation of O-POSSUM scores, and some data fields have been made 
mandatory. This latter concept has been controversial and prevents users jumping 
between sections of the register but previous experience from the ASCOT database 
has shown that making fields mandatory ensures data is complete. A balance was 
made therefore between the number of mandatory and optional fields, with only 
certain things such as operation approach and lymph node yield remaining 
compulsory. In order to encourage complete data entry a downloadable proforma of 
all data fields was provided on the website (following feedback from participating 
consultants,) which can be found in appendix 2. Once all data (except follow-up) has 
been entered data fields can be locked by the system administrator, preventing 
retrospective data tampering. The follow-up section of the register is still in evolution, 
especially with respect to quality of life data and the frequency and duration of 
follow-up required to provide adequate mortality and morbidity information.
The database also collects detailed information on the minimally invasive approach of 
oesophagectomy or gastrectomy. This is vital as a variety of approaches are used and 
preferences vary significantly. The detail of data collection on port siting has been 
criticised and perhaps this could be made more descriptive, including patient 
positioning for the procedure e.g. prone or left lateral. Diagrams have been developed 
to make this section more user friendly and obtain more precise recording of port 
placement during MIOs and MIGs.
Data collection was initially retrospective, to enable clinicians to become familiar 
with the register and enable its development in the early stages. This enabled feedback 
to individual units of their performance and a more critical look at the components of
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the register from multiple sources. All derivative data from the register was reliant on 
individual surgeons’ honesty in providing accurate information on all cases of their 
learning curve. With this in mind, data checks by an independent research fellow 
visiting the units provided quality control.
A number of difficulties were encountered in data collection, some of which were 
confirmed by the use of a questionnaire to all participants. Time constraints were 
reported to be the biggest limitation to the placement of data on the register by 
consultants, especially with the concurrent National Oesophago-Gastric Cancer Audit 
promoted by AUGIS. (It is hoped that the two sites will be linked in the future to 
avoid the duplication of data entry and continuing to address the need for clinical 
governance; although this may give rise to the need for data clerks.) Concerns were 
voiced regarding publication rights and who gained credit for any publication arising 
from data entered into the register. Further concerns involved politics between 
individuals and concerns regarding confidentiality. In order to try and overcome these 
issues, assistance in data placement on the register was initially provided by the 
research registrar (although like later data validity checks this was limited by patient 
case note availability whilst visiting centres.) Publication rights were assured to 
remain with the centre providing data; however data publication as a group was 
planned, with individuals remaining anonymous but acknowledged. The register was 
also supported by the two of the main professional bodies for upper gastrointestinal 
surgeons in the UK — ALS and AUGIS.
Recruitment was addressed by raising the profile of the group by posters and 
presentations of data (by the research fellow and Dendrite pic,) as well as stands at 
major meetings nationally and in Europe.
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Funding issues involved an initial grant by Covidien, self funding and application for 
grants (by private and commercial bodies.)
All surgeons performing minimally invasive upper gastrointestinal cancer surgery are 
eligible for involvement in this study. Maximising centres and clinicians involved 
would optimise and increase the detail of evidence regarding this developing 
technique. The study thus far involves over 60 consultant surgeons in over 40 centres 
around the United Kingdom and a framework for the involvement of surgeons around 
the European Union.
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Chapter 5 -  A Retrospective Study of Minimally Invasive Gastro- 
Oesophageal Cancer Surgery in the UK
5.1 Introduction
In the UK the minimally invasive approach for gastric and oesophageal cancer has 
been gaining popularity since its introduction in the early 1990s (Cushier 1992, 
Manama 1994, Dexter 1996, Sutton 2002.) At present, most procedures tend to be 
carried out by surgeons with a major laparoscopic interest, on carefully selected 
patients and there is a wide variation in reported techniques and outcomes. Few 
British centres have published their results of minimally invasive gastric and 
oesophageal cancer surgery, and those that do tend to be low volume case series and 
case reports (Singh 2008.) In view of this and the weak evidence regarding the safety 
and efficacy of laparoscopic surgery for cancer of the oesophagus and stomach 
(outlined in chapter 3,) a more comprehensive look at procedures currently performed 
was required.
The MIGOCS group and database was set up in 2005 (as outlined in chapter 4.) 
Whilst data collection was in principle prospective, there was concern that the results 
of centres which already had an established programme for minimally invasive 
surgery before the database was set up should not be overlooked. UK centres already 
performing this type of surgery prior to the MIGOCS database being fully established 
therefore invited to contribute to the data collection. (This stage is approximately 
analogous to IDEAL stage 2a/b.)
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5.2 Method
The online database comprises of 24 fields in 5 sections (see chapter 4 for further 
detail):
- Demographic details (confidential identification.)
- Pre-operative assessment and staging 
Surgical intervention 
Post-operative course
- Pathology outcome
Initial retrospective data collection by participating surgeons was encouraged (aided 
by visits from an independent research fellow) for a time-limited period. Operation 
dates from December 1996 to December 2006 (when the data collection ceased) were 
recorded, provided surgeons could provide all the required fields. All retrospective 
data was checked and validated against case records by the research fellow to 
maintain quality control.
For the purposes of this chapter, the following data were extracted: patient selection; 
mortality; morbidity, specifically leak rate and respiratory tract infection; estimated 
operative blood loss; operative time; lymph node retrieval; conversion rate; R0 
resection success and length of stay. Post-operative complications were further 
subdivided into major (life-threatening,) and minor (prolonging hospital stay) using 
definitions proposed by Luketich et al (2003) (see table 5.2.)
130
5.3 Results
26 centres in the UK, comprising 39 consultants with previous experience agreed to 
take part in the study. Nineteen of these centres had no retrospective data or declined 
to participate.
Retrospective data was collected from 7 centres, with operations performed between 
1996 and 2006. 126 cases were recorded in total, 100 oesophagectomies and 26 
gastrectomies. The breakdown of the oesophagectomies by type is shown in the 
diagram below. Four operations were commenced laparoscopically but 3 of these 
were abandoned due to unresectable tumours being found intraoperatively (metastatic 
spread not seen on staging) and 1 was due to the patient having asystole on the table.
Types o f Oesophagectom y perform ed
□ Laparoscopic transhiatal
Æ  v ■ Laparoscopic
thoracoscopic
12 □ Prone thoracoscopic
□ Thoracoscopic
i o \  /  . • ■ W
■ Laparoscopic-assisted
27
thoracotomy
Figure 5.1: Breakdown of Oesophagectomies Performed
All 26 gastrectomies were distal or subtotal, with one being hand-assisted; 4 were 
local resections.
All lesions were apparently resectable at preoperative staging (CT +/- EUS +/- staging 
laparoscopy dependent on centre;) 51 of the 126 patients recorded on the database 
underwent pre-operative chemotherapy.
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1. DEMOGRAPHIC SELECTION
The mean patient age was 67.1 years; 82 were male and 44 were female. The staging 
of patients ranged from T1N0 to T3N2. The mean ASA was grade 2 (12 patients were 
grade 1,40 were grade 2, 17 were grade 3, and 1 was grade 4; the grade was not 
recorded in 37 patients.)
2. MORTALITY
The overall mortality was 6.0% (6 out of 100) for the oesophagectomy cases and 7.7% 
for the gastrectomy cases (2 out of 26.) Of the deaths from oesophagectomy, 1 was 
from a laparoscopic transhiatal procedure (of 32 recorded;) 1 thoracoscopic (of 12;) 1 
thoracoscopic/laparoscopic (of 27) and 3 from procedures with laparoscopic 
mobilisation and right thoracotomy (of 15 recorded.)
3. MORBIDITY
57 complications occurred in oesophagectomy patients (30 major and 29 minor, see 
table 4.1,) giving an overall morbidity of 57%. Complications are also reported by 
oesophagectomy approach, please see figure 5.2 for further details. There were 4 
major (life-threatening) and 9 minor (prolonging hospital stay) complications in the 
gastrectomy group (please see table 5.2.) Criteria for minor and major complications 
were based on those of Luketich et al (2003.)
Figure 5.2: Oesophagectomy Morbidity Breakdown by Approach
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□  laparoscopic transhiatal
■thoracoscopic and 
laparotomy
□  laparoscopic/thoracoscopic
□  laparoscopic-assisted 
thoracotomy
Tabic 5.1: Hospital Prolonging and Life Threatening Morbidity Related to 
Minimally Invasive Gastric and Oesophageal Surgery for Cancer
1 Hospital Prolonging (M inor) Complications Oesophagectom y
n=I00
Gastrectom y
n=26
1 A rrh y th m ia 12 4
S tr ic tu re 7 0
1 C o n g e s tiv e  C a rd ia c  F a ilu re 4 2
1 P leu ra l e f fu s io n 2 1
1 F is tu la 1 0
T ra n s ie n t I s c h a e m ic  A tta c k 1 0
P o rt s i te  h e rn ia 1 0
1 M in o r  h a e m o rrh a g e 1 2
1 Life-threatening (M ajor) Complications
R e s p ira to ry  tra c t in fe c tio n 19 3
I A n a s tig m a tic  le ak  (c o n f irm e d ) ( in c lu d in g  1 re la te d  to  
c o n d u it  is c h a e m ia )
3 0
I M y o c a rd ia l In fa rc tio n 3 1
1 C h y lo th o ra x 3 0
T e n s io n  p n e u m o th o ra x 1 0
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Multiple Organ Uystunction ¡syndrome (MUUS) 0
i) LEAK RATE
There were no reported leaks from the gastrectomies, and 3 confirmed anastomotic 
leaks in the oesophagectomy cases (3%.) One leak related to conduit ischaemia; 1 was 
in a laparoscopic transhiatal operation and 2 were from thoracoscopic procedures. In 
addition, there were 3 chylothoraces post-oesophagectomy (1 prone thoracoscopic and
2 laparoscopic/thoracoscopic,) all were successfully treated conservatively.
ii) RESPIRA TOR Y TRA CT INFECTION
3 gastrectomy cases (11.5%) developed a respiratory tract infection as did 19 
oesophagectomy cases (19%) -  7 laparoscopic transhiatal, 1 prone thoracoscopic, 4 
thoracoscopic, 2 laparoscopic/thoracoscopic and 5 laparoscopic-assisted thoracotomy 
(shown in table 5.2.)
4. BLOOD LOSS
Blood loss recording was too poor in the gastrectomy cohort to derive an average 
figure, but no record of blood loss greater than 100ml was received.
The mean estimated blood loss for all oesophagectomies was 694.6 mis (95% Cl
503.1 -  886.1.) Looking at each approach individually, the mean blood loss was 627.5 
ml for laparoscopic transhiatal, 785.0 ml for prone thoracoscopic, 454.4 ml for 
thoracoscopic and 883.4 ml for laparoscopic/thoracoscopic and 571.4 for laparoscopic 
assisted thoracotomy. See figure 5.3:
134
Minimally Invasive Oesophagectomy - Estimated Blood 
Loss
200 300 400 500 600 700 800 900 1000Blood Lots (mlt)
Figure 5.3: Estimuted Blood Loss During MIOs
Only 2 gastrectomies recorded intra-operative blood loss, both were estimated at 50 
ml.
5. O PERATIVE TIME
The mean operative time for oesophagectomies in the study was 287.2 minutes (95% 
Cl 265.4- 309.0.) For each individual approach the average operative time was: 214.3 
minutes for laparoscopic transhiatal, 320.9 minutes for prone thoracoscopic, 324.0 
minutes for thoracoscopic, 312.5 minutes for laparoscopic/thoracoscopic and 349.0 
minutes for laparoscopic-assisted thoracotomy. See figure 5.4:
Minimally Invasive Oesophagectomy Operative Time
O p e r a t iv «  Tim* (min utes )
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Figure 5.4: Operative Time of MIOs
The mean operative time for gastrectomies was 161.9 minutes. See fimire 5.5:
Minimally Invasive Gastrectom y - Operative Time
O p e r a t i v e  T i me ( mi nut es )
Figure 5.5: Operative Time of MIGs
6. L YM PH  N O D E  RETRIEVAL
Mean lymph node retrieval for the oesophagectomy cases was 16.1 (numbers ranged 
from 0 to 38.) Analysis by approach shows a mean lymph node retrieval of 14.8 by 
laparoscopic transhiatal approach; 13.0 for prone thoracoscopic; 12.4 for 
thoracoscopic, 22.1 for laparoscopic/thoracoscopic and 13.6 for laparoscopic-assisted 
thoracotomy (see table 4.2.)
Lymph node retrieval for gastrectomy cases ranged from 0 to 31 nodes, with a mean 
of 10.3.
7. C O N V E R SIO N  RA TE
The conversion rate for oesophagectomy cases overall was 4 in 100 (4%,) all 4 cases 
being via the laparoscopic/thoracoscopic approach. A further 7 oesophagectomy cases 
were abandoned due to the advancement of disease.
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No gastrectomy cases (of a total of 26) were converted; 3 however were abandoned 
due to an inoperable tumour being found.
8. RO RESECTION SUCCESS
The oesophagectomy RO resection rate was 82 in 100 (82%,) the most commonly 
involved margin being circumferential. Of the approaches with incomplete resection, 
10 were laparoscopic transhiatal, 2 prone thoracoscopic, 1 thoracoscopic, 2 
laparoscopic/thoracoscopic and 3 laparoscopic-assisted thoracotomy.
One of the 26 gastrectomy cases had an involved margin, giving a RO resection rate of 
96%.
9. LENGTH OF STAY
The length of hospital stay for gastrectomy cases ranged from 3 to 175 days, with a 
median of 10 days.
For the oesophagectomies, hospital stay ranged from 7 to 90 days, with a median of 
14 days. The median length of hospital stay by approach was 13 days for laparoscopic 
transhiatal, 10 days for prone thoracoscopic, 14 days for thoracoscopic, 18 days for 
thoracoscopic/laparoscopic and 13 days for laparoscopic-assisted thoracotomy (see 
table 5.2.)
Table 5.2: Main Operative Outcomes by Oesophagectomy Technique Utilised
Respiratory 
tract 
Infection 
(%) _
Estimated
Blood
Loss
(mis)
Operating
time
(mins)
Lymph
node
Yield
Length 
of stay 
(median 
days)
Oesophagectomy 
Technique Used
Laparoscopic transhiatal 21.9 627.5 214.3 14.8 13
Prone thoracoscopic 10.0 785.0 320.9 13.0 10
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Thoracoscopic 33.3 454.4 324.0 12.4 14
Laparoscopic/thoracoscopic 7.4 883.4 312.5 22.1 18
Laparoscopic assisted 
thoracotomy
33.3 571.4 349.0 13.6 13
5.4 Discussion
These results show that minimally invasive surgery for both gastric and oesophageal 
cancer is feasible and safe in a UK setting; although the full benefits, indications and 
optimal techniques have not yet been determined.
Over 5000 minimally invasive operations for gastric and oesophageal cancer have 
been reported in the worldwide literature, with wide variation in unit results and 
techniques.
In comparison to a recent systematic review of this literature (Gemmill 2007,) a 
relatively high overall morbidity and mortality has been found in this cohort of 
patients. The existing surgical literature is subject to considerable publication and 
selection bias, typical of the low methodological quality of case series evidence 
(Lilford 2004) and in most cases has not been independently verified. Our data may 
be affected by some early learning curve issues, whilst the setting of previous reports 
was very different. This is the first multicentre report of minimally invasive surgery 
(for gastro-oesophageal cancer) in the UK NHS and includes some early experiences. 
Therefore it is difficult to interpret our morbidity and mortality results in the context 
of recent world literature.
Estimated blood loss in gastrectomies is apparently very low, consistent with previous 
reports (Gemmill 2007,) but the mean blood loss for oesophagectomies reported here 
is moderately high (see figure 5.3,) possibly influenced by a few cases where 
difficulty was encountered peri-operatively with bleeding vessels. Centres with large 
experience have suggested that this kind of major intraoperative problem is a feature
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of the learning curve and tends not to occur after a certain stage in the experience of a 
unit (Litle 2002.)
The potential benefits of minimally invasive surgery for length of stay were not 
verified in this study and were not markedly shorter than for contemporary reports on 
open surgery. The units supplying data were not involved in fast track policies, such 
as those by Cerfolio (2004,) Kehlet (2004,) and it is uncertain whether there were 
delays related to a reluctance to discharge patients early arising from inexperience in 
some units.
Operative time was comparable to other studies. Operative time for the 
oesophagectomies demonstrates almost a normal distribution (suggesting a lack of 
reporting bias,) with most cases taking between 200- 350 minutes. Majority of the 
gastrectomies cases took 75-150 minutes.
The R0 resection rate and leak rate reported above are acceptable by current standards. 
The lymph node yield reported is considerably lower than that previously reported in 
published case series (Gemmill2007) and that recommended in previous studies of 
open surgery (SIGN guidelines 2006, Rizk 2006.) It seems likely that this is due to a 
less than radical approach to nodal dissection. This in turn could be due to an 
association between enthusiasm for minimally invasive surgery and scepticism about 
the benefits of radical nodal dissection, or to caution in dissection during the early 
stages of introducing a procedure. The latter clearly appears plausible. Clearly, the 
nodal yield for gastrectomy was not adequate for proper UICC staging, but whether 
the resections were nevertheless oncologically adequate cannot be determined from 
the data, although calculation of the Maruyama Index (Kampschoer 1989) would 
give a useful pointer.
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All studies of minimally invasive surgery need to be interpreted with care, as selection 
of patient and tumour characteristics can have considerable affect on outcomes such 
as operative time (Hyung 2006.) Few papers have published data regarding the 
learning curve for minimally invasive gastric and oesophageal cancer surgery. One 
paper, by Jin et al recorded 109 operative procedures (gastrectomies) by a single 
surgeon (Jin 2007.) This paper suggested a multidimensional learning curve, with a 
slight rising trend involving 3 phases that was achieved after 40 procedures. This 
curve was broken by unselected operations and the introduction of advanced 
techniques. This aspect of our results will be discussed in further detail in chapter 6.
This study has a number of limitations: our data was collected retrospectively, over a 
prolonged time span (although majority of procedures were performed after 2002.) 
This undoubtedly led to loss of a significant amount of data in some categories, and 
may have caused inadvertent bias, as there have been advances in inpatient care, pre­
operative staging and general laparoscopic operative experiences in the last 5 years. 
Contributors to the study were also self selected and may be unrepresentative of 
overall UK practice.
The benefits to patient quality of life that minimally invasive surgery may provide 
have not been addressed, as no objective data was available. Few studies have looked 
at this important area, those that do reporting some benefits over open surgery 
(Luketich 2003, Parameswaran 2007, Yasuda 2007.) Since this outcome measure 
seems the most likely to yield a significant benefit for minimally invasive surgery, it 
is clearly important to record reproducible, scientifically valid measures of quality of
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life at specific times after surgery to allow a proper evaluation. This point we aim to 
address in future studies.
Despite these limitations, this study provides data from multiple UK centres with 
experience in minimally invasive gastric and oesophageal cancer surgery, an area in 
which there is limited published evidence. It has been demonstrated that the procedure 
appears safe in terms of RO resection and leak rate, but is clearly still evolving. 
Outcomes in terms of lymph node retrieval, morbidity and mortality were inferior to 
those previously reported, but it is unclear whether the difference is due to more to 
inexperience or poor selection in this cohort, or the undoubted biases in the published 
literature.
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Chapter 6- A Prospective Phase II Surgical Trial of Minimally 
Invasive Gastro-Oesophageal Cancer Surgery in the UK
6.1 Introduction
Following on from work reported in chapter 5, further data collection was performed 
utilising the MIGOCS register. (This is analogous to IDEAL stage 2b.) Data was 
collated prospectively from centres with an established upper gastrointestinal 
laparoscopic practice in the UK, many of whom had already provided retrospective 
data reported in the previous chapter.
Data collection was aimed to not just provide an idea of current practice and outcomes 
of minimally invasive upper gastrointestinal oncological surgery but to be part of a 
phase II surgical trial. Therefore it aimed to aid the definition of the procedure; 
provide information on the learning curve involved; begin to identify suitable sample 
sizes and timing for a RCT; and develop consensus amongst surgeons to move 
towards a RCT.
6.2 Method
Data was submitted by MIGOCS members with an active upper gastrointestinal 
cancer laparoscopic practice prospectively from December 2006. Each centre was 
subjected to quality control checks by random visits from the research fellow.
The MIGOCS register available online at: http://rsl.e- 
dendrite.com/csp/migocs/frontpages/migocs.
It consists of 5 sections as previously outlined:
- Demographic details
- Pre-operative assessment and staging
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Surgical intervention 
Post-operative course 
Pathology outcome
For the purposes of this chapter (consistent with chapter 5,) the following data were 
extracted: patient selection; mortality; morbidity, specifically leak rate and respiratory 
tract infection; estimated operative blood loss; operative time; lymph node retrieval; 
conversion rate; RO resection success and length of stay. Post-operative complications 
were further subdivided into major (life-threatening,) and minor (prolonging hospital 
stay) (see table 5.1.)
6.3 Results
Seven centres comprising 14 consultants provided prospective data on their minimally 
invasive gastro-oesophageal cancer resections, up until August 2008.
278 oesophagectomies were recorded in total and 37 gastrectomies; the breakdown of 
each is demonstrated in the pie charts below.
■ Laparoscopic+thoractomy 
( 12)
■  larynogopharyngooesopha 
gectomy (2)
Laparoscopic Transhiatal 
(33)
■  Thoracoscopic+laparotomy 
(119)
Figure 6.1: Breakdown of Oesophagectomies by Approach
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Figure 6.2: Breakdown of Gastrectomies by Approach
For the purpose of this chapter the oesophagectomy data has mostly been analysed by 
approach (laparoscopic pharyngo-laryngo-oesophagectomies being included in the 
laparoscopic and thoracotomy group); and due to insufficient numbers, the 
gastrectomies have been looked as a single group.
258 minimally invasive oesophagectomies were completed (92.8%,) with 13 
abandoned procedures (mainly due inoperability of tumour) and 7 procedures were 
converted to open (mostly due to bleeding or poor views.) Of the gastrectomies, 33 
procedures were completed laparoscopically (89.2%,) with no conversions and 4 
procedures abandoned due to inoperable tumour.
1. D E M O G R A P H IC  SELEC TIO N
The table below outlines the average age and gender of people undergoing a 
laparoscopic approach to both oesophagectomy and gastrectomy:
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Table 6.1: Age and Gender of People Undergoing a Minimally Invasive
Approach to Oesophagectomy and Gastrectomy
Approach
TOTAL OESOPHAGECTOMIES 
(N=278)
LAPAROSCOPIC+THORACOTOMY
(n=12+2)
MEAN
SD
MEAN
SD
Gender
65.3 210M, 68F 
9.5
66.4 11m, 3f 
9.2
LAPAROSCOPIC TRANSHIATAL
OESOPHAGECTOMY
(n=33)
THORACOSCOPIC+LAPAROTOMY 
(n=l19)
MEAN
SD
MEAN
SD
66 20m 13F 
9.5
64 90M, 29F 
9.5
LAPAROSCOPIC/THORACOSCOPIC
OESOPHAGECTOMY
(n=l12)
GASTRECTOMIES
(N =37)
MEAN
SD
MEAN
SD
66.4 89M, 23F 
9.4
72.6 20M, 18F 
10.2
Figure 6.3: Patient Age Range undergoing Minimally Invasive Oesophagectomy
and Gastrectomy
——  Laparoscopic/Thoracotomy 
— — Laparoscopic/Transhiatal
—  Laparotomy/Thoracoscopic
—  - Laparoscopic/Thoracoscopic
Gastrectomy
Patient Age (years)
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The ASA grade of groups undergoing laparoscopic oesophagectomy and gastrectomy 
was relatively evenly ranged with a mean of grade 2. (There were: 58 grade 1 
patients, 125 grade 2 patients, 27 grade 3 patients, 1 grade 4 patient, the rest were not 
documented.) O-Possum scores for the oesophagectomies ranged from a mean of 16.8 
to 19.1.
The table below demonstrates the grade of oesophageal tumour resected by each 
minimally invasive approach. 158 oesophagectomies underwent pre-operative 
chemotherapy (4 laparoscopic plus thoracotomy; 6 laparoscopic transhiatal; 73 
thoracoscopic plus laparotomy and 75 laparoscopic/thoracoscopic)
GRADE 0 I Ha Hb m  iva Total
APPROACH
Laparoscopic+Thoracotomy 0 2 4 1 5 2 14
Laparoscopic Transhiatal 6 7 7 6 6 1 33
Thoracoscopic+Laparotomy 6 15 45 10 42 1 119
Laparoscopic+Thoracoscopic 7 9 60 5 31 0 112
Total 19 33 116 22 84 4 278
Table 6.2: Pre-Operative Histological Grade of Oesophageal Tumour 
Resected by Approach
Of the gastrectomies performed, 1 was histological grade 0; 19 grade la; 9 grade lb; 5 
grade II, 3 grade Ilia, 1 grade Illb and no grade IV. Six gastrectomies underwent pre­
operative chemotherapy.
2. M O R TA LITY
The overall mortality was 2.5% for the oesophagectomies (7 patients from 278 
procedures; 1 out of 33 laparoscopic transhiatal; 5 out of 119 thoracoscopic with
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laparotomy and 1 out o fl 12 laparoscopic/thoracoscopic.) 4 out of 37 patients 
undergoing gastrectomy died (10.8%.)
3. M O R B ID ITY
Overall there were a total of 146 (92 major, 54 minor) complications in the 
oesophagectomy group and 9 in the gastrectomy group (4 major, 5 minor), which is 
outlined further below. The breakdown of major (life threatening) and minor (hospital 
prolonging) complications recorded in the figure below is based on criteria used by 
Luketich et al (2003,) as in chapter 5. This is analysed in more detail in table 6.4:
Total M ajor 
Complications
Total M inor 
Complications
■ Laparoscopic/Thoracotom 
y (n=14)
■ Laparoscopic Transhiatal 
(n=33)
Thoracoscopic/Laparotom 
y (n=119)
■ Laparoscopic/Thoracosco 
pic (n=112)
0% 20% 40% 60% 80% 100%
Figure 6.4: Major (Life threatening) and Minor (Hospital prolonging) Morbidity 
Related to Minimally Invasive Oesophagectomy (by Approach)
Respiratory tract infections (RTls) and anastomotic leaks are the 2 most commonly 
reported complications of upper gastrointestinal surgery. In this series, there were 38 
RTIs in the oesophagectomy group (13.7%) and 2 (5.4%) in the gastrectomy group; of 
the anastomotic leaks, there were 22 (7.9%) in the oesophagectomy group and 1
147
(2.7%) in the gastrectomy group. The next most common major complication 
occurring was conduit ischaemia (11,4.0% of oesophagectomies;) in all cases a 
confirmed leak occurred. This was most common the laparoscopic/thoracoscopic 
group.
The commonest minor complication in both oesophagectomies and gastrectomies was 
an arrhythmia (5.8% andlO.8% respectively.) The next most frequently occurring 
minor complications were: strictures, congestive cardiac failure and infection (each 
affecting 2.5% of oesophagectomy cases.)
Comparing different oesophagectomy approaches, the highest morbidity (both major 
and minor) was encountered in the laparoscopic transhiatal group.
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Table 6.3: Morbidity from Minimally Invasive Gastro-Oesophageal Cancer Surgery
Complication
Severity Complication
Laparoscopic/
thoracotomy
(n=14)
Total
Oesophagectomies Gastrectomy
(n=278) (n=37)
Minor Arrhythmia 0 3 7 6 16 4
Stricture 0 0 7 0 7 0
Congestive Cardiac Failure 1 1 3 2 7 0
Pleural Effusion 0 2 2 0 4 0
Transient Ischaemic Attack 0 1 0 0 1 0
Port Site Hernia 0 0 1 1 2 0
Minor Haemorrhage 0 1 0 0 1 0
Other infection (Urinary, line 
sepsis, faecal) 0 1 3 3 7 1
Recurrent Laryngeal Nerve 
Injury 0 0 1 8 9 0
otal Minor Complications 1 9 24 20 54 5
Major Respiratory Tract Infection 3 6 13 16 38 2
Respiratory Failure 0 0 5 1 6 0
Leak (confirmed) 2 1 5 14 22 1
Conduit Ischaemia 1 2 0 8 11 0
Myocardial Infarction 0 0 3 0 3 1
Chylothorax 0 0 6 3 9 0
Tension Pneumothorax 0 0 1 0 1 0
Major haemorrhage 0 0 0 1 1 0
Cerebral Vascular Accident 0 0 0 1 1 0
Total Major Complications 6 9 33 36 92 4
Overall Complications 7 18 57 56 146 9
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4. BLOOD LOSS
Mean blood loss in the oesophagectomy group was 558mls (95% Cl 550- 583) (not all 
centres recorded this information, so incomplete data entries in this field occurred.)
By approach, estimated mean blood loss was: 573ml in the laparoscopic/thoracotomy 
group; 579ml in the laparoscopic transhiatal group; 546ml in the 
thoracoscopic/laparotomy group and 563ml in the laparoscopic/thoracoscopic group.
A total of 13 patients undergoing oesophagectomy received a transfusion (1 in the 
laparoscopic/thoracotomy group; 4 in the laparotomy/thoracoscopic group and 8 in 
the laparoscopic/thoracoscopic group.)
The mean estimated blood loss for minimally invasive gastrectomies was 300ml (95% 
Cl 245-356.) No patients in the gastrectomy group received a post-operative blood 
transfusion.
150
Estimated Blood Loss during 
Minimally Invasive 
Oesophagectomies
Estimated Blood Loss (mis)
Figure 6.5: Estimated Blood Loss During Minimally Invasive 
Oesophagectomies
5. O PERA TIV E  TIM E
The mean operating time for laparoscopic oesophagectomies was 281 minutes (95% 
Cl 276-327.) (This breaks down by approach into 207 minutes for 
laparoscopy/thoracotomy; 193 minutes for laparoscopic transhiatal; 321 minutes for 
laparotomy/thoracoscopic; and 402 minutes for laparoscopic/thoracoscopic.) The 
mean operative time for the gastrectomies was 200 minutes (95% Cl 106-295.)
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Operating Time by Approach
18
■  Total MIO
■  Laparoscopic
■  Thoracoscopic
■  LTHE
■  LPLTE
Figure 6.6: Operative Times for Minimally Invasive Oesophageal Cancer 
Resections
Minimally Invasive Gastrectomy 
Operating Time
Operating Time (mins)
Figure 6.7: Operative Times for Minimally Invasive Gastric Cancer Resections
6. L YM PH  N O D E  RETRIEVAL AN D  RO RE SEC TIO N  RA TE
Mean lymph node retrieval for the oesophagectomies was 17.5 (95% Cl 13.1 -24.1) 
and for the gastrectomies was 13.2 (95% Cl -2.79- 37.9.) This is detailed further in 
the table below.
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Approach
Total Oesophagectomies 
(n=278)
Laparoscopic/Thoracotomy
Oesophagectomy
(n=14)
Laparoscopic Transhiatal
Oesophagectomy
(n=33)
Laparotomy/Thoracoscopic
Oesophagectomy
(n=l19)
Laparoscopic/Thoracoscopic
Oesophagectomy
(n=l 12)
Node
Retrieval
mean
median
mean
median
mean
median
mean
median
17.5
16
21.4
21
14
12
16.5
14
Positive Nodes
2.4
0
3.3
2
4.5
I
2.6
0
mean 18.7 1.6
median 18 0
mean 13 .2 3
median 9.5 0
Gastrectomy 
(n=37)
Table 6.4: Nodal Retrieval for Minimally Invasive Oesopliagectomies and
Gastrectomies
Approach
Total Oesophagectomies (n=278) 70.9 25.5 3.6
Laparoscopic/Thoracotomy 
Oesophagectomy (n=14) 57.1 42.9 0.0
Laparoscopic Transhiatal Oesophagectomy 
(n=33) 72.7 24.2 3.0
Laparotomy/Thoracoscopic 
Oesophagectomy (n=l 19) 85.7 13.4 0.8
Laparoscopic/Thoracoscopic 
Oesophagectomy (n=l 12) 56.3 36.6 7.1
Gastrectomy (n=37) 86.5 8.1 5.4
Table 6.5: Resection Margins for Minimally Invasive Oesophagectomies and
Gastrectomies
153
7. L E N G T H  O F  IN T E N S IV E  C A R E  A N D  H O SP IT A L  STA Y
The median length of hospital stay post minimally invasive oesophagectomy was 13.0 
days (95% Cl 17.4-22.0.) For gastrectomies the median length of stay was 7.0 days 
(95% Cl 13.7-17.9.) The table below outlines length of stay in more detail (n.b. data is 
skewed):
Approach Columnl - : A  I t
Oesophagectomy Approach
Oesophagectomy overall MEAN 23 3.9
MEDIAN 13 0
Laparoscopic/Thoracotomy MEAN
MEDIAN
23.2
14
4.8
3.5
Laparoscopic Transhiatal MEAN
MEDIAN
17.4
13.5
4.5
2
Laparotomy/Thoracoscopic MEAN
MEDIAN
18.3
13
7.1
5
Laparoscopic/Thoracoscopic MEAN
MEDIAN
27.1
13
1.8
0
Gastrectomies MEAN 15.8 1.5
MEDIAN 7 0
Table 6.6: Length of Hospital and Intensive Care following Minimally Invasive
Oesophagectomy and Gastrectomy.
6.4 Discussion
These results, in common with the retrospective data in chapter 5, confimi that 
minimally invasive gastro-oesophageal cancer surgery is both safe and feasible in a
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UK setting. The high mortality rate in the gastrectomy group is however 
acknowledged and the length of stay in this group is greater than expected. This could 
be due to a small series (with resultant high percentages on analysis); poor case 
selection and a reluctance to discharge patients from units inexperienced in MIG (that 
also do not operate enhanced recovery programmes.) Further data collection is 
recommended to ascertain the significance of MIG results in this trial.
Patient demographics, including ASA and POSSUM grades are similar to those found 
in other reports of this type of cancer surgery (ASCOT trial, McCulloch 2003.) The 
unit policy varied between centres included in the register; some selected patients for 
this type of surgery however others offered the minimally invasive approach to all 
comers. The overall demographics in the register demonstrate that the population 
studied remains approximately representative of those undergoing open as well as 
laparoscopic upper gastrointestinal resections; (although disease stage tended to be 
lower in some centres when compared to patients undergoing open surgery.) Prudent 
surgeons in the early phases of a developing technique such as minimally invasive 
surgery for gastro-oesophageal cancer frequently however select patients for 
resection. These include patients with: a good body habitus that are not obese; early 
stage tumours and patients with low ASA grades/minimal co-morbidity
Mortality rates for MIO (2.5%) are similar to those reported in systematic reviews of 
this type of surgery (Gemmill 2007, Verhage 2009,) although better than the most 
recent national data on oesophagectomies, which includes open surgery (Palser 2009.) 
Morbidity rates for MIO (53%) including rates specific for anastomotic leak and 
respiratory tract infection are lower than those found on comparable databases
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(Wormuth 2006,) although there is wide variation in the classification degree of 
reported ischaemia. In MIO, intracorporeal gastric conduit formation does not allow 
flattening and stretching of the stomach in an antero-posterior dimension to the extent 
utilised in (extracorporeal) open oesophagectomies, resulting in a shorter gastric tube, 
with a smaller tip prior to anastomosis.
It is difficult to separate whether the gastric tip ischaemia is related to the MIO 
approach (extra-corporeal gastric conduit formation rates are reported between 2.3% 
and 9% (Leibman 2006, Palanivelu 2006;) or the width of the gastric tube formation - 
wider tubes appear to have lower ischemic rates but can result in oncological margin 
compromise (Berrisford 2008.) It is likely however that gastric tip necrosis is 
multifactorial, with both of the previously mentioned causative factors, in addition to: 
failure to mobilise the right crus of the diaphragm sufficiently and a narrow hiatus 
resulting in constriction of the gastric tube; failure to preserve the gastro-epiploic 
arcade at the gastric fundus sufficiently; insufficient mobilisation of the pylorus and 
distal stomach reducing resectable conduit tip; traction forces applied to the conduit 
during mediatinal mobilisation; and conduit route (Anegg 2008, Berrisford 2009;) all 
of which are more difficult in a minimally invasive approach compared with an open 
one.
This centre is currently conducting a randomised controlled trial of ischaemic 
preconditioning of the gastric conduit 2 weeks prior to resection in the aim of 
improving perfusion (Berrisford 2009.) This technique in open surgery has been 
attempted by other centres with potential benefit (Hoelscher 2007, Varela 2008.)
The mortality and morbidity rates for MIG (10.8% and 24% respectively) reported 
here are greater than that expected when compared to recent national and international
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literature (Gemmill 2007, Smith 2007, Yacoub 2008, Palser 2009.) It compares 
however to that published following the ASCOT trial (McCulloch 2003.) This may 
be due to the low number of cases resulting in a disproportionally high outcome rate 
with big percentages; (patient demographics including age and ASA grade for the 
gastrectomy group were comparable to other series.) Although the high morbidity and 
mortality could possibly be a reflection of the early stage of the learning curve this 
trend does not appear to be mimicked in the oesophagectomy group. Again, as with 
chapter 5, the published literature may be subject to publication bias, unlike the data 
recorded here which reflects multicentre practice.
Operating time was comparable to the literature, and was shown to decrease with unit 
experience. This is reflected in CUSUM analysis, which is analysed in further detail 
in chapter 7.
Estimated blood loss was higher in this data collection than in comparable series. This 
may be a reflection of the poor recording of this information and statistical outliers 
increasing the overall mean.
The lymph node yield and ratio are one of the most important factors determining 
patient postoperative prognosis (Eloubeidi 2002, Lagarde 2006, Yoo 2009.) In this 
study, the yield for both oesophagectomy (17.5) and gastrectomy (13.4) are less than 
could be hoped and below that recommended in the literature -  18 and 15 lymph 
nodes respectively (Risk 2008, Van Cutsem 2008.) It is difficult however to ascertain 
whether these apparent yields are the result of the radicality of surgery performed or 
differences in the histological analysis in the laboratory. Indeed more recent studies
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have questioned both the methodology (Jamieson 2009) and lymph node yield and 
ratios (Mariette 2008, Deng 2009) required for accurate staging.
The negative lower confidence interval obtained for gastrectomy lymph node retrieval 
is also indicative of a low sample size and the broad variation in confidence intervals 
demonstrates marked difference between units. It is therefore even more difficult to 
interpret the results obtained in this study with any certainty.
R0 resection rate of the oesophagectomies is also lower than expected, impacting on 
the oncological quality of surgery. The most commonly involved margin was 
circumferential, which has the greatest prognostic significance (Griffiths 2006, 
Sujendran 2008, Wang 2009.) However at least one unit dissected the specimen in the 
operating theatre in order to optimise the lymph node yield; but in the process, 
altering the reported from the true circumferential resection margin.
R0 resection rate documented here is lower than that in the world literature of 
minimally invasive gastrectomies (Gemmill 2007) although it is questionable whether 
these initial reports were subject to publication bias. Its importance in the resection of 
gastric cancer is well documented (Wang 2009) and therefore this low rate is of 
concern. However due to the low numbers of gastrectomies involved in this trial, the 
overall percentage rate is disproportionately high.
Data on length of hospital stay was again disappointing and did not demonstrate the 
reduced time compared to open surgery that was predicted and hoped for from the 
laparoscopic approach. This may be due to overcautious care in centres at the early
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stage of their learning curve and a fast-track type policy not being applied like in 
other units (Kehlet 2006, Low 2007, Gouvas 2009.)
Quality of life analysis has not been addressed in this prospective study, despite it 
being one of the purported benefits of minimally invasive surgery (Parameswaran 
2009;) although it is aimed that this will be a future aspect of study.
Despite the limitations in data collection this prospective study provides further 
information of minimally invasive gastro-oesophageal oncological surgery in multiple 
UK centres where there is limited published evidence. Similar to the retrospective 
study gastrectomy mortality and morbidity are still a concern, however 
oesophagectomy rates were comparable to national and international published 
literature. Again, length of stay benefit was not demonstrated and R0 resection rates 
and lymph node yields were not as good as hoped. It is unclear if these differences 
when compared to previous publications are a result of technical problems not 
encountered in open surgery, which will improve with experience or bias in published 
literature. Further data collection is recommended and comparison to open surgery 
with specific endpoints such as 5-year survival. (This was not done in the above data 
collection which was part of a phase II surgical trial.)
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CHAPTER 7 -  THE LEARNING CURVE ASSOCIATED WITH 
MINIMALLY INVASIVE SURGERY FOR GASTRO- 
OESOPHAGEAL CANCER
7.1 Introduction
Acknowledging and identifying the learning curve associated with evolving surgical 
techniques is important. It was first highlighted and assessed by continuous 
surveillance of unit performance in the UK following the Bristol Royal Infirmary 
inquiry (Stark 2000.) Continuous monitoring which acts as a method of quality 
control can be done by the application of control curves (Mohammed 2001) or 
instruments that monitor sequential probability ratios such as CUSUM (Cumulative 
Sum Control) (Novick 2003, Speigelhalter 2004,) VLAD (Variable Life-Adjusted 
Display) (Lovegrove 1997) or CRAM plots (Cumulative Risk Adjusted Mortality) 
(Polonieck 1998.) These instruments can be updated after each operation and can be 
applied to individual surgeons, thereby producing real-time monitoring of 
performance.
Evaluation of the learning curve has been utilised extensively in the assessment of 
laparoscopic procedures, such as laparoscopic cholecystectomy (Moore 1995) and 
laparoscopic urological procedures (See 1993.) A number of publications have 
utilised CUSUM analysis in the setting of gastro-oesophageal cancer surgery (Kim 
2005, Jin 2006, Lee 2006,) although few relate specifically to the minimally invasive 
approach.
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CUSUM charts allow detection of a deterioration (or improvement) in surgical 
practices and are sensitive to small changes in outcome rates; not overreacting to 
expected fluctuations due to chance (Steiner 1999.) Limits are set to identify 
situations where the frequency of failures is significantly greater than expected, 
causing the system to “trigger.” CUSUM can therefore be applied to help determine 
surgical learning curves and the detection of surgical outliers.
CUSUM methodology has been developed from ammunition production in World 
War II (Montgomery 1991) evaluating a more homogenous (industrial) dataset than 
that which is frequently encountered in a surgical environment, with its heterogeneous 
group of patients both in physiology and clinical presentation. This can result in 
limitations of traditional CUSUM analysis and a risk-adjusted CUSUM, addressing 
the level of pre-operative risk has also been proposed (Steiner 2000.)
A CUSUM analysis of the learning curve typically demonstrates a sigmoid curve with 
a slow beginning, steep acceleration and plateau phase. This represents an initial 
upward trend where failure exceeds the expected levels; followed by either a plateau 
phase where the expected and observed failure rate are equal, or a downward slope 
where the observed outcome is better than the acceptable (expected) one. The point at 
which the slope either plateaus, or demonstrates a consistent downward trend, 
demonstrates the number of procedures required to perform the process under study to 
the required standard.
A number of different variables (both continuous and discrete) can be assessed 
utilising CUSUM analysis, commonly operation time, conversion rate, major
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morbidity and mortality (Novick 1999, Dincler 2003, Grunkemeir 2003;) but other 
factors such as oncological outcome have also been measured (Jin 2007.) Operative 
time was used for CUSUM analysis in this study since it allows objective assessment 
of a surgeons’ technical ability; is a commonly reported variable and has been 
demonstrated to reduce with increasing operative experience (Schlachta 2001, Tekkis 
2005.) It is nevertheless a crude measure of outcome and has limitations, especially as 
speed does not necessarily reflect surgical precision or oncological and post-operative 
outcome including complications; it also does not take in to account patient or tumour 
characteristics e.g. obese patients and T3 tumours.
7.2 Methods
Prospective data derived from the MIGOCS register was collated, looking at 
minimally invasive oesophagectomies from all centres documenting operative time 
for more than 5 cases. The mean operative time and range of time per centre was 
initially assessed then more detailed analysis utilising CUSUM methodology was 
utilised. (Minimally invasive gastrectomies were not looked at, as too few were 
recorded to allow meaningful analysis to occur.)
CUSUM requires classification of each operation as a success or a failure according 
to pre-defined criteria. For this purpose, operation time greater than two standard 
deviations from the overall population mean was defined as a “failure”; similar to that 
by Novick et al (2003.) This allowed an assessment of sequential outcomes and 
identification of any procedure learning curve. A positive curve indicates that the
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acceptable failure rate has been exceeded and conversely a downward, negative slope 
indicates a failure rate less than the accepted rate.
A zero value (the starting point of the plot) is exactly what is predicted by the risk 
model. Transitions from overall positive to overall negative values and vice versa can 
be frequent and reflect normal surgical practice.
The mathematical formula utilised was:
Approach 1 (simple approach): S, = £  (Xj -  Xo); Xo is the sample mean 
Approach 2:
Si = max(U Si - 1  + Wt), where Wt = (X, -  no) / g o -  k; where k = 0.5g
and S0= 0
• g  represents the number of standard deviations one wants to detect (2 
in this case.)
• no represents the mean operation time when the process is considered 
in control,
• (To represents the standard deviation of the series (assumed to exhibit 
no serial correlation.)
Initial data analysis involved that obtained from all centres providing greater than 5 
cases, except Exeter. Data from Exeter was analysed separately as operative times 
were provided combined with anaesthetic time and therefore adjustments had to 
made accordingly. (Future data from this site has been requested to record separate
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anaesthetic and operative times in order for more accurate comparisons between 
centres to be made.)
7.3 Results
Operative time was initially assessed by mean operative time and range by centre 
(including all those recording over 5 minimally invasive oesophagectomies on the 
MIGOCS register.)
An overall mean was then calculated from which 2 standard deviations could be 
calculated in order to identify a “trigger” value for CUSUM analysis. A box plot 
(figure 7.1) and index plot (figures 7.2 and 7.3) were also created to further appreciate 
the variation of operating time between centres.
Table 7.1 Minimally Invasive Oesophagectomies, Mean and Range of Operative 
Times by Centre
C E N T R E  (n u m b e r ) N U M B E R  O F M EA N  O P E R A T IN G R A N G E  (m in s )
O P E R A T IO N S T IM E  (m in s )
C o lch e ste r G e n e ra l H ospital ( 1 ) 15 338 (245, 450)
Hull R o ya l In f irm a ry  (2 ) 45 283 (135, 510)
Im p e ria l ( 3 ) 15 287 (200, 420)
M aidstone &  T u n b rid g e  W e lls  ( 4 ) 25 335 (210, 520)
W o rth in g  &  S o u th la n d  H ospita l (5 ) 5 375 (273, 540)
R oyal D e v o n  &  E x e te r (in c lu d e s 96 402 (104,745)
a n a e sth e tic  t im e )
O V E R A L L  O P E R A T IV E  T IM E  (E x e te r 105 308 (135, 540)
e x c lu d e d )
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Figure 7.1: Box Plot of MIO Operating Times by Centre
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Figure 7.2: Index Plot of Operating Times by Centre (dotted line represents
mean operative time of the entire series)
166
operation number
Figure 7.3: Index Operating (and included Anaesthetic) Time at Exeter (dotted 
line represents Mean Time)
The operative times at all the centres studied demonstrates a range of values. In the 
case of Exeter many of these are clustered around the mean, with outliers; however 
this is not obviously the case in all centres. Therefore CUSUM analysis is of benefit 
to look at operative time in more detail and to give more informative results.
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Figure 7.4: Simple CUSUM Plot and CUSUM Analysis to detect a change of 2 
Standard Deviations
Simple 
CUSUM Plot
CUSUM Pim to 
Detect 2 
Stand.tid
Deviations
Only 6 centres provided enough data for CUSUM analysis in the prospective series. 
(Data from Exeter as mentioned above has been analysed separately as data provided 
combined operative and anaesthetic time.)
In the graph, a downward trend represents an improvement in performance by the 
centre (i.e. operating time is less than the average operating time of the entire series.) 
It can thus be observed from the initial simple CUSUM analysis that the first 25 
operations at Hull Royal Infirmary (centre 2,) resulted in a better than expected 
performance, followed by 20 operations that took longer than expected, but the 
CUSUM remained below the horizontal line (in control.) Centres 1 (Colchester) and 
3 (Imperial) demonstrated a relatively stable performance remaining close to the 
horizontal line. Centre 4 and 5 (Maidstone and Worthing) took longer than expected 
in there operative time, although operative numbers are low.
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Approach 2, is designed to detect a change in 2 standard deviations is demonstrated in 
the lower half of the above graph. For all 5 centres there is no evidence to suggest that 
there is a significant change in operative times across the entire series.
Figure 7.5: Exeter CUSUM Plot- Effect of changing the mean operative time (to 
detect a change of 2 standard deviations)
The mean operative time for the Exeter series in 402 mins (standard deviation of 95 
minutes); higher for that of other series, but it does include anaesthetic time. This is 
difficult to separate into separate components using data provided by the centre. By
169
assuming a lower mean operating time say 320mins, then the CUSUM will produce 
lots of false alarms as seen in the lower left figure. Alternatively, imposing an 
acceptable mean operating time which is much higher, say 420mins, then the CUSUM 
will rarely alert. From looking at this data, it can be seen that the acceptable mean 
operating time should be something which is pre-specified.
Utilising the CUSUM graph closest to Exeter’s mean operative/anaesthetic time at 
400 minutes, it can be seen that the centre demonstrated a relatively stable 
performance with improvements demonstrated in the middle and later operative 
numbers (after 30 cases,) as should be expected.
7.4 Discussion
The learning curve for minimally invasive gastric and oesophageal cancer surgery has 
been addressed by few papers, as outlined earlier in this thesis. Jin et al (2007) 
analysed 109 operative procedures performed by a single surgeon (laparoscopy- 
assisted gastrectomy;) finding a multidimensional learning curve, with a slight rising 
trend involving 3 phases that was achieved after 40 procedures. This curve was 
broken by unselected operations and the introduction of advanced techniques.
An initial slow rising trend is commonly seen in the analysis of minimally invasive 
oesophagectomies, possibly resulting from operating in pairs, mentorship, carefully 
selected patients, hybrid techniques and the realisation of “zones of discomfort.”
Using our data, CUSUM analysis of oesophagectomies is limited by the relatively 
small number of procedures undertaken to date by the centres providing data, but
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illustrates how CUSUM is beneficial in the development of a novel technique. 
Looking at the initial data, variation is demonstrated between the 4 centres with 
experience of over ten procedures (see figures 6.1 and 6.4.) One centre consistently 
over performed (i.e. the surgeons were significantly faster than average) until the final 
few procedures, when their performance suddenly deteriorated. This is probably 
explained by a change in approach from thoracoscopic with laparotomy to a more 
demanding thoracoscopic/laparoscopic technique, which coincided with this. The first 
and third centres demonstrate a relatively stable surgical outcome, suggesting that 
they have almost reached a plateau in their learning curve. The use of the derivative 
graphs where only deviation greater than 2 SD was represented on the graph seemed 
very helpful in detecting trends and changes. It is believed that the complete 
experience has been recorded from these centres from the first case, which suggests 
that prior experience with other complex laparoscopic surgery, together with a 
measured approach, can eliminate the learning curve for this procedure, at least for 
operative time. It is impossible with the information obtained from the centres 
providing data (on operative time alone) to determine the exact number of procedures 
that need to be performed in order to demonstrate an improvement in surgical 
outcome. In particular, the absence of precise information on prior surgical experience 
-  with this procedure or other complex laparoscopic surgery- and patient selection, 
hampers practice effect (learning curve) analysis and data interpretation.
Analysis of the Exeter data has demonstrated the importance of uniformity of data, 
which although is specified in the register, was not provided by the centre (all 
operative time included anaesthetic time.) This made it difficult to compare the centre 
to others in the register. It did however outline the benefit of a pre-specified 
acceptable mean operative time, as this will affect the “trigger” value at which
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CUSUM will alert a problem. Data from Exeter has provided information on the 
largest number of operations performed by any one centre included in the register In 
conjunction with the data from Hull (the second largest contributor to the dataset,) 
CUSUM analysis appears to suggest that a learning curve appears to plateau at after at 
least 30 cases. (This contrasts to the 50 cases recommended in the literature for MIG -  
Fujiwara 2005, Kim 2005- and 40 cases by Jin- 2007.) To date of writing this thesis a 
value at which the learning curve appears to have been overcome has not previously 
been mentioned in the published literature. (This value may have important 
implications in proctorship and introduction of minimally invasive oesophagectomy 
programmes.)
Another limitation of the CUSUM in this chapter is that it was applied to each centre 
rather than to individual surgeons (2 surgeons were involved in operations at 
Maidstone and Exeter in roughly equal numbers of operations and a second surgeon 
responsible for small numbers of cases in Hull and Southampton.) Whilst this affects 
the outcome of learning curves and introduces a confounding factor it was felt that for 
published outcomes to the MIGOCS group, data feedback by centre provided greater 
anonymity. In addition many centres perform minimally invasive resections with 2 
consultants present, as recommended by the consensus statement on MIO by AUGIS 
in 2008 during the operative learning curve. It is therefore difficult to determine the 
exact learning curve of individuals independently.
Operative learning curve is only one of five encountered in minimally invasive 
operations; there is also the anaesthetic assessment, patient selection, team formation, 
post operative care and management of postoperative complications.
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Despite all its limitations, CUSUM is a good tool for providing continuous 
surveillance and is clearly useful in detecting improvement (or deterioration) in 
performance. Thus it helps maintain quality control, demonstrating objective and 
quantified recording of results that allows early detection of problems, leading to 
potential review and remedial action that would prevent future failures.
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CHAPTER 8: THESIS CONCLUSIONS, CRITIQUE AND 
FUTURE PROSPECTS
This thesis presents a phase II surgical study of minimally invasive gastro- 
oesophageal cancer surgery from multiple centres in the United Kingdom. This 
approach has been used as other methodologies such as case series provide weak 
quality of evidence (CEBM) in evaluating this type of surgery.
8.1 Thesis Summary
Surgery remains the treatment of choice for patients with gastro-oesophageal cancer 
beyond its earliest stages. This type of surgery however carries high morbidity and 
mortality rates, with studies demonstrating that patients can take 2 years before 
returning to a reasonable quality of life post-operatively. Therefore options such as 
minimally invasive surgery which have the potential to provide shorter post-operative 
stay; quicker return to function and improved quality of life have been gaining in 
popularity since their introduction in the early 1990s.
RCTs are problematic to perform in surgery due to a number of factors such as 
learning curves, definition of the trial and blinding. The development of novel 
surgical techniques also makes trial timing difficult. The optimal trial design should 
incorporate a comprehensive approach after the initial surgical intervention 
development. An example of this is a phase II surgical trial utilised in this thesis. This 
addresses trial definition, quality control, the learning curve and aims to encourage the 
development of a RCT between participants (thereby integrating natural technique 
development with rigorous scientific evaluation.)
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Following a systematic review of the literature, we know that the majority of the 
published literature on laparoscopic gastro-oesophageal surgery for cancer is in the 
form of case series. Up to the date of writing this thesis, there were no randomised 
controlled trials (RCTs) of minimally invasive oesophagectomies (MIOs) and 4 small, 
single centre RCTs of minimally invasive gastrectomies (MIGs.) Most of the evidence 
on MIOs comes from Western centres (America, Australia and Europe) and most of 
that on MIGs comes from Eastern centres (Japan and Korea.)
The MIGOCS (Minimally Invasive Gastro-Oesophageal Cancer Surgery) group was 
established in 2005 and now has over 60 consultant members from around the UK and 
Europe. It is a research collaboration which through consensus discussions and 
iterative development has established a registry for this type of surgery (available at: 
http://rsl.e-dendrite.com/csp/migocs/frontpages/migocs.! The registry comprises of 
five sections: demographic details; pre-operative assessment and staging; operative 
intervention; post-operative course; pathology and clinical outcome.
8.2 Findings from this Thesis
Retrospective data was initially collated from 7 UK centres and recorded 100 
oesophagectomies and 26 gastrectomies (approximately analogous to IDEAL stage 
2a/b.) From the oesophagectomy group there were 57 complications (30 major, 27 
minor, which included 3 anastomotic leaks and 19 respiratory tract infections) and 6 
deaths; in the gastrectomy group there were 13 morbidities^ major, 9 minor) and 2 
deaths. These morbidity and mortality results were higher than expected. Length of
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stay results (14 and 10 days respectively for MIO and MIG) and estimated blood loss 
for the oesophagectomies were also greater than predicted and lymph node yield was 
lower than hoped. Operative time, R0 resection and leak rate were however 
acceptable and established MIO and MIG in a multicentre setting in the UK as safe 
but clearly evolving with the need for more studies to evaluate it further.
Prospective data collection collected between December 2006 and August 2008 
involved 278 oesophagectomies and 37 gastrectomies (IDEAL stage 2b.) Most 
oesophagectomies were laparoscopic/thoracoscopic or laparoscopic/thoracotomy. In 
the oesophagectomy group there were 146 complications (92 major and 54 minor, 
including 22 anastomotic leaks and 38 respiratory tract infections); there were 7 
deaths. This was comparable to nationally published data. In the gastrectomy group, 
there were 9 complications (4 major and 5 minor) and 4 deaths. Again gastrectomy 
morbidity and mortality were higher than expected (although this could be a reflection 
of the low number of cases recorded.) Estimated blood loss and length of stay were 
higher than expected; RO and lymph node yield were lower than predicted. Other 
variables were acceptable.
CUSUM allows continuous surveillance of performance of individual surgeons or 
units with early warning of quality or outcome deterioration. It is especially important 
in the early phases of a novel technique in monitoring the learning curve of the 
procedure, such as demonstrated in this thesis with minimally invasive gastro- 
oesophageal cancer surgery. Majority of the units evaluated in this thesis 
demonstrated improvements in their learning curves, however data sample sizes were 
small resulting in limitation of result interpretation. The two larger centres (Hull and
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Exeter) did however demonstrate the beginnings of an apparent plateau in their 
learning curves at around 30 procedures.
With reference to the aims of a phase II surgical study:
- The procedure has been defined; although which approaches should be 
evaluated in a RCT needs further clarification (see chapters 1 and 8.)
- A trial question has been evaluated.
- Effective quality control measures have been undertaken
- Data has been collected, however more data is required (especially of 
gastrectomies) in order to accurately calculate end points and power 
calculations. (Although data thus far has enabled some basic analysis.)
- Participant learning curve has been evaluated, by means of CUSUM 
analysis
- Although no definite date for a RCT into minimally invasive gastro- 
oesophageal cancer surgery in the UK has been set, opinion regarding 
potential participation has been improving. However whether it will be the 
future gold standard has yet to be determined.
This approach, including quality control measures and addressing the trial question 
demonstrates improved evidence compared with case series, the most commonly 
published evidence of minimally invasive gastro-oesophageal cancer surgery present 
in the literature. In addition, utilizing the IDEAL recommendations, the approach 
described in this thesis (a phase 2 surgical study) represents stage 2a/b of surgical 
innovation stages, with the need for randomized controlled trials and long-term
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studies still required. The initial hypothesis of this thesis that current methodology of 
this type of surgery is inadequate to enable comparison to conventional, open surgery 
is thus confirmed.
Subsequent to the establishment of the MIGOCS group and database, NICE (the 
National Institute of Clinical Excellence) has published overview statements on 
thoracoscopically assisted oesophagectomies and laparoscopic gastrectomies as part 
of its interventional procedures guidance (NICE 2006, 2008.) These both recommend 
submission of data to the MIGOCS registry. In addition AUGIS and ALS have 
sponsored meetings between interested surgeons on the topic o f minimally invasive 
gastro-oesophageal cancer resections.
A consensus meeting sponsored by AUGIS was held in the Pelican Centre at 
Basingstoke in March 2008 proposing a classification system of minimally invasive 
oesophagectomies:
- Minimally Invasive Oesophagectomy (MIO) with cervical 
anastomosis
- MIO with intra-thoracic anastomosis
- Laparoscopically Assisted Oesophagectomy (LAO) with standard 
thoracotomy and intra-thoracic anastomosis
- LAO with mini-thoracotomy and intra-thoracic anastomosis
- LAO with thoracotomy and cervical anastomosis
- Thoracoscopically Assisted Oesophagectomy (TAO) with 
laparotomy and cervical anastomosis.
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The meeting further suggested that the minimally invasive approach was an additional 
technique for oesophageal resection, which should only be offered to those fit enough 
for open surgery. It offered advice regarding patient selection, introducing MIO into 
clinical practice and recommended data entry for audit and learning curve analysis.
8.2.1 Thesis Strengths
This thesis reports the first multicentre report of minimally invasive gastro- 
oesophageal cancer resections in the UK (data collection being supported by AUG IS, 
ALS and NICE.) It includes detailed data collection on aspects of minimally invasive 
surgery: patient demographics; tumour staging and characteristics; intra-operative 
details; post-operative and oncological outcomes. During the latter stages of data 
collection, information was concurrently collated by the National Oesophago-Gastric 
Audit, which has since published its findings, but contains less detailed information 
specific to the minimally invasive approach.
The study reported in this thesis contained integral quality control measures, such as 
mandatory fields on the database and utilisation of a research fellow to visit centres 
involved and validate data entry.
The methodology utilised in this thesis involved analysis of learning curves and 
helping to establish consensus between participants. This helped provide feedback to 
clinicians on their own performance and anonymous comparison to other centres. This 
information has additionally been helped give an indication towards the number of 
procedures required for proctorship and to reach a plateau. (Data was presented at the 
consensus meeting for MIO, hosted by AUGIS in Basingstoke in 2008.)
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8.2.2 Thesis Weaknesses
One of the biggest flaws to this thesis and study is the limited data collection and 
involvement of centres. This was a result of a number of difficulties, many of which 
have previously been mentioned, such as: politics between individuals and units; 
concerns regarding publication rights and utilisation of data collected; time limitations 
and the optimal time for data collation.
Selection bias has undoubtedly occurred during data collection. Patients undergoing 
this relatively new and still investigational technique are likely to have less co­
morbidity; have smaller tumours and morphologically be better for this approach. In 
addition not all centres offered this approach to all comers, increasing the likelihood 
of bias.
The thesis and study has not concentrated on quality of life and long term follow up 
data collection which are important outcome measures in minimally invasive surgery 
(especially when comparing it to conventional open surgery.)
8.3 Improvements and Areas for Future Study
Further data collection, initially as a prospective case series as part of a phase II 
surgical trial, especially of gastrectomies needs to occur. MIG numbers were too low 
in this study to provide an accurate reflection of its current status and outcome within 
the UK in a multicentre setting (and which to date has not been published by any 
other group.) This data would then enable power calculations and end points to be 
made. In addition further evaluation of learning curves could be made (for 
gastrectomies as well as oesophagectomies.) A specific primary outcome that requires
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measuring is 5-year survival. Other secondary endpoints would include morbidity, 
especially respiratory tract infection and anastomotic leak and oncological outcome, 
with particular reference to lymph node yield (and positivity,) circumferential margin 
involvement and tumour recurrence. These measures would thus allow comparison to 
open surgery.
Improvements
Evaluation of patient subgroups, for example by ASA grading or HGD versus T4 
tumours would provide information on who might benefit most from minimally 
invasive approaches. It would require oncological evaluation of this type of surgery 
(especially if it were to be offered in preference to open surgery to those with 
potentially the best prognosis); conversely to offer it to those with a poor prognosis 
oncological adequacy is less of an issue than quality of life and return to normal 
function post surgery. Subgroup evaluation would also help determine which patients 
should be selected in the early stages of the learning curve, potentially reducing its 
steepness.
Further thesis and trial improvement could be made by extending data collection. 
Initially by linking up with the National Audit data collection to prevent duplication 
of data entry (this was considered but unfortunately not taken further;) and 
international data collection. Around thirty consultant surgeons involved in this type 
of surgery were contacted, some as part of the European Union Network of 
Excellence on gastric cancer, and approximately a half expressed an interest in taking 
part in an international multicentre randomised controlled trial. (Unfortunately this 
was not taken further by the student’s supervisor.)
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Establishing Consensus
The trial reported in this thesis aimed to help establish consensus between participants 
to help move towards a randomised controlled trial.
Regular group meetings, providing feedback on factors such as learning curve and 
data reports and to aid technique discussion were held. This included a meeting at 
Trinity College, Oxford where Delphi methodology was used to aid feedback on the 
problems associated with establishing a minimally invasive oesophagectomy service.
Centres involved in the trial were visited by the student to aid data entry and to 
encourage it (further entry and registration for the database was encouraged by 
presentations and attendance of meetings nationally and internationally.)
It was also intended for group publication of data after the first 100 cases, to help 
reassure publication concerns and provide some incentive for data collection to 
participants. Unfortunately despite multiple drafts, including trial participants, the 
final draft did not progress far beyond the supervisor’s desk.
More active involvement with AUGIS and ALS would also have helped establish 
national consensus (beyond an initial meeting) as well as assist in proctorship issues 
(which in turn would have aided relationships between centres.)
Conclusion
Using the IDEAL framework, minimally invasive gastrectomy and oesophagectomy 
utilising a phase 2 surgical trial approach has been studied at stage 2a and 2b. A 
randomised controlled trial is now needed initially in a UK setting of both MIO and
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MIG (IDEAL stage 3.) This would need to compare conventional practice i.e. open 
surgery with minimally invasive surgery (utilising at least one approach in the case of 
oesophagectomies); thereby providing sufficient evidence levels for optimal practice.
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Unique patient-identifier
Date of birth
Gender
Study centre
Study case number
Study case consultant
Date of admission
Demographics and other identifiers
dd /  m m  /  yyyy 
O  Male O Female O Unknown
dd /  m m  /  yyyy
Pre-operative staging
Initial T-stage O  None (high grade dysplasia) O T3
O T1 O T3a
0  Tla O T3b
0  T ib O T4
O T2 O T4a
O T2a O T4b
O T2b O TX (unknown)
Initial N-stage O NO O N2
O N1 0  NX
Initial M-stage O MO O  M1a
O Ml O M lb
Pre-operative chemotherapy O No O Yes
Post-CXT T-stage O  None (high grade dysplasia) O T3
O T1 O T3a
0  Tla O T3b
O Tib O T4
0  T2 O T4a
O T2a 0  T4b
O T2b O TX (unknown)
Post-CXT T-stage 0  NO O N2
0  N1 O NX
Post-CXTT-stage O  MO O M ia
O Ml O  M lb
Staging modalities used □  CT scan
□  MRI scan
□  EUS
□  EUS and FNA
□  Laparoscopy
□  LapU/S
□  Isotope bone scan
□  PET scan
□  PET scan /  CT scan
□  Bronchoscopy
□  Thoroscopy
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£2
D
Unique patient identifier 
Date of procedure
Histological type
Histological grade 
Position of primary tumour
Length of tumour 
Width of tumour
Physiological O POSSUM score 
ASA grade
Operating surgeon 1 
Operating surgeon 2 
Mentor
Position of primary tumour
Hand assisted
d d /m m /y y y y
Pre-operative staging continued ...
o Adenocarcinoma O GIST
0 Squamous O Lymphom a
o Small cell O Others
o U ndifferentiated
o Well defined O Poorly d ifferentia ted
Tumour details
o Upper oesophagus O Hiatus hernia
o M iddle oesophagus O Fundus o f stomach
o Lower oesophagus O Body o f stomach
o Gastro-oesophageal ju n c tio n O Antrum
o Barrat's oesophagus O Pylorus
mm
mm
Pre-operative health status
use
O Grade 1 O Grade 4
O Grade 2 O Grade 5
O Grade 3 O Unknown
O Total oesophagectm y (G01.1)
O Sub-tota l-oesophagectom y (G01.1)
O  Partial oesophagectom y (G01.1)
O O esopho-gastrectom y (G01.1)
O Extended to ta l gastrectom y w ith  D2 node dissection (G27.1)
O Total gastrectom y w ith  o ther node dissection (G27.5)
O Sub-total gastrectom y (G28.3)
O Distal gastrectom y (G28.3)
O Segmental gastrectom y (G28.8)
O Local resection o f pa rt o f stomach (G29.2)
O Well defined O Poorly d iffe ren tia ted
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U n iq u e  p a tie n t id e n tif ie r
D ate o f  procedure d d /m m /y y yy
Port site
Port site
Port distance from
axillary line
Port details
Port 1 Port 2 Port 3
0 Left upper quadrant O Left upper quadrant O Left upper quadrant
o Right upper quadrant O Right upper quadrant O Right upper quadrant
o Epigastrium O Epigastrium O Epigastrium
o Left flank O Left flank o Left flank
o Um bilical area O Umbilical area o Um bilical area
o Right flank O Right flank o Right flank
o Hypogastrium O Hypogastrium O Hypogastrium
o Left iliac fossa O Left iliac fossa O Left iliac fossa
o Right iliac fossa O Right iliac fossa O Right iliac fossa
o Ribspace 1 O Ribspace 1 O Ribspace 1
o Ribspace 2 O Ribspace 2 O Ribspace 2
o Ribspace 3 O Ribspace 3 O Ribspace 3
o Ribspace 4 O Ribspace 4 O Ribspace 4
o Ribspace 5 O Ribspace 5 O Ribspace 5
o Ribspace 6 O Ribspace 6 o Ribspace 6
o Ribspace 7 O Ribspace 7 o Ribspace 7
o Ribspace 8 O Ribspace 8 o Ribspace 8
o Ribspace 9 0 Ribspace 9 o Ribspace 9
o Ribspace 10 o Ribspace 10 o Ribspace 10
o 5 mm o 5 m m o 5 mm
o 10 mm o 10 mm o 10 mm
o 12 mm 0 12 mm o 12 mm
o 15 mm 0 15 mm o 15 mm
o 30 mm o 30 mm o 30 mm
o H andport o H andport o H andport
o Endostitch o Endostitch o Endostitch
o Nathanson retractor o Nathanson retractor 0 Nathanson retractor
o m id-axilla -14 o m id-axilla -14 o m id -ax illa -14
o m id-axilla -12 o m id-axilla -12 o mid-axilla -12
o m id-axilla -10 o m id-axilla -10 o mid-axilla -10
o m id-axilla -8 o m id-axilla -8 o m id-axilla -8
o mid-axilla -6 o m id-axilla -6 0 m id-axilla -6
o m id-axilla -4 o m id-axilla -4 o m id-axilla -4
o m id-axilla -2 o m id-axilla -2 o mid-axilla -2
o On m id axillary line o On m id axillary line o On m id axillary line
o m id-axilla +2 0 m id-axilla +2 0 m id-axilla +2
o m id-axilla +4 o mid-axilla +4 o m id-axilla +4
o m id-axilla +6 o m id-axilla +6 o m id-axilla +6
o m id-axilla +8 o m id-axilla +8 o m id-axilla +8
o m id-axilla +10 o m id-axilla +10 o m id -a x illa +10
o mid-axilla +12 o m id-axilla +12 o m id-axilla +12
o m id-axilla +14 o mid-axilla +14 o m id-axilla +14
o m id-axilla +16 o mid-axilla +16 o m id-axilla +16
o m id-axilla +18 o mid-axilla +18 o m id-axilla +18
o m id-axilla +20 o m id-axilla +20 o m id-axilla +20
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Unique p a tie n t id e n tifie r
D ate o f  procedure dd /  mm / yyyy
Operative technique details
Type of reconstruction O No anastomosis O Oesophagogastrostom y (neck)
o Gastrojejunostom y O Oesophagogastrostom y (chest)
o O esophagojejunostom y O G astrojejunostom y Roux-en-Y
o Jejunal loop in te rposition O Billroth II
o Colon in te rposition
Method of anastomosis o Sutured
o Stapled 0 Both
Staple type o 3.5 mm O Vascular
o 4.8 mm O O ther
Staple length o 30 mm
Oo 40 mm 60 mm
Nodal dissection performed 0 DO O D1 & L gastric artery
o D1 O 2-field
o D2 O Other
Thoracic dissection o No O Yes
Thoracic dissection method o Laparoscopic th rough  hiatus
o Thorascopic
o Blind transhiatal
o Prone thorascopic
o Com bined laparoscopic & b lind
o Com bined thorascopic & laparoscopic
o Com bined thorascopic & b lind
Brief description of technique
Outcome o Completed
o Converted to  open O Abandoned
Reason for abandonment /  conversion
Operation statistics
Anaesthetic time m in
Operating time (skin to skin) m in
Blood loss ml
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U n iq u e  p a tie n t id e n tifie r
D a te  o f procedure d d / m m / y y y y
Post-operative course
ITU stay days
Time to free fluids days
Time to diet days
Anaesthetic time days
Time to bowel action days
Time to walking down ward days
Last parenteral post-op analgesia given days
Post-operative transfusion O  No
O  Yes
Morbidity
Complications O  No
O  Yes
Chest infection / respiratory infection O  None 
O  Chest infection
O  Respiratory infection
Wound infection O  No
O  Yes
Abscess
O  None
CH Intra-abdominal
□  Lung
□  Liver
□  Empyema
D  Other
Haemorrhage O  No
O  Yes
Haematoma O  No
O  Yes
DVT/PE O  None
O  Confirmed DVT
O  Suspected DVT 
O  Confirmed PE
Ml /CCF/ arrhythmia O  None
□  Ml
□  CCF
□  Arrhythmia
□  Cardiac arrest 
D  Unstable angina
Anastomotic/staple line leak O  None 
O  Confirmed leak
O  Suspected leak
Conduit ischaemia O  No
O  Yes
Chyl°thorax 0  No
O  Yes
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Unique patient identifier
Date of procedure d d / m m / y y y y
Morbidity continued...
Other complication O No
Nature of other complication 
Was a secondary operation performed O No
Reason for secondary operation
O  Yes 
O  Yes
Tumour pT-stage
Tumour pN-stage
Tumour pM-stage
Nodes found 
Nodes positive 
Resection margins - proximal 
Resection margins - distal 
Resection margins - circumferential 
R grade
Pathology outcome
O  Tis 
O  T1 
O  T2 
O  T2a 
O  T2b
O  NO 
O  N1
O  MO 
O  M l
O  Clear
O  Clear
O  Clear
O 0 
O 1
O  T3 
O  T3a 
O  T3b 
O  T4
O  TX (unknown)
O  N2 
O  NX
O  M ia  
O  M lb
O  Involved 
O  Involved 
O  Involved
O 2
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Unique patient identifie r
Date of procedure . . .a d /  m m / y y y y
Clinical outcome
Quality of life score at 30 days 
Quality of life score at 90 days 
Quality of life score at 6 months
Date of recurrence dd /  m m  /  yyyy
Site of recurrence 0 Anastomosis
O Other local recurrence
0 Regional lymph nodes - chest
O Regional lymph nodes - abdomen
O Liver
O Lung/p leura
O Peritoneal cavity /  ascites
O Bone
o Brain
o Other
Death in hospital o No q
Date of death
dd / mm / yyyy
Cause of death □ Primary cancer
□ Recurrent or secondary upper Gl cancer
□ Treatment-related complications
□ Other illness
□ Trauma
□ Other
□ Unknown
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